

Index

- 3TC *see* lamivudine
- AAO-HNS Guidelines, eardrop delivery 115
- AAP/AAPF 2013 Guidelines, acute otitis media treatment 118t16.2
- AASLD (American Association for the Study of Liver Diseases), HCV updates 160
- abacavir
 HIV post-exposure regimens 381t57.7
 side effects and toxicities 183t27.5, 381t57.7
- abdominal pain differentiation 165–66
 cholecystitis and cholangitis, in sickle cell disease 478
 imaging 166t25.10
 pelvic inflammatory disease 203
 peritonitis, referred patterns 163t25.2
 peritonitis, secondary 163–64
 in pregnancy 392
 pyelonephritis, in adults 165–66
 upper abdominal pain 147
 see also peritonitis
- Abelset *see* amphotericin B
- abortions *see* endometritis;
 postpartum and post-abortion infections
- abscess, differentiated
 breast 410t59.4, 410t59.5
 deep mandibular space 141
 epidural brain 34
 hepatic 164
 liver 164
 liver abscess classification 164
 multiple 80–81
 parotitis 128
 penetrating head trauma 36–37
 perinephric 326
 peripancratic 164–65
 peritonsillar, aspiration 133
 retropharyngeal 131, 135, 136
 solid organ 164–65
 splenic 165
 tubo-ovarian abscess 165–66
 see also brain abscess; deep mandibular space abscess/ infections; epidural abscess; intracranial abscess;
 intraparenchymal brain abscess; periapical abscess; peritonsillar abscess; retropharyngeal abscess, pediatric; spinal cord infections; spinal epidural abscess, IDU-associated; subcutaneous abscess, IDU-associated
- abscess, undifferentiated 79–82
 — epidemiology and microbiology 79
 — clinical features 79–81
 — differential diagnosis 81
 — laboratory and radiographic findings 81
 — treatment 81–82, 84t12.3
 — complications and admission criteria 82
- bacteremia and sepsis 82
- bedside ultrasound 81
- CA-MRSA 79, 81, 544, 545
- cellulitis, purulent 80, 81f12.5, 82
- CT scans 81
- cutaneous furuncle 80f12.3
- general approach 80f12.1
- hidradenitis suppurativa 80–81
- IDU-associated 79
- immunocompromised patients 82
- loop drain 81f12.6
- MSSA 79
- multiple 80–81
- purulent cellulitis 80, 81f12.5, 82
- ruptured and healing furuncle 80f12.4
- ultrasound visualization 80f12.2
- abscess classification, liver abscess 164
- abscess/cellulitis/NSTI differentiation 82
- ABthrax (raxibacumab) 488
- abuse, sexual (suspected)
 conjunctivitis 260t41.1
 pubic lice (*Phthirus pubis*) 91, 92t13.5
- Acanthamoeba*, uveitis and retinitis 276t43.1
- accidental myiasis 93, 95t13.8, 96t13.9
- ACCP (American College of Chest Physicians), sepsis standardized diagnostic criteria 467–68
- acetaminophen
 acute otitis media 118
 dengue fever 422
 hepatotoxicity 159t24.3
 otitis externa 115
 pericarditis 10t2.3
 rubella 109t14.11
 sinusitis 122
- acetaminophen overdose 158, 161
- acetaminophen-opioid agents, pulpitis 142–43
- ACG (American College of Gastroenterology)
 C. difficile infection, diagnostic definitions 189t28.1
- Acinetobacter*
 cephalosporins, third- and fourth-generation 564
 ertapenem, clinical issues 554t77.3
- Acinetobacter baumannii*
 ESBL production 553t77.1
- oncology patients 450
- open fractures 239
- ACIP (Advisory Committee on Immunization Practices)
 influenza updates, viruses, and treatments 306
- ACS *see* acute chest syndrome, in sickle cell disease
- Actinobacillus*
 actinomycetemcomitans, infective endocarditis 1
- Actinobacillus pleuropneumoniae*, ESBL production 553t77.1
- Actinomyces*
 acute necrotizing ulcerative gingivitis 145
 deep mandibular space infections 141
 deep neck space infections 135, 136t21.1
 HIV pulmonary infections 289t45.1
- intraparenchymal brain abscess 34t6.2
- periapical abscess 140–41
- pericoronitis 144
- periodontal infections 143, 144t22.2
- pulpitis 142–43
- activity spectra, commonly used drugs 557–59
- acute acalculous cholecystitis 150
- acute bacterial cholangitis 150–53
 — epidemiology and microbiology 150
 — clinical features 150–51
 — treatment 151–52
 — laboratory and radiographic findings 150–51, 151t23.3
 — special considerations 152–53
 — pearls and pitfalls 153–54
- altered mental status 150
- biliary decompression 151–52, 152t23.5
- biliary parasites 152–53
- Charcot's triad 150
- cholecystectomy 152t23.5
- choledocholithiasis 150
- cholelithiasis 150
- critically ill patients 152
- endoscopic drainage and extraction, common bile duct stone 152f23.2
- ERCP intervention 150, 151–52
- mortality rates 150
- MRCP 150
- parasitic cholangitis 152–53
- Reynold's pentad 150
- Tokyo Guidelines (2013) 150, 151t23.4
- acute bacterial meningitis *see* meningitis, acute bacterial
- acute bacterial prostatitis 196–98, 324–25
 — epidemiology and microbiology 196–97
 — clinical features 197
 — differential diagnosis 197
 — laboratory and radiographic findings 197, 197t29.5
 — treatment and prophylaxis 197–98, 197t29.5
 — complications and admission criteria 198
- acute calculous cholecystitis 146–50
 — epidemiology and microbiology 146
 — clinical features 146–47
 — differential diagnosis 147
 — laboratory and radiographic findings 146, 147–48, 147t23.1
 — complications and admission criteria 148–49
 — special considerations 149–50
 — pearls and pitfalls 153–54
- abdominal pain differentiation 165–66
- acute acalculous cholecystitis 150

Index

- acute calculous cholecystitis (*cont.*)
 biliary colic 146, 147
 biliary scintigraphy 147–48
 cholecystectomy 148–49, 149t23.2
 choledocholithiasis (Mirizzi's syndrome) 146
 critically ill patients 148
 CT scans 148
 gangrenous cholecystitis 148, 149
 HIDA scan 147–48
 Murphy's sign 146, 147, 147t23.1
 opioid effects 148
 in pregnancy 149–50
 resuscitation 149t23.2
 sonographic findings 148f23.1
 surgical intervention 148, 149t23.2
 treatment 148
 upper abdominal pain differentiation 147
- acute care setting, VRE infections 549
- acute chest syndrome, in sickle cell disease 474–77
 — epidemiology and pathophysiology 474
 — clinical features 474–76
 — differential diagnosis 475
 — laboratory and radiographic findings 476t66.2
 — treatment 476–77, 476t66.2
 — complications and admission criteria 478
 — pearls and pitfalls 478–79
- bacterial pneumonia and ACS 476t66.2
- children 474, 476, 476t66.2
- Cooperative Study of Sickle Cell Disease (CSSCD) trial 475
- mortality rates 478
- acute cystitis *see* lower urinary tract infection, in adults
- acute diarrhea *see under* diarrhea
- acute diarrhea, definition 182
- acute disseminated encephalomyelitis (ADEM) 46
- acute exacerbations of chronic bronchitis
 fluoroquinolones 568–69
 macrolides and ketolides 570
- acute flaccid paralysis, West Nile virus infections 75, 75t11.1
- acute generalized exanthematous pustulosis (AGEP) 100t14.1
- acute hepatitis *see* hepatitis
- acute hepatitis B 157, 160
- acute hepatitis C 158, 159, 160
- acute hepatitis E 158
- acute HIV infection (acute retroviral syndrome) 107
 fever and rash, in adults 107
 pharyngitis 130t20.1, 134
- acute infections
 diabetic foot infections 228
 VRE infections 548–49
- acute infectious diarrhea *see* diarrhea, acute
- acute liver failure, viral hepatitis 160–61
 — clinical features 156–57
 — laboratory and radiographic findings 157t24.2
 — treatment and prophylaxis 157t24.2, 160–61
 and acute viral hepatitis 156
 common causes 158
 hepatitis B virus 156, 157
 hepatitis D virus 156
 hepatotropic viruses 161
 ICU admission 160, 161
 liver transplants 156, 160
 mortality rates 156
 SIRS 156
see also acute viral hepatitis; viral hepatitis
- acute mastoiditis complication, acute otitis media 118–19
- acute meningitis *see under* meningitis
- acute necrotizing ulcerative gingivitis (ANUG) (Vincent's angina) 144–45, 144t22.2
 — epidemiology and microbiology 144–45, 144t22.2
 — clinical features 144t22.2, 145
 — differential diagnosis 145
 — laboratory and radiographic findings 144t22.2, 145
 — treatment 144t22.2, 145
 — complications and admission criteria 144t22.2
 — pearls and pitfalls 145
- HIV patients 145
- pharyngitis 130t20.1
- young adults 145
- acute osteomyelitis 242, 243–44
- acute otitis media (AOM) 117–19
 — microbiology 117
 — epidemiology 117
 — clinical features 117
 — differential diagnosis 117–18
 — laboratory and radiographic findings 118
 — treatment and prophylaxis 118–19
 — complications and admission criteria 118–19
 — pearls and pitfalls 119
- AAP/AAFP 2013 Guidelines for AOM Treatment 118t16.2
- acute mastoiditis complication 118–19
- babies and young children (1 month to 5 years) 118t16.2
- babies under 2 months, blood counts 118
- cephalosporins 118, 119t16.3, 562t78.10
- children 117, 118, 118t16.2
- cleft palates 117
- macrolides and ketolides 570
- meningitis complication 119
- neonates 118, 329
- otitis media with effusion 117
- penicillin-allergic patients 118
- perforated tympanic membrane complication 118
- acute pancreatitis, peripancreatic abscess 164
- acute paronychia 236–37
 — microbiology 236
 — clinical features 236
 — differential diagnosis 236
 — treatment 236, 237t35.3
- C. albicans*, chronic paronychia 236
- vs. herpetic whitlow 236, 237, 238
- nail plate skin folds 236f35.3
- acute pericarditis *see* pericarditis
- acute respiratory distress syndrome *see* ARDS
- acute retinal necrosis 277f43.4
- acute sinusitis definition 120
- acute suppurative parotitis 126
- acute viral hepatitis *see* hepatitis, acute
- acyclovir (Zovirax)
 — crystallization, nephrotoxicity 578
 — properties and dosages 577–78
- altered mental status, HIV patients 24t4.6
- herpes genitalis, mucocutaneous 211t31.2
- herpes simplex virus, fever in pregnancy 399t58.12
- herpes simplex virus meningitis 54
- herpes simplex virus, neonates 332
- herpes virus infections 577–78
- herpetic whitlow 238t35.4
- HSV-1 encephalitis 39, 40
- meningitis, febrile child 337t51.1
- meningitis, neonates 336, 337t51.1
- varicella, fever in pregnancy 399t58.12
- varicella zoster, HIV patients 107–08
- viral encephalitis 52–53
- viral keratitis 262
- Adacel vaccine, tetanus 71
- ADEM (acute disseminated encephalomyelitis) 46
- adenovirus
 acute infectious viral diarrhea 170, 170t26.1
 conjunctivitis 258, 260t41.1
 diarrhea, HIV patients 182t27.2
 fever in the newborn 328, 330t50.1
 influenza-like illnesses 301
 keratitis 261t41.3
 myocarditis 11
 non-gonococcal urethritis 202
 non-inflammatory diarrhea 170t26.1
 parotitis 126, 127t19.1
 pericarditis 6
 pharyngitis 129, 130t20.1
 solid organ transplants 460t64.1
 urethritis (male infections) 192
- adhesive bowel obstruction, abdominal pain differentiation 165–66
- adolescents
 deep neck space infections 135
- mumps 54
- musculoskeletal infections, pediatric 352t53.4
- necrotizing periodontitis 143
- peritonsillar abscess 132, 134
- advanced-generation cephalosporins — properties and dosages 564
- ESBL-producing organisms and infections 564
- adverse drug reactions *see* drug reactions, severe
- Advisory Committee on Immunization Practices (ACIP)
 influenza updates, viruses, and treatments 306
- Aedes aegypti* mosquito, dengue fever 418
- Aeromonas hydrophila*, cellulitis, fresh water exposure 82t12.2
- Africa, fever in the returning traveler
 African tick-bite fever 94t13.7, 425f60.1, 426t60.9
- endemic infectious disease table 414t60.1
- rickettsial infections 426t60.9
- AGEP (acute generalized exanthematous pustulosis) 100t14.1
- AIDS patients (acquired immunodeficiency syndrome)
 aseptic and viral meningitis 61
- C. cayetensis* diarrhea 178t26.12
- chronic diarrhea, parasitic 173–74
- fever and rash, in adults 106–08
- IRIS 19–20, 22t4.5
- osteomyelitis 242
- otitis externa 114
- ova and parasite testing 175t26.8, 178
- TMP-SMX cautions 572
- uveitis and retinitis, susceptibilities 274
- see also under* altered mental status; *under* HIV
- AIG human (anthrax immune globulin) (Anthraxil) 488
- airborne infection isolation room (AIIR), novel influenza A viruses 539
- airway emergencies *see* supraglottitis
- Alaska Natives, influenza 300
- albendazole
 microsporidium diarrhea, HIV patients 185t27.6
- parasitic cholangitis, *C. sinensis* 153t23.6
- Alcaligenes xylosoxidans*, ESBL production 553t77.1
- alcohol, nitroimidazoles caution 573
- ALF *see* acute liver failure, viral hepatitis
- allergic conjunctivitis, treatment 259, 260t41.2
- allergic fungal sinusitis 121

- allergy and toxicity principles,
 antimicrobials 557
see also drug reactions, severe
 allergy documenting, penicillin-
 allergic patients 557
 allopurinol medications, severe drug
 reactions 109
 alopecia, secondary syphilis 215f31.12
 ALT levels (alanine
 aminotransferase), acute viral
 hepatitis 158
 altered mental status (AMS)
 acute bacterial cholangitis 150
 cerebral malaria 413
 delusional parasitosis 97
 elderly people, influenza 305
 altered mental status (AMS), HIV
 ART patients 18
 — treatment and prophylaxis
 24, 25
 — pearls and pitfalls 25
 ART therapy 18
 initial treatment, selected
 infections 24t4.6
 IRIS complication 19–20, 22t4.5
 neuroimaging, brain disorders
 22t4.5
 altered mental status, HIV
 patients 18–25
 — general points 18
 — epidemiology 18
 — clinical features 18–19
 — differential diagnosis 19–20
 — laboratory and radiographic
 findings 20–22
 — treatment and prophylaxis 24
 — complications and admission
 criteria 22
 — infection control 25
 — pearls and pitfalls 25
 CD4 counts 18–19, 21t4.4, 22
 cerebral toxoplasmosis 22t4.5,
 23f4.1, 24t4.6
 CNS infections, initial treatment
 24t4.6
 diffuse cerebral dysfunction
 features 19
 focal cerebral dysfunction
 features 19–20
 HIV dementia 21t4.4, 22t4.5
 injection drug users 20
 metabolic encephalopathies 21t4.4
 neuroimaging, brain disorders
 22t4.5
 primary CNS lymphoma, head CT
 scan 23f4.2
 progressive multifocal
 leukoencephalopathy 23f4.3
 subtle CNS infections in advanced
 HIV disease 19t4.1
 AmBisome *see* liposomal
 amebiasis
 acute infectious diarrhea 175t26.7
 nitroimidazoles 573
 American Academy of
 Otolaryngology and Head
 and Neck Surgery Guidelines,
 eardrop delivery 115
 American Association for the Study
 of Liver Diseases (AASLD),
 HCV updates 160
 American College of Chest
 Physicians (ACCP), sepsis
 standardized diagnostic criteria
 467–68
 American College of
 Gastroenterology (ACG)
C. difficile infection, diagnostic
 definitions 189t28.1
 American Indians, influenza
 viruses 300
 American Thoracic Society (ATS)
 guidelines
 HIV pulmonary infections 290,
 294
 tuberculosis treatment 312
 amikacin (various brands), activity
 spectrum 557–59
 aminoglycosides
 — activity spectrum 557–59
 — properties and dosages 569
 nephrotoxicity 388, 450, 557,
 569t78.22
 otitis externa 115
 toxicity/nephrotoxicity/ototoxicity
 557, 569
 tularemia 511–12
 VRE infections 551
 aminopenicillins, antimicrobial
 properties 560t78.2
 amiodarone, hepatotoxicity 159t24.3
 amitriptyline, hepatotoxicity
 159t24.3
 amnionitis *see* chorioamnionitis
 amoxicillin
 — activity spectrum 557–59
 — properties and dosages 560t78.2
 acute otitis media 118, 119t16.3
 anthrax 486t67.3
C. difficile colitis 172
 cystitis, in pregnancy 389t58.4
 febrile child, pneumonia 337t51.1
 HIV pulmonary infections 294
 infectious endocarditis,
 prevention 143
 infective endocarditis 51t.3
 Lyme disease 106t14.8
 pharyngitis 132t20.4
 pneumonia, pediatric 364t54.8
 pyelonephritis, outpatient therapy
 326t49.2
 sinusitis 121t17.3
 ticks/tick-borne illnesses 94t13.7
 VRE infections 550t76.3, 551
 amoxicillin-clavulanate (Augmentin)
 — activity spectrum 557–59
 — properties and dosages 561–62
 acute cystitis 320t48.1
 acute necrotizing ulcerative
 gingivitis 145
 acute otitis media 118, 119t16.3
 acute paronychia 237t35.3
 bite infections 372t56.1
 CAP, outpatient therapy 283t44.2
 felon 237t35.3
 fight bites 234, 234t35.1
 foot infections, diabetic 230t34.1
 hepatotoxicity 159t24.3
 HIV pulmonary infections 294
 periapical abscess 142t22.1, 143
 periodontal infections 144,
 144t22.2
 peritonsillar abscess 134t20.5
 sinusitis 121t17.3
 amphotericin, nephrotoxicity 577,
 577t78.43
 amphotericin B (Abelcet, Amphotec)
 — caution, nephrotoxicity 577
 — properties 577
 children, post-transplant, febrile
 464t64.2
 endophthalmitis 278t43.3
 febrile post-transplant patients
 464t64.2
 amphotericin B deoxycholate
 (various brands) 577
 ampicillin
 — activity spectrum 557–59
 acute bacterial meningitis 58t8.9
 altered mental status, HIV patients
 24t4.6
 antimicrobial properties 560t78.2
 cesarean section, endometritis
 prophylaxis 408
 chorioamnionitis 394t58.8
 fever, neonates 332
 meningitis, neonates 336, 337t51.1
 pneumonia, neonates 332,
 364t54.8
 pyelonephritis, in pregnancy
 389t58.4
 VRE infections 550t76.3, 551
 ampicillin-sulbactam (Unasyn)
 — properties and dosages 561–62
 acute bacterial cholangitis
 152t23.5
 acute calculous cholecystitis,
 resuscitation 149t23.2
 appendectomy in pregnancy
 392t58.7
 bacterial tracheitis, pediatric 358,
 358t54.3
 bite infections 372t56.1
 chorioamnionitis 394t58.8
 deep mandibular space infections
 142t22.1
 deep neck space infections 137
 fight bites 234t35.1
 HIV pulmonary infections 294
 Lemierre's syndrome 138t21.2, 139
 musculoskeletal infections,
 pediatric 352t53.4
 periodontal infections 144t22.2
 peritonsillar abscess 134t20.5
 postpartum endometritis 407t59.1
 purulent tenosynovitis 236t35.2
 pyelonephritis, inpatient therapy
 326t49.2
 retropharyngeal abscess, pediatric
 359, 359t54.4
 supraglottitis (epiglottitis) 124
 amputations, diabetic foot infections
 228, 230–31
 AMS *see* altered mental status
 anabolic steroids, hepatotoxicity
 159t24.3
 anaerobes/anaerobic bacteria
 — antibacterial drug spectra
 558t78.1
 — antibacterials, commonly used
 557–59
 acute paronychia 237t35.3
 chronic diabetic foot wounds 228
 felon 237t35.3
 purulent tenosynovitis 235
Anaplasma phagocytophilum, ticks/
 tick-borne illnesses 94t13.7
 anastomotic leaks
 surgical risks 455t63.3
 viscous perforation, secondary
 peritonitis 164
 ancylovir caution,
 nephrotoxicity 578
 anemia, linezolid (Zyvox)
 caution 575
 aneuruptive fever (ricketsial
 infections) 426t60.9
 angioinvasive fungi, focal cerebral
 dysfunction
 HIV/AIDS patients 20t4.3
Angiostrongylus cantonensis,
 parasitic meningitis 60, 60t8.11
 anidulafungin (Eraxis)
 — activity spectrum 557–59
 — properties and dosages 576–77
 animal bites and scratches, returning
 traveler 415t60.3
see also bite infections; rabies;
 tetanus
 animal contact, returning traveler
 415t60.3
 ankle, osteomyelitis, AP radiograph
 244f37.1
Anopheles mosquito, malaria 416
 anthrax 480–88
 — epidemiology 480–81
 — clinical features 481–84
 — differential diagnosis 484
 — laboratory and radiographic
 findings 484–85
 — treatment and prophylaxis
 485–88
 — complications and admission
 criteria 488
 — infection control 488
 — pearls and pitfalls 488
 as a biological weapon 481
 children, treatment 486t67.3
 confirmed or suspected 485
 contained casualty setting 485
 cutaneous anthrax 482, 484, 485,
 488
 decontamination 488
 fluoroquinolones 486t67.3, 568–69
 gastrointestinal anthrax 482–83,
 484, 485
 HICPAC 488
 immunocompromised patients
 486t67.3
 inhalational anthrax 481–82, 484,
 485, 488
 mass casualty setting 485–87

Index

- anthrax (*cont.*)
 natural occurrences 480–81
 post-exposure prophylaxis 485–88, 486t67.3
 pregnant women, clinical features 484
 pregnant women, treatment 486t67.3
 tetracyclines and glycyclines 571
 transmission modes 480
 United States occurrence 481
 Working Group for Civilian Biodefense 488
 worldwide occurrence 480–81
 anthrax immune globulin (AIG human) (Anthraxil) 488
 anthrax meningitis 483, 484, 485
 anthrax vaccine absorbed (AVA) 488
 Anthriscil *see* anthrax immune globulin
 antibacterials, common emergency department 557–59
 antibiotic-associated diarrhea (AAD) 456
 antibiotics
 — activity spectra, commonly used drugs 557–59
 — ESBL-producing organisms and infections 553, 554t77.3
 acute infectious bacterial diarrhea 177t26.10
see also antimicrobials, properties; *under* drug; ESBL-producing organisms and infections; *specific drugs*
 anticoagulation, Lemierre's syndrome 139
 antidepressants, oxazolidinone interactions 574–75
 antiepileptic medications, severe drug reactions 109
 antifungal azoles, antimicrobial properties 575–76
 antigenic drift, influenza 299
 antigenic shift, influenza 299
 anti-herpes-virus drugs
 — nephrotoxicity 578t78.44
 — properties 577–78
see also under herpes; *specific drugs*
 antihistamines, sinusitis 122
 anti-inflammatory (non-steroidal) *see* NSAIDs
 anti-influenza drugs, antimicrobial properties 578–79
 antimalarial regimens 420t60.6
 antimicrobial therapy
 acute infectious bacterial diarrhea 176–77
 acute infectious parasitic diarrhea 177–78
 antimicrobial toxicity *see under* drug
 antimicrobials, properties 556–79
 — activity spectra, commonly used drugs 557–59
 — allergy and toxicity principles 557
 — pharmacokinetics and pharmacodynamics 556
 — prior use impact on therapy choice 556–57
 aminoglycosides 569
 aminopenicillins 560t78.2
 antifungal azoles 575–76
 anti-herpes-virus drugs 577–78
 anti-influenza drugs 578–79
 anti-staphylococcal penicillins 560–61
 antivirals 577–79
 beta-lactams 557–65
 beta-lactamase inhibitor combinations 561–62
 carbapenems 565
 cephalosporins, advanced-generation 564
 cephalosporins, first-generation 562
 cephalosporins, second-generation 562–63
 cephalosporins, third-/fourth-generation 563
 echinocandins 576–77
 fluoroquinolones 568–69
 glycopeptides 566–68
 glycyclines 571t78.27
 ketolides 570
 lincosamides 571–72
 macrolides 570
 monobactams 565
 natural penicillins 560t78.2
 nitrofurans and fosfomycin 573–74
 nitroimidazoles 573
 oxazolidinones and lipopeptides 574–75
 penicillin-beta-lactamase inhibitor combinations 561–62
 penicillins 560562t78.2
 polyenes 577
 post-antibiotic era 135
 tetracyclines 571
 TMP-SMX 572
see also specific antimicrobials
 antimotility agents (loperamide) 175–76, 186
 anti-pseudomonal aminoglycoside, severe sepsis 471t65.8
 antipyrine, acute otitis media 118
 antiretrovirals
 ART therapy 18
 diarrhea reports, HIV patients 183t27.5
 hepatotoxicity 159t24.3
 anti-staphylococcal penicillins
 — properties and dosages 560–61
 infective endocarditis 560t78.3
 antituberculosis drugs, first-line 313t47.3, 314t47.5
 antivirals
 — properties and dosages 577–79
 anti-herpes-virus 577–78
 anti-influenza 303–04, 578–79
 avian influenza 538
 DAAs (direct acting antivirals) 160
 Ebola virus disease 523–24
 hepatitis C virus 160
 neuraminidase inhibitors 537, 578, 579
 novel influenza A 537–39
 peramivir 304t46.5, 537, 538, 578–79
 zanamivir 304t46.5, 537, 578–79
see also oseltamivir; vaccines
 anti-WNV antibodies 77
 ANUG (Vincent's angina) *see* acute necrotizing ulcerative gingivitis
 anxiolysis, peritonsillar abscess 133
 AOM *see* acute otitis media
 apnea risk, fever in the newborn 332
 appendectomy, anastomotic leak risks 455t63.3
 appendicitis
 acute diarrhea differentiation 171, 172
 viscus perforation, secondary peritonitis 164
 appendicitis, in pregnancy 391–93
 — epidemiology 391
 — clinical features 391–92
 — differential diagnosis 392
 — laboratory and radiographic findings 392, 392t58.7
 — treatment 392–93, 392t58.7
 — complications and admission criteria 393
 — pearls and pitfalls 403–04
 appendectomy, antibiotics 392t58.7
 arbovirus diseases (ARthropod-BORne virus) 74
 testing algorithm, Zika virus 528t73.1
 Arcanobacterium, pharyngitis 129
 ARDS (acute respiratory distress syndrome)
 — clinical features 468t65.2, 469t65.3, 471
 CA-MRSA 544
 complication in severe sepsis 468t65.2, 470–71
 malaria 413, 416
 novel influenza A 538
 pneumonic tularemia 512
S. mitis bacteremia 443t62.1
 varicella (chickenpox) 397t58.10
 ARG (room-air arterial blood gas), HIV pulmonary infections 290
 ART therapy timing, HIV pulmonary infections 293
 artemether-lumefantrine, *P. falciparum* malaria 419t60.5
 artemisinin derivatives with caution, malaria, in pregnancy 403t58.17
 artesunate, *P. vivax* malaria 419t60.5
 arthritis, Lyme disease associated 106t14.8
see also osteomyelitis and septic arthritis, in sickle cell disease; septic arthritis
 arthropod bites, returning traveler 415t60.3
 ARthropod-BORne virus (arbovirus diseases) 74
 testing algorithm, Zika virus 528t73.1
Ascaris lumbricoides
 gallbladder, parasitic cholangitis 153t23.6
 parasitic cholangitis 153, 153t23.6
 aseptic meningitis 52
 aseptic meningitis and viral meningitis 52–54
 — complications and admission criteria 61–62
 AIDS patients 61
 CSF evaluation 56–57
 enteroviruses (nonpolio) 53
 Epstein-Barr virus 54
 flaviviruses 54
 herpes simplex virus 54
 herpes viruses 54
 HHV-6 54
 HIV patients 54, 61
 immunocompromised patients 61
 West Nile virus infections 54
 Asia, rickettsial infections 426t60.9
 aspartate aminotransferase levels (AST levels), acute viral hepatitis 158
Aspergillus
 antifungal azoles 575
 endophthalmitis 278t43.2
 HIV pulmonary infections 289t45.1, 293–94, 294t45.4
 invasive fungal rhinosinusitis 121
 keratitis 261t41.3
 meningitis 59
 neutropenic oncology patients 443, 445
 otitis externa 114
 sensitivity, sinusitis 121
 solid organ transplants 459, 460
 spinal epidural abscess 42
 spine infections, epidural abscesses 256t40.2
 uveitis and retinitis 276t43.1
 aspiration pneumonia, lincosamides 571–72
 aspirin (salicylic acid)
 pericarditis treatment 10t2.3
 pharyngitis 132
 Reye syndrome risk 304
 AST levels (aspartate aminotransferase), acute viral hepatitis 158
 asthma, patients with, zanamivir caution 578
 astrovirus diarrhea
 acute infectious 170
 HIV patients 182t27.2
 asymptomatic bacteriuria
 acute cystitis 321, 322
 in pregnancy 387–88
 atazanavir (Reyataz, ATV)
 HIV PEP regimens, occupational 379t57.5, 380t57.6, 381t57.7
 side effects and toxicities 381t57.7
 atovaquone-proguanil (Malarone)
 antimalarial regimens 420t60.6
Plasmodium falciparum malaria 419t60.5

Index

- ATS (American Thoracic Society) guidelines
 HIV pulmonary infections 290, 294
 tuberculosis treatment 312
 ATV *see* atazanavir
 atypical bacteria, antibacterial drug spectra 558t78.1
 Augmentin *see* amoxicillin–clavulanate
 Australia, rickettsial infections 426t60.9
 automatic implantable cardioverter defibrillators (AICDs) 14
 AVA (Anthrax vaccine absorbed) 488
 Avelox *see* moxifloxacin
 AVI-7535 antiviral 523–24
 avian influenza A viruses
 — microbiology 531–32
 antivirals 538
 children 532, 533, 533t74.1
 H10N8 532, 533t74.1, 534
 HPAI viruses (highly pathogenic) 531–32, 533
 LPPI viruses (low pathogenic) 531–33
 transmission 534–35
 viral pneumonia 535, 536t74.5, 538
 young adults 533, 533t74.1, 534t74.2
see also H5N1; H5N6; H7N9
 Avycaz *see* ceftazidime–avibactam
 Azactam *see* aztreonam
 azathioprine (Azasan, Imuran), post-transplant patients 466t64.4
 azithromycin (Zithromax)
 — activity spectrum 557–59
 — properties and dosages 570
 acute chest syndrome, in sickle cell disease 476t66.2
 bite infections 372t56.1
C. jejuni diarrhea, HIV patients 185t27.6
Campylobacter diarrhea 177t26.10
 chancroid 218t31.6
 chlamydia 200t30.2
 chlamydia co-infections 104
 community-acquired pneumonia 283t44.2, 284t44.3
Cryptosporidium diarrhea, HIV patients 185t27.6
 diarrhea, acute bacterial 177t26.10
 disseminated gonococcal infection 104
 endometritis, post-abortion prophylaxis 408
 epididymitis 196t29.4
 gonorrhea 203t30.4
 health-care-associated CAP 284t44.3
 HIV pulmonary infections, ICU treatment 294
 MAC diarrhea, HIV patients 185t27.6
 non-gonococcal urethritis 202, 203t30.5
 pertussis, pediatric 360–61, 360t54.5
 pneumonia, pediatric 364t54.8
Salmonella diarrhea 177t26.10
Shigella diarrhea 177t26.10
 sinusitis 121t17.3
 urethritis (male infections) 194t29.2
 azoles, hepatotoxicity 557
 azoles, QT interval prolongation 557
 AZT *see* zidovudine
 aztreonam (Azactam) 565
 — activity spectrum 557–59
 — cross-reactivity 557
 meningococcemia (meningococcal disease) 101t14.2
 pyelonephritis, in pregnancy 389t58.4
 spine infections, epidural abscesses 256t40.2
 spontaneous bacterial peritonitis 167t25.11
Babesia, hematopoietic stem cell transplants, transfusion fever 462
Babesia microti (protozoa), ticks/tick-borne illnesses 93
 babesiosis (deer tick illness) 94t13.7
 babies, newborn *see* fever in the newborn; neonates
 babies, 1 month plus *see* infants
Bacillus anthracis
 rare infections, influenza differential diagnosis 301
 Working Group for Civilian Biodefense 480
see also anthrax;
 bioterrorism risks
Bacillus cereus, endophthalmitis 277
 baclofen, muscle spasms, tetanus 71
 bacteremia
 acute VRE infections 548–49
 ESBL-producing organisms and infections 553
 fever in the newborn 330t50.1
 occult, febrile child 334–35
 and sepsis, abscess 82
 bacteremia and fungemia, neutropenic oncology patients
 — clinical features 443
 — differential diagnosis 447
 — laboratory findings 443t62.1
 — treatment 443t62.1, 448–50
 Ecthyma gangrenosum 444t62.1
 bacteremia and sepsis, in sickle cell disease 474
 — epidemiology and microbiology 474
 — clinical features 474–75
 — differential diagnosis 474
 — laboratory and radiographic findings 474, 475t66.1
 — treatment 474, 475t66.1
 — complications and admission criteria 478
 — risks and associations 475t66.1
 — pearls and pitfalls 478–79
 children 474, 475t66.1
 MRSA 474
 bacterial brain abscess, differential diagnosis 558t.4
 bacterial community-acquired pneumonia 281
 bacterial conjunctivitis, treatment 259, 260t41.2
 bacterial diarrhea *see under* diarrhea
 bacterial endocarditis, HIV/AIDS patients 20t4.3
 bacterial keratitis 261t41.3, 262
 bacterial meningitis *see* meningitis, acute bacterial
 bacterial myocarditis 11
 bacterial pneumonia and acute chest syndrome, in sickle cell disease 476t66.2
 bacterial resistance mechanisms, ESBL-producing organisms and infections 552
 bacterial rhinosinusitis 120
 bacterial sinusitis 120, 568–69, 570
see also sinusitis
 bacterial skin/soft-tissue infections
see skin and soft-tissue infections
 bacterial tracheitis, pediatric 357–58
 — epidemiology and microbiology 357, 358t54.3
 — clinical features 357–58
 — differential diagnosis 357
 — laboratory and radiographic findings 358, 358t54.3
 — treatment and prophylaxis 358, 358t54.3
 — complications and admission criteria 358
 — pearls and pitfalls 364
 bacterial vaginosis (vulvovaginitis) 220–21
 — epidemiology and microbiology 220
 — clinical features 220–21
 — differential diagnosis 223
 — laboratory and radiographic findings 220, 221t32.1
 — treatment 221
 — complications 221
 — infection control 221
 — pearls and pitfalls 223
 pregnant women, treatment 221
 bactericidal drug activity 556
 bacteriostatic drug activity 556
Bacteroides
 acute bacterial cholangitis 150, 152t23.5
 acute necrotizing ulcerative gingivitis 145
 bacterial vaginosis 220, 221t32.1
 cat bite infections 369
 deep neck space infections 136t21.1
 dental abscess, intraparenchymal brain abscess 34t6.2
 dog bite infections 369
 ear infection, intraparenchymal brain abscess 34t6.2
 intraparenchymal brain abscess 34t6.2
 Lemierre's syndrome 138
 periodontal infections 144t22.2
 peritonitis, liver abscess 165t25.6
 sinusitis, intraparenchymal brain abscess 34t6.2
 surgical site infections 453
Bacteroides bivius, chorioamnionitis 394t58.8
Bacteroides fragilis
 — antibacterial drug spectra 558t78.1
 — antibacterials, commonly used 557–59
 abscess 79
 appendicitis, viscus perforation 164t25.4
 cephalosporins, second-generation 563
 cephalosporins, third- and fourth-generation 564
 chorioamnionitis 394t58.8
 deep mandibular space infections 141
 diverticulitis, viscus perforation 164t25.5
 ESBL production 553t77.1
 solid organ transplants 460t64.1
 subcutaneous abscess, IDU-associated 433, 433t61.3
 Bactrim *see* TMP-SMX
 barbiturates, muscle spasms, tetanus 71
Bartonella (cat scratch disease) 494
B. henselae, uveitis and retinitis 276t43.1
B. quintana, vertebral osteomyelitis 254t40.1
 osteomyelitis, pediatric 348
 BCX-4430 antiviral 523–24
 bedbugs (*Cimex lectularius*) 88
 bedding and towels, scabies 89
 bed mite and dust mite infestations (*Dermatophagoides*) 89, 90, 90t13.4
 bedside ultrasound
 abscess 81
 peritonsillar abscess 133
see also POCUS
 Bell's palsy, Lyme disease 94t13.7, 105, 106t14.8
 benzathine penicillin G (Bicillin-LA, BPG)
 pharyngitis 132t20.4, 560t78.2
 syphilis 105t14.6, 215–16, 216t31.4
 benzocaine, acute otitis media 118
 benzodiazepines, muscle spasms, tetanus 70–71
 benzyl alcohol, human lice 93t13.6
 benzyl benzoate, scabies 89t13.3
 beta-agonists, bronchiolitis, pediatric 361t54.6
 beta-blockers, contraindicated, congestive heart failure myocarditis/pericarditis 13t2.4
 beta-hemolytic *Streptococcus*, plantar puncture wounds 246, 247t38.1

Index

- beta-lactamase inhibitors
 — properties and dosages 561–62
 calculous cholecystitis 148
 fight bite infections 234
 MSSA 561
 see also specific drugs
 beta-lactamases 552
 dental flora 135
 see also extended spectrum
 beta-lactamase
 beta-lactams (beta-lactam antimicrobials) 552
 — allergic reactions/toxicity 557
 — cross-reactivity 557
 — mechanism of action 557–60
 — properties and dosages 557–65
 advanced-generation, cephalosporins 564
 aminopenicillins 560t78.2
 anti-staphylococcal penicillins 560–61
 carbapenems 565
 cephalosporins 562–63, 564
 first-generation
 cephalosporins 562
 monobactams 565
 natural penicillins 560t78.2
 penicillin-beta-lactamase inhibitor combinations 561–62
 penicillins 560562t78.2
 second-generation cephalosporins 562–63
 severe drug reactions 109
 third- and fourth-generation
 cephalosporins 552, 563
 bichloroacetic acid, human papilloma virus 206t30.7
 Bicillin-LA *see* benzathine penicillin G
 biliary colic, acute calculous cholecystitis 146, 147
 biliary decompression, acute
 bacterial cholangitis 151–52, 152t23.5
 biliary diseases *see* acute bacterial cholangitis; *under* cholecystitis
 biliary intervention *see* ERCP intervention
 biliary obstructions *see* acute bacterial cholangitis
 biliary parasites 152–53
 acute bacterial cholangitis 152–53
 biliary scintigraphy, acute calculous cholecystitis 147–48
 biliary tree infections, fluoroquinolones 568–69
 biodefense, HICPAC infection control
 anthrax 488
 botulism 31
 tularemia 512
 biodefense, Working Group on
 Civilian Biodefense
 anthrax 480, 488
 botulism 26, 31
 plague 490
 smallpox 498
 tularemia 506, 512
 bioterrorism risks
 anthrax ix, 480, 481, 482f67.1, 488
 anthrax meningitis 483
 anthrax treatment, mass casualty setting 485–87
 botulism 26, 27, 31
 oculoglandular tularemia 508
 plague 490, 491
 pneumonia, uncommon causes 282
 pneumonic tularemia, risk assessment 513
 primary pneumonic plague 491
 smallpox 498, 499
 tularemia 506, 507–08, 512, 513
 see also mortality rates; *specific diseases*
 Biothrax 488
 BiPAP, congestive heart failure pericarditis/myocarditis 13t2.4
 bird mite (*Ornithonyssus*) infections 90, 90t13.4
 birth defect risks
 fever in pregnancy 386
 radiologic considerations 386
 Zika virus 527, 528
 bismuth subsalicylate, acute infectious diarrhea 176
 bite infections 369–74
 — microbiology 369
 — epidemiology 369–70
 — clinical features 371
 — laboratory and radiographic findings 371
 — treatment and prophylaxis 371–73, 372t56.1
 — complications and admission criteria 374
 — pearls and pitfalls 374
 cat bites 370, 371–73, 372t56.1
 cellulitis 373–74
 cephalosporins, first-generation, cautions 562
 children, treatment 371
 discharge instructions, non-infected bites 373
 dog bites 370, 371–73, 372t56.1
 exotic animal bites 369
 foul-smelling wounds 369
 Herpesvirus simiae (monkey B virus) 369
 human bites 369, 370, 371–73, 372t56.1
 infected wounds 373
 initial evaluation 370–71
 macaque monkeys 369
 MRSA coverage 374
 non-infected wounds 373
 physical evaluation 371
 rare systemic infections, human bites 371
 rat bite fever 369
 returning traveler 415t60.3
 rodent bite infections 369
 systemic diseases, non-infected bites 373
 wound care 373
 wound closure, non-infected bites 373
see also acute paronychia; cellulitis; felon infection; fight bite infections; purulent tenosynovitis; rabies; tetanus
 BiVADs (biventricular assist devices) 14
 biventricular assist devices (BiVADs) 14
 black fly bites, returning traveler 415t60.3
 black tar heroin users, IDU-associated infections
 drug and paraphernalia 435f61.2
 necrotizing soft-tissue infections 84, 434–35
 wound botulism 438
Blastocystis hominis diarrhea, HIV patients 182t27.2
Blastomyces, uveitis and retinitis 276t43.1
Blastomyces dermatiditis, HIV pulmonary infections 289t45.1
 blepharitis (eyelid infection) 266–67
 — epidemiology and microbiology 266–67, 267t42.1
 — clinical features 267
 — differential diagnosis 267
 — laboratory findings 267t42.1
 — treatment and prophylaxis 267
 — pearls and pitfalls 273
 dacryocystitis 266f42.3
 blindness 259, 261, 262
 keratitis 259, 261, 262
 malaria, cortical blindness 417
 onchocerciasis (river blindness) 261, 414t60.1
 orbital cellulitis (eyelid infections) 273
 variola major 501t69.1
 blood or body fluid exposure *see* exposure management, blood or body fluid
 bocavirus, influenza-like illnesses 301
 body lice (*Pediculus humanus corporis*) 91–92
 bone marrow suppression, ganciclovir caution 578
 bone probing, diabetic foot infections 228
 bone scan, distal lower extremities, osteomyelitis 245f37.4
 Boostrix vaccine, tetanus 71
Bordetella pertussis, community acquired bacteria, influenza 301
Borrelia, ANUG (Vincent's angina) 145
Borrelia burgdorferi (Lyme disease) 103–06
 chronic meningitis 60
 ticks/tick-borne illnesses 94t13.7
 uveitis and retinitis 276t43.1
Bortadella pertussis, in pregnancy 391
 botfly (*Dermatobia hominis*), myiasis 93, 95, 95t13.8, 96t13.9
 botulism 26–31
 — microbiology 26
 — epidemiology 26–27
 — clinical features 27–28
 — differential diagnosis 29
 — laboratory and radiographic findings 29–30
 — treatment and prophylaxis 30–31
 — complications and admission criteria 31
 — infection control and decontamination 31
 — pearls and pitfalls 31
 adult intestinal toxemia botulism 26, 28t5.1, 29
 aerosol pathogenicity 27
 antitoxin 30
 bed position 30f5.2
 beverage contamination risk 27
 biological weapon 26, 27
 botulinum toxin 26
C. botulinum 26
 foodborne botulism 26, 27–28, 28t5.1
 HICPAC 31
 iatrogenic botulism 26, 28t5.1, 29
 infant botulism 26, 28–29, 28t5.1, 29f5.1
 inhalational botulism 26, 27, 28, 28t5.1
 natural occurrences 26–27
 post-exposure prophylaxis 30–31
 reservoirs 26
 secondary infections 30
 supportive care 30
 transmission modes 26–27
 US occurrence 27
 vaccine 31
 water supply contamination risk 27
 Working Group for Civilian Biodefense 26, 31
 worldwide occurrence 27
 wound botulism 26, 28, 28t5.1
 wound botulism, IDU-associated 438–39
 BPG *see* benzathine penicillin G
 brackish water emersion, necrotizing soft-tissue infections 84
 brain abscess
 acute bacterial meningitis, differential diagnosis 55t8.4
 epidural abscess, likelihood 42
 focal cerebral dysfunction in HIV/AIDS patients 20t4.3
 spinal cord infections differential diagnosis 44
 see also intracranial abscess
 brain images, HSV-1 encephalitis 39f6.2
 BRAT diet, acute diarrhea 175, 184
 breakbone fever (historical) 417, 418
 breast abscess 410t59.4, 410t59.5
 British Thoracic Society (BTC), CURB-65 severity assessment tool 285–86

- bronchiolitis (pediatric respiratory infections) 361–62
 — epidemiology and microbiology 361, 361t54.6
 — clinical features 361
 — differential diagnosis 361
 — laboratory and radiographic findings 361–62, 361t54.6
 — treatment and prophylaxis 361t54.6, 362
 — complications and admission criteria 362
 — pearls and pitfalls 364
- bronchitis
 pharyngitis 130t20.1
 viral, in pregnancy 390t58.6
- bronchitis, acute exacerbations of chronic
 fluoroquinolones 568–69
 macrolides and ketolides 570
- bronchoplastic lung resection, anastomotic leak risks 455t63.3
- bronchospasm, zanamivir caution 578
- Brucella*
 chronic meningitis 60
 hematopoietic stem cell transplants, transfusion fever 462
 spinal epidural abscess 42
- Brucellosis, uveitis and retinitis 276t43.1
- buboes management, fluctuant, chancroid 218t31.6
- bubonic plague
 clinical features 492, 493
 differential diagnosis 493–94
 septicemic plague 492
- budesonide, croup 356t54.2, 357
- bulbo, ulcer accompanied by ruptured chancroid 217f31.15
- bullae 99, 340t52.1
- Bundibugyo ebolavirus 521
- Burkholderia*, cephalosporins, third- and fourth-generation 564
- calculous cholecystitis *see* acute calculous cholecystitis
- calicivirus, acute infectious viral diarrhea 170
- Campylobacter* diarrhea
 — microbiology and epidemiology 170–71
 — clinical features 173
 — treatment 173, 176–77
 — complications 171t26.3
 antibiotic therapy 177t26.10
 HIV patients 182t27.1, 182t27.2
 liver disease, adults with 171t26.3
 pregnant women, antibiotics 176–77
 travelers' diarrhea 171
 young adults 171t26.3
- Campylobacter jejuni* diarrhea 170–71, 170t26.1
 HIV patients 181, 182, 183t27.3, 184, 185t27.6
- campylobacteriosis diarrhea (“food poisoning”) 175t26.7
- CA-MRSA (community associated MRSA)
 — features 541, 542t75.1
 — epidemiology 541–42
 — clinical features 542–44
 — differential diagnosis 544
 — laboratory and radiographic findings 544–45
 — treatment and prophylaxis 544–46
 — infection control 546
 abscesses 79, 81, 544, 545
 ARDS (acute respiratory distress syndrome) 544
 bacteremia, suspected 545t75.4
 carbuncles 543
 cellulitis 543
 chest X-ray, CA-MRSA pneumonia 544t75.3
 coverage, infections requiring 545t75.4
 decolonization 545
 furuncles 542
 infections with a high prevalence 543t75.2
 infective endocarditis, IDU-associated 431
 infective endocarditis, suspected 545t75.4
 invasive infections, coverage requirements 545t75.4
 musculoskeletal infections 543t75.2
 necrotizing soft-tissue infections 84, 86, 543t75.2, 545t75.4
 osteomyelitis 543, 543t75.2, 545t75.4
 osteomyelitis, pediatric orthopedic infections 348
 Panton–Valentine leukocidin 79
 patient instructions, infection control 547
 pneumonia 545t75.4
 purulent cellulitis 543t75.2, 544, 545, 545t75.4
 pyomyositis 543, 543t75.2, 545t75.4
 risk factors 542, 547
 septic arthritis 543, 543t75.2, 544, 545t75.4
 skin abscess 545t75.4
 skin and soft-tissue infections 543t75.2, 544, 546, 547
 “spider bite” lesion (necrotic furuncle) 543, 543t75.2
 spinal epidural abscess 545t75.4
 surgical site infections 453
- CA-MRSA CAP *see* community-acquired pneumonia, CA-MRSA
- CA-MRSA coverage, acute care infections 545t75.4
- Canada, rickettsial infections 426t60.9
- Candidas *see* caspofungin
- Candida albicans*
 candidiasis 222
 chronic paronychia 236
- diarrhea, HIV patients 183t27.3
- echinocandins 577
- endophthalmitis 278t43.2
- otitis externa 114
- solid organ transplants 460t64.1
- Candida* infections
 acute bacterial cholangitis 152t23.5
 antifungal azoles 575
 antimicrobial consequences 557
 bacterial vaginosis 220
 candidiasis 222
 catheter-associated peritonitis 163
 CIED infections 14–15
 echinocandins 577
 fungal meningitis 58–59
 hematopoietic stem cell transplants, phase 1 infections 461
 immunocompromised patients, epidural abscesses 256t40.2
 infective endocarditis, IDU-associated 431
 keratitis 261t41.3
 meningitis, shunt infections 61
 neutropenic oncology patients 443t62.1, 446t62.5
 osteomyelitis, injection drug users 244
 pericarditis 7
 peripancreatic abscess 164
 sepsis 467
 supraglottitis (epiglottitis) 124t18.1
 urethritis (male infections) 192
 uveitis and retinitis 276t43.1
- candidiasis 222–23
 — epidemiology and microbiology 222
 — clinical features 222–23
 — differential diagnosis 223
 — laboratory findings 222–23, 223t32.5
 — treatment and prophylaxis 223
 — complications 223
 — infection control 223
 — pearls and pitfalls 223
- CAP *see* community-acquired pneumonia
- Capnocytophaga animorsus*
 cat bite infections 369
 dog bite infections 369
- captopril, congestive heart failure pericarditis/myocarditis 13t2.4
- carbamazepine
 hepatotoxicity 159t24.3
 severe drug reactions 109
- carbapenems
 — cross-reactivity 557
 — properties and dosages 565
 ESBL-producing organisms and infections 554
 exposure, VRE risk 549t76.1
 Lemierre's syndrome 139
 meningitis, shunt infections 61
 sepsis 471t65.8, 565
see also specific drugs
- carbuncles, CA-MRSA 543
- carcinomatous meningitis 46, 52
- cardia arrhythmias, West Nile virus infections 75
- cardiac arrest, tetanus 71
- cardiac block, Lyme disease 106t14.8
- cardiac disease patient, congenital intracranial abscess, initial therapy 37
- cardiac implantable electronic device infections (CIED infections) 14–16
 — epidemiology and microbiology 14–15
 — clinical features and presentation 15
 — differential diagnosis 15
 — laboratory findings 15
 — radiographic findings 16
 — treatment 16
 — complications and admission criteria 16
 — pearls and pitfalls 16
 mortality rates 16
 MRSA coverage 16
 osteomyelitis 16t3.2
 pathogenesis 14–15
 patient risk factors 15
Pseudomonas coverage 16
Staphylococcus 14–15, 16
- cardiac infections, classification 6
- cardiac tamponade
 myocarditis 12, 13t2.4
 pericarditis 10f2.3, 13t2.4
- Cardiobacterium hominis*, infective endocarditis 1
- cardiogenic shock
 myocarditis 12, 13t2.4
 pericarditis 13t2.4
- cardiopulmonary arrest, children 354
- cardiovascular disease patients, viral pneumonia 304
- carditis, Lyme disease 12
- caspofungin (Candidas) 576–77
 post-transplant, febrile, children 464t64.2
 severe sepsis 471t65.8
- cat bite infections
 — microbiology 371
 — epidemiology 370
 — treatment and prophylaxis 371–73, 372t56.1
 cellulitis risks 82t12.2
- cat exposure, toxoplasmosis 274
- cat flea rickettsiosis 426t60.9
- cat mite (*Cheyletiella*) 90
- cat scratch disease (*Bartonella*) 494
- cataract operations,
 endophthalmitis 277
- catheter-associated susceptibilities
 acute cystitis 322
 peritonitis 162–63, 163t25.1, 167t25.11
 VRE infections 549, 551
- CDAD (*Clostridium difficile*-associated diarrhea) 188
see also Clostridium difficile diarrhea; *Clostridium difficile* infection

Index

- CDC guidelines (Centers for Disease Control and Prevention)
 chlamydia 199
 gonorrhea 199
 HCV screening 155
 influenza updates 306
 malaria 418
 PEP resources 383
 pubic lice 91
 sexually transmitted diseases 199
 West Nile virus activity, endemic regions 77
- CDC guidelines, TB tests and treatment
 HIV patients 316
 latent tuberculosis 312t47.2
 pulmonary tuberculosis 311
 tuberculosis 312
- CDI *see Clostridium difficile* infection
- cefazolin (Kefzol)
 — activity spectrum 557–59
 — properties and dosages 562
 cellulitis 84t12.3
 infective endocarditis 562
 MSSA osteomyelitis, antibiotics 243t37.1
 open fractures 241t36.1
 osteomyelitis 562
 vertebral osteomyelitis 254t40.1
- cefdinir
 acute otitis media 118, 119t16.3
 pneumonia, pediatric 364t54.8
- cefepime (Maxipime)
 — activity spectrum 557–59
 — properties and dosages 563
 acute bacterial cholangitis 152t23.5
 acute calculous cholecystitis, resuscitation 149t23.2
 febrile post-transplant patients 464t64.2
 health-care-associated CAP 284t44.3
 intracranial abscess 37t6.4
 meningitis, shunt infections 61
 oncology patients 449–50
 plantar puncture wounds 248, 248t38.2
 severe sepsis 471t65.8
 spinal epidural abscess 47t7.3
- cefixime
 gonorrhea 203t30.4
 urinary tract infections, febrile child 337t51.1
- cefotaxime (Claforan)
 — properties and dosages 563
 acute bacterial meningitis, neonates 58t8.9
 disseminated gonococcal infection 107t14.9
 epiglottitis, pediatric respiratory infections 355t54.1
 fever, neonates 332
 HIV pulmonary infections 294
 intracranial abscess 37t6.4
 Lyme disease, cardiac second- or third-degree block 106t14.8
 meningitis, febrile child/neonate 337t51.1
 meningococcemia (meningococcal disease) 101t14.2
 neonates, meningitis 336, 337t51.1
 pelvic inflammatory disease 204t30.6
 spontaneous bacterial peritonitis 167t25.11
 supraglottitis (epiglottis) 124
 cefotaxime (Claforan), epiglottitis infection, pediatric 355t54.1
 cefotetan (Cefotan)
 — properties and dosages 562–63
 postpartum endometritis 407t59.1
 ceftioxin (Mefoxin)
 — activity spectrum 557–59
 — properties and dosages 562–63
 appendectomy in pregnancy 392t58.7
 chorioamnionitis 394t58.8
 pelvic inflammatory disease 204t30.6
 postpartum endometritis 407t59.1
 cefpodoxime, acute otitis media 118, 119t16.3
 cefprozil (Cefzil) 562t78.10
 ceftaroline (Teflaro) 564
 ceftazidime
 — activity spectrum 557–59
 — cross-reactivity 557
 — properties and dosages 563
 catheter-associated peritonitis 167t25.11
 meningitis, shunt infections 61
 oncology patients 449–50
 plantar puncture wounds 248
 post-transplant, febrile, children 464t64.2
 septic arthritis and osteomyelitis, IDU-associated 437t61.8
 ceftazidime–avibactam (Avycaz)
 — properties and dosages 563
 ESBL-producing organisms and infections, clinical issues 554t77.3
 Ceftin *see* cefuroxime
 ceftizoxime, disseminated gonococcal infection 107t14.9
 ceftolozane–tazobactam (Zerbaxa), properties and dosages 564
 ceftotaxime, pneumonia, neonates 332
 ceftriaxone (Rocephin)
 — activity spectrum 557–59
 — development 552
 — properties and dosages 563
 acute bacterial cholangitis 152t23.5
 acute bacterial diarrhea 177t26.10
 acute bacterial meningitis 58t8.9
 acute bacterial prostatitis 197t29.5
 acute calculous cholecystitis, resuscitation 149t23.2
 acute chest syndrome, in sickle cell disease 476t66.2
 acute chest syndrome, in sickle cell disease, children 476
 acute otitis media 118, 119t16.3
 bacteremia and sepsis, in sickle cell disease 475t66.1
 bacterial tracheitis, pediatric 358, 358t54.3
 bite infections 372t56.1
 cardiac second- or third-degree block, Lyme disease 106t14.8
 chancroid 218t31.6
 community-acquired pneumonia 284t44.3
 disseminated gonococcal infection 107t14.9
 enteric fever 424, 424t60.8
 epididymitis 196t29.4
 epiglottitis infection, pediatric 355t54.1
 febrile child 337t51.1
 gonorrhea 203t30.4
 HIV pulmonary infections 294
 infective endocarditis 4t1.2, 5t1.3
 infective endocarditis, prevention 143
 intracranial abscess 37t6.4
 Lyme disease, cardiac block 106t14.8
 meningitis chemoprophylaxis 62t8.13
 meningococcemia (meningococcal disease) 101t14.2
 musculoskeletal infections, pediatric 352t53.4
 pelvic inflammatory disease 204t30.6
 pneumonia, pediatric 364t54.8
 pyelonephritis, in adults 326t49.2
 pyelonephritis, in pregnancy 389t58.4
Salmonella diarrhea, HIV patients 185t27.6
 secondary peritonitis 167t25.12
 septic arthritis, adults 226t33.1
 severe sepsis 471t65.8
Shigella diarrhea, HIV patients 185t27.6
 spinal epidural abscess 47t7.3
 spontaneous bacterial peritonitis 167t25.11
 supraglottitis (epiglottis) 124
 urethritis (male infections) 194t29.2
Yersinia enterocolitica diarrhea 177t26.10
 cefuroxime (Ceftin)
 — activity spectrum 557–59
 — properties and dosages 562–63
 acute otitis media 118, 119t16.3
 Lyme disease 106t14.8
 supraglottitis (epiglottis) 124
 cefuroxime axetil, Lyme disease 106t14.8
 Cefzil *see* cefprozil
 cellulitis 80t12.1, 82–84
 — epidemiology and microbiology 82
 — clinical features 82–83
 — differential diagnosis 82–83
 — laboratory and radiographic findings 83
 — treatment and prophylaxis 80, 81f12.5, 83–84
 — complications and admission criteria 84
 abscess/cellulitis/NSTI differentiation 82
 around abscess 80, 80f12.4, 81f12.5, 82
 bite infections 82t12.2, 373–74
 CA-MRSA 543
 deep neck space infections 137
 erysipelas 82
 IDSA recommendations 83, 84
 lymphangitis 83f12.8
 MRSA coverage 83–84
 non-purulent cellulitis 82f12.7, 84t12.3
 penicillin-allergic patients 83
 peritonsillar, young children 133
 plantar puncture wounds 247, 247t38.1, 248t38.2
 post-operative infections (surgical site infections) 453
 purulent cellulitis 80, 81f12.5, 83, 84t12.3
 risk factors and pathogens 82t12.2, 86
 systemic toxicity 82, 83
see also orbital and periorbital cellulitis
 Centers for Disease Control and Prevention *see* CDC guidelines
 central America, rickettsial infections 426t60.9
 central Asia, rickettsial infections 426t60.9
 central nervous system dysfunction, severe sepsis 468t65.2
 central nervous system infections (CNS infections)
 botulism differential diagnosis 29
 HIV/AIDS patients, initial treatment 24t4.6
 central nervous system infections, neutropenic oncology patients
 — clinical features 446
 — differential diagnosis 448
 — laboratory findings 446t62.6
 — treatment 446t62.6
 cephalixin (Keflex)
 — properties and dosages 562
 acute cystitis 320t48.1
 acute paronychia 237t35.3
 breast abscess 410t59.5
 cellulitis 84t12.3
 cystitis, in pregnancy 389t58.4
 diabetic foot infections, mild to moderate infections 230t34.1
 felon 237t35.3
 lower urinary tract infection 320t48.1
 mastitis 410t59.5
 pharyngitis 132t20.4
 plantar puncture wounds 248t38.2
 urinary tract infections, febrile child 337t51.1

Index

- cephalic tetanus 70
 cephalosporin–betalactamase inhibitors 554
 cephalosporins
 — activity spectra 558t78.1
 — cross-reactivity 118, 557
 acute otitis media 118, 119t16.3, 562t78.10
C. difficile colitis 172
 caution, community-acquired pneumonia 563
 community-acquired pneumonia 563, 564
 exposure, VRE risk 549t76.1
 meningitis, shunt infections 61
 in pregnancy 388
 cephalosporins, advanced-generation
 — properties and dosages 564
 ESBL-producing organisms and infections 564
 cephalosporins, first-generation
 — properties and dosages 562
 bite infections, cautions 562
 postpartum endometritis 408
 cephalosporins, second-generation
 — properties and dosages 562–63
 fight bites 234
 sinusitis 562–63
 cephalosporins, third-generation
 — development 552
 acute otitis media 119t16.3
 cautions 564
 ESBL-producing organisms and infections 552
 fight bites 234
 Lemierre's syndrome 138t21.2, 139
 supraglottitis (epiglottitis) 124
 cephalosporins, third- and fourth-generation
 — properties and dosages 563
 acute calculous cholecystitis 148
 infective endocarditis 563
 osteomyelitis, dosage 563
 sepsis 563
 severe sepsis 471t65.8
 spinal epidural abscess 47
 cerebral dysfunction, diffuse, HIV/AIDS patients 19
 cerebral dysfunction, focal, HIV/AIDS patients 19–20
 see also fever and focal cerebral dysfunction
 cerebral malaria 416–17
 cerebral toxoplasmosis, in HIV/AIDS patients
 altered mental status 22t4.5, 23f4.1, 24t4.6
 CNS infections, initial treatment 24t4.6
 CT scan 23f4.1
 focal cerebral dysfunction in HIV/AIDS patients 20t4.3
 HIV-related brain disorders, neuroimaging 22t4.5
 cervicitis, acute
 chlamydia (STDs) 200
 gonorrhea 200–02
 cervix, strawberry 221
 cesarean section
 chorioamnionitis 394t58.8, 395
 endometritis prophylaxis 408
 hepatitis B virus 399
 hepatitis C virus 400
 herpes simplex virus 398, 399t58.12
 HIV patients 402
 postpartum endometritis 406, 408
 septic pelvic thrombophlebitis 408
 SSI risks 453
 Chagas' disease, solid organ transplants 460t64.1
 chalazia (eyelid infection) 268
 chancres, primary syphilis 212
 chancroid 216–18
 — epidemiology and microbiology 216–17
 — clinical features 217
 — differential diagnosis 217
 — laboratory and radiographic findings 217, 217t31.5
 — treatment and prophylaxis 217–18
 — complications and admission criteria 217–18
 — infection control 218
 — pearls and pitfalls 218
 fluctuant buboes management 218t31.6
 HIV patients 218t31.6
 HIV transmission and acquisition risk 217
 incubation periods 217t31.5
 pregnant women 218t31.6
 ulcer accompanied by ruptured bulbo 217f31.15
 Charcot arthropathy, diabetic foot infections 231
 Charcot's triad, acute bacterial cholangitis 150
 chemical meningitis 52
 chemoprophylaxis, novel influenza A 537–39
 chemotherapeutic agent effects, oncology patients 442, 443
 chemotherapy, combination, tuberculosis 313, 317
 chemotherapy patients, hepatitis B virus 160
 chest pain, differential diagnosis 7–8
 chest X-rays
 CA-MRSA pneumonia 544f75.3
 myocarditis 9f2.1
 pregnant women 403–04
Cheyletiella mite infestations 90
 chickenpox (varicella)
 otitis externa 115t15.1
 see also varicella-zoster virus
 chiggers (*Eutrombicula alfreddugesi*) 90, 90t13.4
 Chikungunya (fever in the returning traveler) 417, 425
 childcare contacts, meningococcal disease, infection control 111
 children
 acute bacterial meningitis 50–52, 58t8.9
 acute malaria treatment 419t60.5
 acute otitis media 118t16.2
 acute otitis media, cleft palates 117
 antimalarial regimens 420t60.6
 bacteremia and sepsis, in sickle cell disease 474, 475t66.1
 bite infections 371
 cerebral malaria 416
 cleft palates, acute otitis media 117
 conjunctivitis 260t41.1
 contiguous otitis 33
 with cystic fibrosis, risks, sinusitis 120
 dacryocystitis, periocular infections (eyelid infections) 270t42.5
 deep neck space infections 135
 dengue fever, pulse pressure 421, 423
 ESBL-producing organisms and infections, antibiotics 554t77.3
 fever *see* febrile child
 fever and rash *see* pediatric fever and rash
 fever and rash differential diagnosis 100t14.1
 HCPS (hantavirus cardiopulmonary syndrome) 518t71.3, 519t71.4
 head lice treatment 92–93
 hepatitis A virus, transmission 157
 hepatitis E virus 158
 herpetic whitlow 237
 HSV-1 encephalitis 38
 infective endocarditis 4t1.2, 5t1.3
 intracranial abscess 33
 keratitis, bacterial 262
 meningitis, acute bacterial 58t8.9
 meningitis chemoprophylaxis 62t8.13
 meningococcal disease, infection control 111
 myocarditis 11, 12–13
 necrotizing soft-tissue infections 84
 older, febrile 336
 otitis externa 114
 pericarditis, initial treatment 10t2.3
 pericoronitis 144
 periocular and orbital cellulitis, treatment 272t42.7
 peritonsillar abscess 134
 peritonsillar cellulitis 133
 pharyngitis 129, 132
 plantar puncture wounds 248
 pneumonia, treatment 364t54.8
 post-transplant, febrile, treatment 464t64.2
 Rocky Mountain spotted fever 101t14.3
 with sickle cell disease, *H. influenzae* bacteremia 474
 supraglottitis (epiglottitis) 123–24
 tetracyclines, cautions 571
 ticks/tick-borne illnesses 93
 toxic shock syndrome 84
 tuberculosis, clinical features 310
 tuberculosis, first-line antituberculosis drugs 313t47.3
 tularemia, treatment and PEP 512t70.4
 varicella infection 84
 Zika virus 528, 530
 see also acute chest syndrome, in sickle cell disease; acute otitis media; infants; neonates; pediatric orthopedic infections
 children, acute infectious diarrhea antimotility agents 175
 bismuth subsalicylate 176
 Campylobacter diarrhea 171t26.3
 chronic diarrhea, EAEC 171–72
 chronic parasitic diarrhea 173–74
 Cryptosporidium diarrhea 173–74
 EHEC HUS complication 172
 rotavirus, severe diarrhea 170, 170t26.2
 Salmonella diarrhea 171
 Shigella diarrhea, treatment 177t26.10
 V. cholerae diarrhea, treatment 177t26.10
 children with diarrhea, exposure to ova and parasite testing 175t26.8, 178
 China
 novel influenza A 539
 ricketsial infections 426t60.9
 chlamydia 199–200
 — epidemiology and microbiology 199
 — clinical features 199–200
 — differential diagnosis 200
 — laboratory and radiographic findings 200t30.1
 — treatment 200
 — complications and admission criteria 200
 — pearls and pitfalls 206–07
 CDC guidelines 199
 cervicitis, acute 200
 fever and rash, in adults 107
 fever in the newborn 332
 infection control 111
 NAAT testing 196, 200t30.1
 neonates, erythromycin, conjunctivitis 260t41.2
 chlamydia co-infections
 epididymitis 196
 gonorrhea 104, 194, 196
Chlamydia pneumoniae
 acute chest syndrome, in sickle cell disease 474, 476
 atypical bacteria, influenza-like illnesses 301
 susceptibility, sickle cell disease 473
Chlamydia trachomatis 199, 200t30.1
 acute bacterial prostatitis 196–97
 conjunctivitis 259, 260t41.1, 262
 epididymitis 195, 195t29.3
 macrolides and ketolides 570
 NAAT testing 196, 200t30.1
 non-gonococcal urethritis 192, 193t29.1, 202, 203t30.5

Index

- Chlamydia trachomatis* (cont.)
 pelvic inflammatory disease 202–03
 pneumonia 362
 pyelonephritis, adults 324
Chlamydophila, pharyngitis 129
Chlamydophila pneumoniae
 — antibacterials, commonly used 557–59
 community-acquired pneumonia 280
 pharyngitis 130t20.1
Chlamydophila psittaci, pharyngitis 130t20.1
 chloramphenicol
 anthrax 486t67.3
 enteric fever 424t60.8
 plague 495t68.4
 Rocky Mountain spotted fever 101t14.3
 supraglottitis (epiglottitis) 124
 tularemia 511–12
 chlorhexidine gluconate (Peridex)
 pericoronitis 144
 periodontal infections 144, 144t22.2
 chloroquine, malaria, in pregnancy 403t58.17
 chloroquine phosphate (Aralen and generic)
 acute malaria 419t60.5
 prophylactic antimalarial regimens 420t60.6
 chlorpromazine, muscle spasms, tetanus 71
 cholangitis *see* acute bacterial cholangitis
 cholecystectomy
 acute bacterial cholangitis 152t23.5
 acute calculous cholecystitis 148–49, 149t23.2
 cholecystitis, abdominal pain differentiation 165–66
see also acute calculous cholecystitis
 cholecystitis and cholangitis, in sickle cell disease 478
 — differential diagnosis 478
 — laboratory and radiographic findings 478
 — complications and admission criteria 478
 — pearls and pitfalls 478–79
 abdominal pain differentiation 478
 choledocholithiasis (Mirizzi's syndrome)
 acute bacterial cholangitis 150
 acute calculous cholecystitis 146
 cholelithiasis, acute bacterial 150
 cholera *see* *Vibrio cholerae* diarrhea
 chorioamnionitis 393–95
 — epidemiology and microbiology 393
 — clinical features 393
 — differential diagnosis 393
 — laboratory and radiographic findings 393
 — treatment 393–95, 394t58.8
 — complications and admission criteria 395
 — infection control 395
 — special considerations 395
 — pearls and pitfalls 403–04
 cesarean section 394t58.8, 395
Listeria infection 394t58.8, 395
 chorioretinitis
 uveitis and retinitis 275f43.2
 West Nile virus infections 75
 chronic bronchitis, acute
 exacerbations of
 fluoroquinolones 568–69
 macrolides and ketolides 570
 chronic diarrhea
 children, EAEC 171–72
 definition 182
 ova and parasite testing 175t26.8, 178
 parasitic 173–74
 chronic diarrhea in HIV, causes 183t27.3
 chronic hepatitis 156–57
 hepatitis B virus 155, 156–57
 hepatitis C virus 155–56, 158, 159, 160
 hepatitis D virus 156
 chronic liver disease patients, viral hepatitis 158
 chronic liver disease, viral hepatitis 161
 chronic osteomyelitis 242, 244
 chronic paronychia 236
 chronic parotitis 126
 chronic pulmonary disease patients, viral pneumonia 304
 chronic sinusitis 120
 chronic ulcers, acute VRE infections 548–49
 CIEDs *see* cardiac implantable electronic device infections
 cilastin, ESBL-producing organisms and infections 554t77.3
Cimex lectularius (bedbugs) 88
 ciprofloxacin (Cipro)
 — activity spectrum 557–59
 — properties and dosages 568–69
 acute bacterial cholangitis 152t23.5
 acute bacterial prostatitis 197t29.5
 acute calculous cholecystitis, resuscitation 149t23.2
 acute cystitis 320t48.1
 anthrax 486t67.3
 bacterial keratitis 262
 bite infections 372t56.1
C. jejuni diarrhea, HIV patients 185t27.6
Campylobacter diarrhea 177t26.10
 diarrhea, acute bacterial 177t26.10
 enteric fever, pediatric patients 424t60.8
 fight bites 234t35.1
 infective endocarditis 41t.2
 meningitis chemoprophylaxis 62t8.13
 meningococcal disease (meningococcemia) 101t14.2
 oncology patients 449–50
 plague 495t68.4
 plantar puncture wounds 248t38.2
 purulent tenosynovitis 236t35.2
 pyelonephritis, adults 326t49.2
Salmonella diarrhea 177t26.10
Salmonella diarrhea, HIV patients 185t27.6
 secondary peritonitis 167t25.12
 septic arthritis, adults 226t33.1
Shigella diarrhea 177t26.10
Shigella diarrhea, HIV patients 185t27.6
 tularemia 511–12
Y. enterocolitica diarrhea 177t26.10
 circumcised boys, fever in the newborn 329
 cirrhosis, viral hepatitis 156–57
Citrobacter
 — antibacterial drug spectra 558t78.1
 — antibacterials, commonly used 557–59
 cephalosporins, third- and fourth-generation 563
Citrobacter freundii, ESBL production 553t77.1
 Claforan *see* cefotaxime
 clarithromycin (Biaxin)
 — properties and dosages 570
 community-acquired pneumonia 283t44.2
 pertussis, pediatric 360–61, 360t54.5
 sinusitis 121t17.3
 clean/clean-contaminated (operation sterility) 454t63.2
 cleft palates, acute otitis media 117
 clenched fist injury *see* fight bite infections
 clindamycin (Cleocin)
 — activity spectrum 557–59
 — cautions, *C. difficile* 572
 — exposure, VRE risk 549t76.1
 — properties and dosages 571–72
 — resistance, *Eikenella corrodens*, fight bites 234
 abscess 81
 acute necrotizing ulcerative gingivitis 145
 acute otitis media 118, 119t16.3
 acute paronychia 237t35.3
 altered mental status, HIV patients 24t4.6
 anthrax 486t67.3
 bacterial vaginosis 221
 bite infections 372t56.1
 breast abscess 410t59.5
C. difficile colitis 172, 572
 CA-MRSA coverage 545t75.4
 cellulitis 84t12.3
 chorioamnionitis 394t58.8
 deep mandibular space infections 142t22.1, 143
 deep neck space infections 137
 diabetic foot infections, mild to moderate 230t34.1
 diarrhea risk 572
 felon 237t35.3
 fight bites 234, 234t35.1
 hepatotoxicity 159t24.3
 infective endocarditis 5t1.3
 infective endocarditis, prevention 143
 Lemierre's syndrome 138t21.2, 139
 malaria 419t60.5
 malaria, in pregnancy 403t58.17
 mastitis 410t59.5
 MRSA susceptibilities 545t75.3
 necrotizing soft-tissue infections 86
 open fractures 241t36.1
 pelvic inflammatory disease 204t30.6
 periapical abscess 142t22.1, 143
 periodontal infections 144, 144t22.2
 peritonsillar abscess 134t20.5
 pharyngitis 132t20.4
 plantar puncture wounds 248t38.2
Plasmodium 419t60.5
Pneumocystis pneumonia (PCP), HIV 296t45.6
 postpartum endometritis 407t59.1, 408
 pulpitis 142–43
 retropharyngeal abscess, pediatric 359, 359t54.4
 subcutaneous abscess, IDU-associated 434
 supraglottitis (epiglottitis) 124
 toxic shock syndrome 102t14.4
 Clinical and Laboratory Standards Institute (CLSI)
 vancomycin resistance definition 549
Clonorchis, acute parasitic cholangitis 153
Clonorchis sinensis, parasitic cholangitis 153, 153t23.6
 clopidogrel, hepatotoxicity 159t24.3
Clostridium
 brain abscess 34t6.2
 necrotizing soft-tissue infections 84
 necrotizing soft-tissue infections, IDU-associated 435t61.5
 open fractures 240
Clostridium botulinum 26
 wound botulism, IDU-associated 438, 439t61.11
Clostridium difficile, antimicrobial agents
 — antibacterial drug spectra 558t78.1
 antimicrobial consequences 557
 antimicrobial drug range 557–59
 cephalosporins, third-generation, cautions 564
 clindamycin cautions 572
 glycopeptides 566–68
 macrolides and ketolides 570
 nitroimidazoles 573

Index

- Clostridium difficile* diarrhea
 — microbiology 172
 — clinical features 170t26.1, 173t26.4
 — treatment 170t26.1, 173t26.4
 antibiotic therapy 177t26.10
 isolation, hospitalized patients 178
 post-operative infections, antibiotic associated 456
 toxin screening 174
 transmission modes 173t26.4
- Clostridium difficile* diarrhea, HIV patients
 — microbiology 181
 — clinical features 182
 — infection control 186
 acute bacterial infections 182t27.2
 anti-motility agents, complications risk 186
 CD4 counts 183t27.4
 large bowel diarrhea 182t27.1
 medication exposures 181, 184
 persistent infections 183t27.3
- Clostridium difficile* infection (CDI) 188–90
 — microbiology 188
 — epidemiology 188
 — clinical features 189
 — differential diagnosis 189
 — laboratory and radiographic findings 189
 — treatment and prophylaxis 189
 — complications and admission criteria 189–90
 — infection control 190
 — pearls and pitfalls 190
- American College of Gastroenterology, definitions 189t28.1
- colitis 446
- colitis, solid organ transplants 459
- FMT (fecal microbiota transplant) 189, 190
- mild to moderate infections 189t28.1, 190t28.2
- NAP1/BI/027 epidemic strain 188
- recurrent infections 189t28.1
- severe complicated 189–90, 189t28.1, 190t28.2
- stool tests 189, 190
- vancomycin recommendation 189, 190
- Clostridium perfringens*
 food poisoning, HIV patients 182
- necrotizing soft-tissue infections 84
- necrotizing soft-tissue infections, IDU-associated 434–35, 435t61.5
- open fractures 240
- post-operative antibiotic-associated diarrhea 456
- Clostridium sordellii*
 necrotizing soft-tissue infections 84
- necrotizing soft-tissue infections, IDU-associated 434–35, 435t61.5
- Clostridium tetani* 69, 70t10.1
 plantar puncture wounds 247
- spinal epidural abscess 44
- tetanus, IDU-associated 439
see also tetanus
- clotrimazole, candidiasis 223t32.6
- CLSI (Clinical and Laboratory Standards Institute)
 vancomycin resistance definition 549
- CMV *see under* cytomegalovirus
- CNS *see under* central nervous system
- coagulase-negative *Staphylococcus*, blepharitis 267t42.1
- cobicistat, diarrhea effect 183t27.5
- cocaine effects, AMS differential diagnosis 19t4.2
- Coccidioides*, influenza-like illnesses 301
- Coccidioides immitis*
 fungal meningitis 58
 solid organ transplants 460t64.1
- colchicine, pericarditis 10t2.3
- colectomy, anastomotic leak risks 455t63.3
- colitis, *C. difficile* infection 446
- Colorado tick fever 94t13.7
- combination antiretroviral therapy (ART), HIV/AIDS patients 18
- combination chemotherapy, tuberculosis 313, 317
- combivir, HIV PEP regimens, occupational 379t57.5
- community-acquired pneumonia (CAP) 280–86
 — microbiology 280–81, 281t44.1
 — epidemiology 281
 — clinical features 281
 — differential diagnosis 282
 — laboratory and radiographic findings 281t44.1, 282
 — treatment 283–84
 — complications and admission criteria 283–86
 — special considerations 286
 — pearls and pitfalls 286
- advanced-generation cephalosporins 564
- bacterial 281
- cephalosporins 563, 564
- cephalosporins, caution 563
- CURB-65 severity assessment tool 285–86
- elderly patients 281, 281t44.1, 286
- fluoroquinolones 568–69
- fluoroquinolones warning 283
- health-care-associated 280, 283, 284t44.3, 286
- ICU patients, therapy 284t44.3
- influenza, suspected, treatment 284t44.3
- inpatient therapy 284t44.3
- macrolides and ketolides 570
- mortality rates 281, 285, 285t44.5
- MRSA CAP 280
- nursing home residents, special considerations 286
- outpatient therapy 283, 283t44.2
- pneumonia severity index 285, 285f44.1, 285t44.5
- pregnant women, treatment 283t44.2
- second-generation cephalosporins, caution 563
- sepsis or septic shock 281t44.1
- sputum studies 282, 544
- tetracyclines and glycyclines 571
- third- and fourth-generation cephalosporins 563
- tuberculosis differential diagnosis 281
- vaccine recommendation 284t44.4
- community-acquired pneumonia, CA-MRSA (CA-MRSA CAP)
 — clinical features 543–44
 — treatment 283, 284t44.3
 — complications and admission criteria 546
 — pearls and pitfalls 547
- chest X-ray 544f75.3
- following influenza virus infection 280
- mortality rates, CAP 546
- post-influenza CAP 280, 543t75.2
- prevalence levels 543t75.2
- sputum culture value 544
- community-onset MRSA 542t75.1
- complete blood count (CBC), viral hepatitis 158
- computed tomography *see* CT scans
- condyloma accuminata (genital wart) 205, 207f30.2
- condyloma lata, female genitalia 215f31.14
- condyloma lata, on the scrotum 215f31.13
- congenital herpes infection
 neonates 212
- congestive heart failure
 myocarditis 12
 pericarditis 13t2.4
- conjunctiva 258
- conjunctival and corneal eye infections 258–62
 — general points 258
 — pearls and pitfalls 262
- conjunctivitis 258–59, 262
- eye anatomy 259f41.1
- keratitis 259–62
- Neisseria* complications 259
see also specific disorders
- conjunctivitis 258–59
 — epidemiology and microbiology 258
 — clinical features 258–60
 — differential diagnosis 258
 — laboratory and radiographic findings 258
 — treatment 258–60
 — complications and admission criteria 259
 — pearls and pitfalls 262
- allergic conjunctivitis, treatment 259
- bacterial conjunctivitis, treatment 259
- children 260t41.1
- contact lens wearers 258–59
- eye anatomy 259f41.1
- gonorrheal 201, 203t30.4, 259, 260t41.1, 261f41.3, 262
- neonates 260t41.1, 262
- sexual abuse, suspected 260t41.1
- viral conjunctivitis, treatment 259
- connective tissue diseases, fever and rash differential diagnosis 100t14.1
- constipation, abdominal pain differentiation 165–66
- contact lens wearers
 conjunctivitis 258–59, 260t41.2
- keratitis 259, 261t41.3
- contained casualty setting, tularemia 511
- contaminated environments, open fractures 240
- Cooperative Study of Sickle Cell Disease (CSSCD) trial, acute chest syndrome 475
- COPD (chronic obstructive pulmonary disease) patients, zanamivir caution 578
- Cordylobia anthropophaga* (tumbu fly), myiasis 95t13.8, 96t13.9
- cornea 258
- coronavirus, pharyngitis 130t20.1
- corticosteroids (prednisone, methylprednisolone)
 allergic fungal sinusitis 121
- enteric fever 424t60.8
- oncology patients 445, 450
- post-transplant patients 466t64.4
- septic shock 470
- sinusitis 121t17.3
- supraglottitis (epiglottitis) 124
- corticosteroids, croup 357
- Corynebacteria*, deep neck space infections 135
- Corynebacterium diphtheriae*, pharyngitis 130t20.1
- cough, causes 281t44.1
- Coxiella burnetii* (rickettsial infections) 426t60.9
- coxsackievirus
 myocarditis 11
- parotitis 126, 127t19.1
- pericarditis 6
- pharyngitis 129
- coxsackievirus differentiation, fever in pregnancy 396
- cranial nerve involvement, sinusitis 122
- Cresemba *see* isavuconazole
- cross-reactivity between drugs
 beta-lactams 557
- carbapenems 557
- ceftazidime 557
- cephalosporins 118, 557
- fluoroquinolones 557
- crotamiton (Eurax), scabies 89t13.3

Index

- croup (laryngotracheobronchitis) 356–57
 — microbiology 356t54.2
 — epidemiology and microbiology 356
 — clinical features 356
 — differential diagnosis 356
 — laboratory and radiographic findings 356–57, 356t54.2
 — treatment and prophylaxis 356t54.2, 357
 — complications and admission criteria 357
 — pearls and pitfalls 364
 pharyngitis 130t20.1
 viral croup with steeple sign 357f54.2
- cruise ships
 influenza checks 300
 norovirus diarrhea 170
- crusted/Norwegian scabies 88, 88t13.2
- cryotherapy, human papilloma virus 206t30.7
- cryptococcal meningitis
 amphotericin B 577
 echinocandins caution 577
 HIV/AIDS patients 214t4.4, 22t4.5, 24t4.6
 neuroimaging, HIV brain disorders 22t4.5
- Cryptococcus*
 fungal causes, influenza-like illnesses 301
 spinal epidural abscess 42
 uveitis and retinitis 276t43.1
- Cryptococcus neoformans*
 fungal meningitis 58
 HIV pulmonary infections 289, 289t45.1, 290, 293–94, 294t45.4
 pyelonephritis, adults 324
 solid organ transplants 460t64.1
 spine infections, epidural abscesses 256t40.2
- cryptogenic hepatitis 155
- cryptosporidiosis 175t26.7
- cryptosporidiosis diarrhea, HIV patients 183t27.3
- Cryptosporidium* diarrhea 173–74, 174t26.5, 178t26.12
- Cryptosporidium parvum* diarrhea, AIDS patients 170t26.1
- Cryptosporidium* diarrhea, HIV patients
 — clinical features 181, 182
 — pearls and pitfalls 186
 CD4 counts 183t27.4, 186
 massive volume loss 186
 persistent and chronic diarrhea 183t27.3, 186
 small bowel diarrhea 182t27.1
- CSF (cerebral spinal fluid) studies and interpretation
 aseptic and viral meningitis 56–57
- CT scans (computed tomographic scans)
 abscess, deep or intramuscular 81
 acute calculous cholecystitis 148
- cerebral toxoplasmosis, in HIV/AIDS patients 23f4.1
- fetal exposures, estimated 387t58.1
- HIV pulmonary infections 291
- oncology patients, lumbar punctures 446
- primary CNS lymphoma, HIV patients 23f4.2
- renal pathology 325
- viral hepatitis 159
- Cubicin *see* daptomycin
- Culex*, mosquito transmissions, West Nile virus infections 74
- CURB-65 severity assessment
 community-acquired pneumonia 285–86
 HIV pulmonary infections 295, 296t45.7
- cutaneous anthrax 482, 484, 485, 488
- cutaneous furuncle (superficial skin abscess) 80f12.3
- cutaneous myiasis, in papule
 diagnosis 96t13.10
- Cyclospora cayetenensis* diarrhea
 acute infectious parasitic diarrhea 174, 174t26.5, 178t26.12
 TMP-SMX 178t26.12
- Cyclospora* diarrhea, HIV patients 183t27.3
- cyclosporiasis (*Cyclospora* infection) diarrhea 175t26.7
- cyclosporine (Gengraf, Neoral, Restasis, Sandimmune)
 nephrotoxicity 465t64.3
 post-transplant patients 466t64.4
- cysticercosis, uveitis and retinitis 276t43.1
- cystitis, acute *see* lower urinary tract infection, in adults
- cystitis, in pregnancy
 prophylaxis in pregnancy 389t58.5
 pyelonephritis risk associated with 387–88
 treatment in pregnancy 388, 389t58.4
- cystitis vs. pyelonephritis, in pregnancy
 — clinical features 388t58.2
 — differential diagnosis 388
 — laboratory diagnosis 388
- Cystoisospora belli* diarrhea, HIV patients 183t27.3
- Cystoisospora* diarrhea, HIV patients 185t27.6
- cytomegalovirus (CMV)
 diarrhea, HIV patients 182, 183t27.3
 encephalitis, HIV/AIDS patients, initial treatment 24t4.6
 febrile post-transplant patients 462
 focal signs and symptoms 38
 ganciclovir 578
 hematopoietic stem cell transplants 462
 HIV pulmonary infections 288, 289, 289t45.1, 294t45.4
 keratitis 261t41.3
- mononucleosis, pharyngitis 130t20.1
- myocarditis 11
- parotitis 126, 127t19.1
- radiculitis, AIDS patients, differential diagnosis 44
- retinitis 274–75
- solid organ transplants 459–60, 460t64.1, 461
- uveitis and retinitis 274, 276t43.1
- ventriculoencephalitis, in HIV/AIDS patients 20t4.3, 22t4.5
- viral encephalitis 52–53
- viral hepatitis, immunocompromised patients 156
- cytomegalovirus, fever in pregnancy
 — epidemiology and microbiology 396
 — clinical features 396–97
 — laboratory tests 398t58.11
 — treatment and prophylaxis 396
 — complications and admission criteria 396–97
 — infection control 397
- Cytovene *see* ganciclovir
- DAAs (direct acting antivirals), HCV hepatitis 160
- dacryocystitis (eyelid infection) 266f42.3, 268–69
 — epidemiology and microbiology 268, 269
 — clinical features 269
 — differential diagnosis 269
 — laboratory and radiographic findings 269
 — treatment and prophylaxis 269
 — complications and admission criteria 269
 children 270t42.5
- dalbavancin (Dalvance) 566–68
- dantrolene, muscle spasms, tetanus 71
- dapsone, post-transplant, febrile children 464t64.2
- daptomycin (Cubicin) 574–75
 — activity spectrum 557–59
 MRSA susceptibilities 545t75.3
 multidrug-resistant organisms 550t76.3
 VRE infections 550t76.3, 551
- darunavir (Prezista, DRV)
 HIV PEP regimens, non-occupational 381t57.8
 HIV PEP regimens, occupational 379t57.5, 380t57.6, 381t57.7
 side effects and toxicities 183t27.5, 381t57.7
- day care centers
 HA-MRSA 542
 parasitic diarrhea, acute infectious 173, 174
 Shigella diarrhea 171
 viral diarrhea, acute infectious 170
- death predictor, HIV patients 181
- decolonization, CA-MRSA 545
- decontamination
 anthrax 488
 botulism 31
 plague 496
 smallpox 504
 tularemia 513
- deep mandibular space abscess/infections
 — epidemiology, pathophysiology and microbiology 141
 — clinical features 141, 142t22.1
 — differential diagnosis 141
 — laboratory and radiographic findings 142
 — treatment and prophylaxis 142t22.1, 143
- infective endocarditis, prevention 143
- Lemierre's syndrome 143
- Ludwig's angina 141
- mortality rates 143
- osteomyelitis complication 143
- parapharyngeal space infections 143
- penicillin-allergic patients 143
- sublingual infections 141
- submandibular infections 141
- submental infection 124, 141
- trismus, severe (lockjaw) 141
- deep neck space infections 135–38
 — epidemiology and microbiology 135
 — clinical features 135–36
 — differential diagnosis 136
 — laboratory and radiographic findings 136–37
 — treatment 137
 — complications and admission criteria 137
 — pearls and pitfalls 139–38
- adolescents 135
- cellulitis 137
- children, young 135
- IDU-associated 135
- immunocompromised patients 135
- Ludwig's angina 135, 136, 137
- odontogenic infections 135
- parapharyngeal neck infections 137
- pericoronitis 144
- pharyngeal space infections 135–36
- pharyngitis 131
- prevertebral space infections 136
- retropharyngeal abscess 135
- retropharyngeal space infections 136
- submandibular space infections 136, 141
- surgical intervention 137
- tracheotomy 137
- trismus, severe (lockjaw) 136, 136t21.1
 see also Lemierre's syndrome;
 parotitis; pericoronitis;
 peritonsillar abscess;
 retropharyngeal abscess

Index

- deer mouse (*Peromyscus maniculatus*), hantavirus 514–15
- deer tick bite, Lyme disease 94t13.7, 103
- dehydration/fluid replacement, acute diarrhea 175, 177, 186
- delusional parasitosis 97
- dengue fever 413, 418–23
- epidemiology and microbiology 418, 422t60.7
 - clinical features 418–21
 - differential diagnosis 417, 421
 - laboratory and radiographic findings 421–22, 422t60.7
 - treatment and prophylaxis 422, 422t60.7
 - complications and admission criteria 422–23
 - pearls and pitfalls 428–29
- Aedes aegypti* mosquito 418
- hemorrhagic fever and shock 418, 421, 422t60.7
- incubation period 414t60.1, 422t60.7
- travel region 414t60.1
- vaccine position 422
- young adults, pulse pressure 421, 423
- dengue virus (DENV) 156, 422t60.7
- dental and odontogenic infections 140–45
- pearls and pitfalls 145
- intracranial abscess 37
- mortality rates 143
- sinusitis 120, 121
- see also deep mandibular space abscess; dentoalveolar infections; periapical abscess; pericoronitis; periodontal infections; pulpitis
- dental flora, deep neck space infections 135
- dentoalveolar infections 140–43
- epidemiology, pathophysiology, and microbiology 140–41
 - clinical features 141
 - differential diagnosis 141
 - laboratory and radiographic findings 141–42, 142t22.1
 - treatment and prophylaxis 142t22.1
 - complications and admission criteria 143
 - pearls and pitfalls 145
- dental plaque 140
- Lemierre's syndrome 143
- pharyngeal space infections 143
- trismus, severe (lockjaw) 142t22.1
- see also deep mandibular space abscess/infections; periapical abscess; pulpitis
- Dermatobia hominis* (botfly) myiasis 93, 95, 95t13.8, 96t13.9
- returning traveler 95
- dermatologic conditions, systemic infection 109–10
- Dermatophagoides* (dust and bed mite) 89, 90, 90t13.4
- dexamethasone
- croup 356t54.2, 357
 - intracranial/brain abscess 36
 - Ludwig's angina 137
 - peritonsillar abscess 134t20.5
 - pharyngitis 132, 132t20.4
- diabetic foot infections (DFIs) 228–32
- microbiology 228, 230t34.1
 - epidemiology 228
 - clinical features 228–30
 - differential diagnosis 229
 - laboratory and radiographic findings 229, 230t34.1
 - treatment 229–31, 230t34.1
 - complications and admission criteria 231
 - special considerations 231
 - pearls and pitfalls 231–32
- acute infections 228
- amputations 228, 230–31
- bone probing 228
- Charcot arthropathy 231
- dorsum of the foot 229f34.1
- IDSA classification system 228–29
- IDSA guidelines 230, 231
- mild to moderate infections 230, 230t34.1
- mortality rates 228
- MRSA treatment 230, 230t34.1
- MSSA treatment 230t34.1
- neuropathic arthropathy 231
- osteomyelitis, underlying 228, 229, 231, 242
- penicillin-beta-lactamase inhibitor combinations 561–62
- rocker-bottom foot with plantar ulcer 231f34.2
- surgery indications 230–31
- systemic toxicity 229–30, 230t34.1
- VRE infections 228, 230
- diabetic foot ulcers (chronic) cellulitis risks 82t12.2
- diabetic foot infections 228
- osteomyelitis 242
- diabetic neuropathy
- botulism differential diagnosis 29
 - neuropathic arthropathy 231
 - plantar puncture wounds 246
- diabetic patients
- invasive fungal rhinosinusitis 121
 - malignant otitis externa 114, 115
- diarrhea 182
- diarrhea, acute infectious 169–79
- epidemiology 169
 - clinical features 169
 - differential diagnosis and microbiology 169–74
 - laboratory and radiographic findings 174–75
 - treatment and prophylaxis 175–77
 - complications and admission criteria 177–78
 - infection control 178
 - pearls and pitfalls 178–79
- antimotility agents 175–76
- appendicitis differential diagnosis 171, 172
- bacteria causing acute diarrhea 170–73
- bismuth subsalicylate 176
- BRAT diet 175
- children, antimotility agents 175
- children, bismuth subsalicylate 176
- dehydration/fluid replacement 175, 177, 186
- dietary therapy 175
- electrolyte imbalances 177
- gastroenteritis 170, 171
- inflammatory diarrhea 169
- mechanical diarrhea 169
- mortality rates 169
- non-inflammatory diarrhea 169
- osmotic diarrhea 169
- parasites causing acute diarrhea 172–74
- probiotics 176
- public health reporting 175t26.7, 178
- secretory diarrhea 169
- stool test indications 175t26.6, 178
- traveller's diarrhea, bismuth subsalicylate 176
- viruses causing acute diarrhea 170
- see also *Clostridium difficile* infection; *under* diarrhea, acute infectious bacterial; diarrhea, acute infectious parasitic; diarrhea, acute infectious viral; *under* diarrhea, in HIV patients
- diarrhea, acute infectious bacterial 170–73
- antibiotic therapy 177t26.10
 - antimicrobial therapy 176–77
 - C. difficile* diarrhea 170t26.1, 172, 173t26.4, 174, 177t26.10, 178
 - C. jejuni* diarrhea 170–71, 170t26.1
 - Campylobacter* diarrhea 170–71, 171t26.3, 173, 176–77, 177t26.10
 - cholera *Vibriosis* diarrhea 173t26.4
 - day care centers, *Shigella* diarrhea 171
 - EAEC diarrhea 171–72, 173t26.4, 177t26.10
 - EHEC diarrhea 170t26.1, 172, 173t26.4, 176, 177t26.10, 178
 - EIEC diarrhea 170t26.1, 171, 173t26.4, 177t26.10
 - elderly patients, EHEC diarrhea HUS complication 172
 - elderly patients, *Salmonella* diarrhea 171
 - ETEC diarrhea 170t26.1, 171, 173t26.4
 - gastroenteritis, *Salmonella* diarrhea 171
 - hospital isolation, *C. difficile* diarrhea 178
 - hospitalized patients, *C. difficile*, exposure risk 172
 - HUS (hemolytic-uremic syndrome) 172
 - infants, *Campylobacter* diarrhea, antibiotics 176–77
 - liver disease patients, *Campylobacter* diarrhea 171t26.3
 - neonates, *Campylobacter* diarrhea, antibiotics 176–77
 - non-cholera *Vibrio* strains 172
 - non-typhi *Salmonella* 170t26.1
 - nursing home residents, *Shigella* diarrhea 171
 - returning traveler 171–72
 - S. dysenteriae* 171
 - S. sonnei* diarrhea 171
 - salmonellosis 171, 175t26.7, 178
 - shellfish, contaminated, diarrhea 172
 - Shigella* diarrhea 170t26.1, 171, 173t26.4, 177t26.10, 178
 - Shigellosis 175t26.7, 178
 - STEC diarrhea 170t26.1, 172, 173t26.4, 177t26.10, 178
 - V. cholerae* diarrhea 170t26.1, 172, 173t26.4, 177t26.10
 - V. parahemolyticus* diarrhea 172, 177t26.10
 - V. vulnificus* diarrhea 172
 - Y. enterocolitica* diarrhea 172, 173t26.4, 176, 177t26.10
- diarrhea, acute infectious bacterial, children
- Campylobacter* diarrhea 171t26.3
 - chronic diarrhea, EAEC 171–72
 - EHEC HUS complication 172
 - Salmonella* diarrhea, severe diarrhea 171
 - Shigella* diarrhea, treatment 177t26.10
 - V. cholerae* diarrhea, treatment 177t26.10
- diarrhea, acute infectious bacterial, *Salmonella*
- microbiology 171
 - clinical features 170t26.1, 171, 173
 - treatment 170t26.1, 171, 173, 176
 - complications 171
 - infection control 178
- antibiotic therapy 177t26.10
- transmission modes 171, 173t26.4
- diarrhea, acute infectious parasitic 172–74
- AIDS patients 173–74, 175t26.8, 178, 178t26.12
 - antimicrobial therapy 177–78
 - C. cayetensis* diarrhea 174, 174t26.5, 178t26.12
 - C. parvum* diarrhea, AIDS patients 170t26.1
 - children, chronic diarrhea, *Cryptosporidium* 173–74
 - chronic diarrhea, AIDS patients 173–74

Index

- diarrhea, acute infectious
 parasitic (*cont.*)
 Cryptosporidium diarrhea 173–74,
 174t26.5, 178t26.12
 day-care center patients 173, 174
E. histolytica diarrhea 170t26.1,
 174, 174t26.5, 178t26.12
G. lamblia diarrhea 170t26.1, 173,
 174t26.5, 178t26.12
 HIV patients 174, 178t26.12
 homosexually active men
 175t26.8, 178
 hospitalized patients, *Isospora*
 diarrhea 174
 immigrants, *E. histolytica*
 diarrhea 174
 immunocompromised patients,
 Isospora diarrhea 174
 infants with diarrhea, exposure to
 175t26.8, 178
Isospora diarrhea 174, 174t26.5
 nursing home residents, *G.*
 lamblia diarrhea 173
 ova and parasite testing 175t26.8,
 178
 returning traveler 172–74,
 175t26.8, 178
 diarrhea, acute infectious viral 170
 — laboratory and radiographic
 findings 174
 adenovirus 170t26.1
 astrovirus 170, 170t26.2
 calicivirus 170
 children, severe diarrhea, rotavirus
 170, 170t26.2
 cruise ship diarrhea, norovirus 170
 day-care centers 170
 enterovirus diarrhea 170
 gastroenteritis, norovirus 170
 hospital epidemics 170
 hospital isolation 178
 infants, severe diarrhea, rotavirus
 170, 170t26.2
 mortality rates, rotavirus 170
 non-inflammatory diarrhea
 170t26.1, 170t26.2
 norovirus 170, 170t26.2
 Norwalk virus 170, 170t26.1,
 170t26.2
 rotavirus 170, 170t26.2
 transmission modes,
 norovirus 170
 diarrhea, definitions 182
 diarrhea, in HIV patients 181–86
 — microbiology 181
 — epidemiology 181
 — clinical features 181–82
 — differential diagnosis 182–83
 — laboratory and radiographic
 findings 183–84
 — treatment and prophylaxis
 184–86
 — complications and admission
 criteria 186
 — infection control 186
 — pearls and pitfalls 186
 acute diarrhea, common causes
 182t27.2
 antiretroviral medication effects
 183t27.5
 bacterial infections, common
 182t27.2
 bacterial infections, persistent
 183t27.3
C. jejuni diarrhea 181, 182,
 183t27.3, 184, 185t27.6
C. perfringens food poisoning 182
Campylobacter diarrhea 182t27.1,
 182t27.2
 CD4 counts 181, 183t27.4, 186
 chronic diarrhea, common causes
 183t27.3
Cystoisospora diarrhea 185t27.6
 cytomegalovirus diarrhea 182
 death predictor 181
 definitions, diarrhea 182
 dehydration/fluid replacement
 175, 177, 186
E. coli 0157:H7 diarrhea 182
E. coli diarrhea 182, 182t27.1,
 183t27.3
E. histolytica diarrhea 181,
 182t27.2, 183t27.3, 183t27.4,
 184
 EIEC diarrhea 182, 182t27.1
Entamoeba diarrhea 181
 fever 182
 foods recommended 184
 fungal infections, persistent
 diarrhea 183t27.3
G. diarrhea 181, 184
G. lamblia diarrhea 181, 182t27.1,
 182t27.2, 183t27.3, 183t27.4
 hepatitis A virus diarrhea 181
 herpes simplex virus diarrhea 181
 HIV enteropathy 183t27.3, 186
 Kaposi's sarcoma 182, 183t27.3,
 186
 large bowel diarrhea 182t27.1
M. tuberculosis 183t27.3, 183t27.4
 MAC diarrhea 182t27.1, 185t27.6,
 186
 microsporidium diarrhea
 182t27.1, 183t27.3, 185t27.6,
 186
 mycobacterial infections,
 persistent 183t27.3
 non-infectious causes 181
 ova and parasite testing 175t26.8,
 178, 186
 persistent diarrhea, common
 causes 183t27.3
 protozoal infections, acute
 diarrhea 182t27.2
 protozoal infections, persistent
 and chronic diarrhea 183t27.3
 public health reporting 184
 rehydration therapy 184–86
S. aureus diarrhea 182
 sexual history record 181–82
 small bowel diarrhea 182t27.1
 social history 182
 viral infections, acute diarrhea
 182t27.2
 viral infections, persistent and
 chronic diarrhea 183t27.3
Yersinia diarrhea 181, 182t27.2,
 184
 diarrhea, in HIV patients, *C. difficile*
 — microbiology 181
 — clinical features 182
 — infection control 186
 acute infections 182t27.2
 anti-motility agents, complications
 risk 186
 CD4 counts 183t27.4
 large bowel diarrhea 182t27.1
 medication exposures 181, 184
 persistent infections 183t27.3
 diarrhea, in HIV patients,
 Cryptosporidium
 — clinical features 181, 182
 — pearls and pitfalls 186
 CD4 counts 183t27.4, 186
 massive volume loss 186
 persistent and chronic diarrhea
 183t27.3, 186
 small bowel diarrhea 182t27.1
 diarrhea, in HIV patients,
 non-infectious 181
 diarrhea, in HIV patients, *Salmonella*
 — microbiology 181
 — clinical features 181, 182,
 185t27.6
 — treatment 184, 185t27.6
 — pearls and pitfalls 186
 acute diarrhea in HIV 182t27.2
 bacteremia and septicemia
 risks 186
 CD4 counts 183t27.4
 persistent diarrhea 183t27.3
 small bowel diarrhea 182t27.1
 diarrhea, in HIV patients, *Shigella*
 — microbiology 181
 — clinical features 181, 182,
 185t27.6
 — treatment 184, 185t27.6
 acute bacterial diarrhea 182t27.2
 persistent diarrhea 183t27.3
 diazepam, tetanus muscle spasms
 440t61.14
 dicloxacillin 560–61
 — activity spectrum 557–59
 acute paronychia 237t35.3
 breast abscess 410t59.5
 cellulitis 84t12.3
 diabetic foot infections 230t34.1
 felon 237t35.3
 mastitis 410t59.5
Dicrocoelium dendriticum, parasitic
 cholangitis 153
 dietary therapy, acute infectious
 diarrhea 175
 diffuse cerebral dysfunction in HIV/
 AIDS patients 19
 altered mental status, differential
 diagnosis 19t4.2
 diffuse stromal haze, keratitis
 261f41.5
 Difcid *see* fidaxomicin
 Diflucan *see* fluconazole
 diphtheria
 botulism differential diagnosis 29
 pharyngitis 130t20.1
 direct acting antivirals (DAAs),
 hepatitis C virus 160
 dirty (operation sterility) 454t63.2
 diskitis, pediatric orthopedic
 infections 352
 disseminated gonococcal infection
 fever and rash, in adults 104
 gonococcal arthritis 225
 treatment 203t30.4
 distal tibia, grade II open fracture
 240f36.2
 disulfiram (Antabuse)-like
 reaction, nitroimidazoles
 caution 573
 diverticulitis, viscus perforation,
 secondary peritonitis 162, 164
 dobutamine, cardiogenic shock,
 pericarditis/myocarditis 13t2.4
 dog bite infections
 — microbiology 371
 — epidemiology 370
 — treatment and prophylaxis
 371–73, 372t56.1
 see also bite infections
 dog mite (*Cheyletiella*)
 infestations 90
 dolutegravir (Tivicay, DTG)
 HIV PEP regimens, non-
 occupational 381t57.8
 HIV PEP regimens, occupational
 380t57.6, 381t57.7
 side effects and toxicities 183t27.5,
 381t57.7
 doripenem (Doribax) 565
 dorsum of the foot, diabetic foot
 infections 229f34.1
 dosage adjustments *see specific drugs:*
 properties and dosages
 doxycycline
 — activity spectrum 557–59
 — properties and dosages 571
 anthrax 486t67.3
 antimalarial regimens 420t60.6
 CA-MRSA coverage 545t75.4
 cellulitis 84t12.3
 chlamydia 200t30.2
 chlamydia co-infections 104
 community-acquired pneumonia
 283t44.2
 ehrlichiosis (HME) 94t13.7
 endometritis, post-abortion
 prophylaxis 408
 epididymitis 196t29.4
 gonorrhea 203t30.4
 human granulocytic ehrlichiosis
 94t13.7
 latent syphilis 216t31.4
 Lyme disease 94t13.7, 106t14.8
 malaria 419t60.5
 MRSA susceptibilities 545t75.3
N. gonorrhoeae 203t30.4
 non-gonococcal urethritis 202,
 203t30.5
 pelvic inflammatory disease
 204t30.6
 plague 495t68.4
Plasmodium 419t60.5
 primary syphilis 216t31.4

Index

- Rocky Mountain spotted fever 94t13.7, 101t14.3
 secondary syphilis 216t31.4
 syphilis, secondary 105t14.6
 ticks/tick-borne illnesses 94t13.7
 tularemia 512t70.4
V. cholerae diarrhea 177t26.10
V. parahemolyticus 177t26.10
 doxycycline contraindications, malaria, in pregnancy 403t58.17
 DRESS (drug rash with eosinophilia and systemic symptoms) 100t14.1
 drug activity spectra 557–59
 drug cross-reactivity 557
 cephalosporins 118, 557
 drug effects, altered mental status differential diagnosis 19t4.2
 drug interactions, solid organ transplants 465t64.3
 drug reactions, severe
 acute generalized exanthematous pustulosis (AGEP) 100t14.1
 drug rash with eosinophilia and systemic symptoms (DRESS) 100t14.1
 fever and rash 100t14.1, 109
 hepatotoxic medications, common 159t24.3
 HIV patients 108
 immunosuppressed patients 109
 nitrofurantoin caution, respiratory adverse effects 574
 Stevens–Johnson syndrome 100t14.1, 108, 109, 572
 toxicity and allergy principles 557
 see also nephrotoxicity; penicillin-allergic patients; toxic epidermal necrolysis
 drug tables *see specific disease: treatment; specific drug: properties and dosages*
 drug trials, West Nile virus infections 76–77
 drug-resistant organisms
 — activity spectra, antibacterial drugs 557–59
 — drug therapy 556–57
 enteric fever 423
 ESBL-producing organisms and infections 552
 neutropenic oncology patients 450
 prior antimicrobial use 556–57
 tuberculosis (MDR-TB) 308, 316
 VRE infections 548, 551
 see also CA-MRSA; ESBL-producing organisms and infections; MRSA; vancomycin-resistant *Enterococcus* infections
 drug-susceptible tuberculosis 313
 DRV *see* darunavir
 DTaP vaccine (tetanus-acellular pertussis vaccine adsorbed) 71
 DTG *see* dolutegravir
 Duke criteria 2t1.1
 dust and bed mite (*Dermatophagoides*) infestations 89, 90, 90t13.4
 dysrhythmias, myocarditis 12
 EAEC diarrhea (enteroaggregative *E. coli*) 171–72, 173t26.4, 177t26.10
 ear infections
 intracranial abscess 37
 intraparenchymal brain abscess 34t6.2
 eardrop delivery, otitis externa 115
 early goal-directed therapy (EGDT), sepsis 468–69
 eastern Asia, rickettsial infections 426t60.9
 Ebola virus disease (EVD) 521–25
 — microbiology and pathophysiology 521–22
 — epidemiology and microbiology 521, 522
 — clinical features 522–23
 — differential diagnosis 523–22
 — laboratory and radiographic findings 522–23
 — treatment and prophylaxis 523–24
 — complications and admission criteria 524
 — infection control 524
 — pearls and pitfalls 524–25
 frontiers in care 524
 immunotherapy 523–24
 incubation periods 522
 malaria co-infection 524
 pathophysiology 521
 post-exposure prophylaxis, EBOV percutaneous exposure 523–24
 presenting signs 523
 returning traveler, West Africa 523–22
 screening algorithm 523
 supportive care 524
 transmission modes 522, 524
 vaccines 523–24
 Zaire ebolavirus 521, 522
 see also fever in the returning traveler
 Ebola virus, uveitis and retinitis 276t43.1
 Ebolavirus, acute infectious diarrhea 175t26.7
 Ebolavirus and species 521
 EBOV percutaneous exposure, post-exposure prophylaxis 523–24
 EBV *see* Epstein-Barr virus
 ecchymoses 99
 echinocandins
 — properties and dosages 576–77
 see also *specific drugs*
 echocardiography
 cardiac tamponade image 10f2.3
 coronary aneurysm 346
 infective endocarditis 4
 infective endocarditis, injection drug users 431t61.1, 432
 myocarditis 12, 13
 pericarditis 8, 10, 13
 suspected CIED infection 16
 echoviruses
 myocarditis 11
 pericarditis 6
 ectoparasites/ectoparasitosis 87–97
 — epidemiology and microbiology 87
 — complications and admission criteria 96
 — infection control 96–97
 — pearls and pitfalls 97
 bedbugs 88
 cutaneous larva migrans 88
 delusional parasitosis 97
 human louse (Pediculosis) 89–90, 91–93
 mites 88t13.1, 89–90
 myiasis 88t13.1, 93–97
 scabies 87–89
 tick removal 93–94
 ticks/tick-borne illnesses 88, 93–94
 tungiasis 88
 see also *specific parasites*
 ectopic pregnancy, abdominal pain differentiation 165–66
 Edurant *see* rilpivirine
 efavirenz
 HIV PEP regimens, occupational 381t57.7
 side effects and toxicities 183t27.5, 381t57.7
 EGDT (early goal-directed therapy), sepsis 468–69
 EHEC diarrhea (enterohemorrhagic *E. coli*)
 — microbiology 172
 — clinical features 170t26.1, 173t26.4
 — treatment 173t26.4, 176
 — infection control 178
 antibiotic therapy 177t26.10
 hemolytic-uremic syndrome 172
 transmission modes 173t26.4
Ehrlichia chaffeensis (tick), ehrlichiosis 94t13.7
 Ehrlichiae (ticks) 93
 EIEC diarrhea (enteroinvasive *E. coli*) 170t26.1, 171, 173t26.4, 177t26.10
 HIV patients 182, 182t27.1
Eikenella
 abscess 80t12.1
 cephalosporins, first-generation, cautions 562
 deep neck space infections 136t21.1
 fight bites 233–34, 234t35.1
 Lemierre's syndrome 138
 microbiology 369
 subcutaneous abscess, IDU-associated 433, 433t61.3
Eikenella corrodens
 cellulitis 82t12.2
 clindamycin resistance 234
 human bite infections 233–34, 238, 369
 infective endocarditis 1
 elbow, grade I open fracture 240f36.1
 elderly patients
 acute cystitis 322
 brain abscess 33
 community-acquired pneumonia 281, 281t44.1, 286
 EHEC diarrhea HUS complication 172
 fluoroquinolones, cautions 568
 HSV-1 encephalitis 38
 intracranial 33
 malignant otitis externa 114, 115
 parotitis 126, 128
 Salmonella diarrhea 171
 viral hepatitis, admission criteria 160
 viral pneumonia 304, 305
 West Nile virus infections 74, 76, 77
 elderly patients, influenza viruses
 — clinical features 301t46.1
 — complications and admission criteria 300, 302t46.3, 305
 altered mental status 305
 H10N8 533t74.1
 novel influenza A 533t74.1
 electrocardiography (ECG), pericarditis 8
 electrolyte imbalances, acute infectious diarrhea 177
 Elimite *see* permethrin
 ELISA test, West Nile virus infections 75–76
 elvitegravir
 HIV PEP regimens, occupational 381t57.7
 side effects and toxicities 183t27.5, 381t57.7
 emergency department, common antibacterials 557–59
 emphysematous pyelonephritis 326
 emtricitabine (Emtriva, FTC)
 non-occupational HIV PEP 381t57.8
 occupational HIV PEP regimens 379t57.5, 380t57.6, 381t57.7
 side effects and toxicities 183t27.5, 381t57.7
 Emtriva *see* emtricitabine
 encephalitis
 acute bacterial meningitis, differential diagnosis 55t8.4
 focal encephalitis 37
 mumps parotitis complication 128
 viral encephalitis 52–53
 see also herpes simplex virus encephalitis; West Nile encephalitis
 endemic infectious diseases, by travel region 414t60.1
 endocarditis
 congenital, intraparenchymal brain abscess 34t6.2
 left-sided, CIED complications 16t3.2
 MRSA screening 546
 see also infective endocarditis

Index

- endocrine dysfunction, severe sepsis 468t65.2
- endometritis (postpartum and post-abortion infections) 406–08
- epidemiology and microbiology 406
 - clinical features 407
 - differential diagnosis 407
 - laboratory and radiographic findings 407, 407t59.1
 - treatment and prophylaxis 407t59.1, 408
 - pearls and pitfalls 411
- C. sordellii* infection 406, 407
- cesarean prophylaxis 408
- cesarean section 406, 408
- incubation periods 407t59.1
- post-abortion endometritis 408t59.2
- post-abortion prophylaxis 408
- postpartum endometritis 407t59.1
- toxic shock syndrome 406, 407
- endophthalmitis 276–79
- epidemiology and microbiology 277
 - clinical features 277–78
 - differential diagnosis 278
 - laboratory and radiographic findings 278
 - treatment 278
 - complications and admission criteria 278–79
 - pearls and pitfalls 279
- cataract operations 277
- ophthalmologist involvement 278t43.3
- Endophthalmitis Vitrectomy Study (EVS) 278
- endoscopic drainage and extraction, common bile duct stone 152f23.2
- endoscopic retrograde cholangiopancreatography (ERCP)
- acute cholangitis 150, 151–52
 - bacterial exposures 150
 - parasitic cholangitis 153
- enfuvirtide
- HIV PEP regimens, occupational 381t57.7
 - side effects and toxicities 381t57.7
- Entamoeba histolytica*
- acute infectious parasitic diarrhea 170t26.1, 174, 174t26.5, 178t26.12
 - peritonitis, liver abscess 165t25.6
- Entamoeba histolytica* diarrhea, HIV patients 181, 182t27.2, 183t27.3, 183t27.4, 184
- enteric fever (typhoid fever) 423–24
- epidemiology and microbiology 423
 - clinical features 423–24
 - differential diagnosis 417, 423
 - laboratory findings 423, 424t60.8
 - treatment and prophylaxis 423–24, 424t60.8
 - complications and admission criteria 424
 - pearls and pitfalls 428–29
- immunocompromised patients, vaccines 424
- incubation period 423, 424t60.8
- multidrug-resistant organisms 423
- pregnant women, vaccines 424
- vaccines 423, 424, 424t60.8
- enteric gram-negative bacilli, solid organ transplants 460t64.1
- Enterobacter*
- acute bacterial cholangitis 152t23.5
 - acute calculous cholecystitis 146
 - acute calculous cholecystitis, resuscitation 149t23.2
 - cephalosporins, third- and fourth-generation 563
 - hematopoietic stem cell transplants, phase 1 infections 461
 - intraparenchymal brain abscess 34t6.2
 - keratitis 261t41.3
 - liver abscess, peritonitis 165t25.6
 - oncology patients 450
 - pyelonephritis, adults 324
 - septic arthritis and osteomyelitis, IDU-associated 435
 - urinary tract infections, in pregnancy 387–88
- Enterobacter cloacae*, ESBL production 553t77.1
- Enterobacteriaceae* 563
- cephalosporins, advanced-generation 564
 - chronic diabetic foot wounds 228, 231
 - ESBL production 552
 - ESBL screening 553
 - intraparenchymal brain abscess 34t6.2
 - keratitis 261t41.3
 - peripancreatic abscess 165t25.7
 - spinal epidural abscess 47
- enterococci
- prosthetic joint infections 250
 - pyelonephritis 324
- Enterococcus* 548, 549
- antibacterial drug spectra 558t78.1
 - antibacterials, commonly used 557–59
 - acute bacterial cholangitis 150, 152t23.5
 - acute bacterial prostatitis 196–97, 198
 - acute calculous cholecystitis, resuscitation 149t23.2
 - appendicitis, viscus perforation 164t25.4
 - chorioamnionitis 393, 394t58.8
 - chronic diabetic foot wounds 228
 - diverticulitis, viscus perforation 164t25.5
 - endophthalmitis 278t43.2
 - fever in the newborn 328, 330t50.1, 332
 - infective endocarditis 2t1.1
 - infective endocarditis, IDU-associated 431, 431t61.1
 - open fractures 239
 - peripancreatic abscess 164
 - solid organ transplants 459
 - VRE infections 548, 549
- Enterococcus faecalis*
- antibacterial drug spectra 558t78.1
 - VRE bacteremia 551
 - VRE infections 548, 550t76.3
- Enterococcus faecium*
- antibacterial drug spectra 558t78.1
 - oncology patients 450
 - VRE bacteremia 551
 - VRE infections 548, 550t76.3
- enterocolitis, pharyngitis 130t20.1
- enteroinvasive *Escherichia coli* (EIEC) diarrhea 170t26.1, 171, 173t26.4, 177t26.10
- HIV patients 182, 182t27.1
- enteroviruses
- acute infectious diarrhea 170
 - aseptic and viral meningitis 53
 - focal signs and symptoms 38
 - influenza-like illnesses 301
- epidemic syphilis, men who have sex with men 102
- epidemic typhus (rickettsial infections) 426t60.9
- epidermal necrolysis, TMP-SMX cautions 572
- epididymitis 195–96
- epidemiology and microbiology 195
 - clinical features 195
 - differential diagnosis 195–96
 - laboratory and radiographic findings 195t29.3, 196
 - treatment and prophylaxis 196
 - complications and admission criteria 196
 - infection control 196
 - pearls and pitfalls 198
- NAAT testing (nucleic acid amplification test) 196
- non-infectious causes 195
- epidural abscess 256–57
- epidemiology and microbiology 256
 - clinical features 256
 - differential diagnosis 256
 - laboratory and radiographic findings 256–57, 256t40.2
 - treatment 256t40.2, 257
 - complications and admission criteria 257
 - pearls and pitfalls 257
- immunocompromised patients 256t40.2
- sagittal MRI of spine 257f40.4
- vertebral osteomyelitis association 256
- see also* spinal cord infections; spinal epidural abscess, IDU-associated
- epidural brain abscess 34
- epiglottitis, pediatric infections 354–56
- microbiology 355t54.1
 - epidemiology and microbiology 354–55
 - clinical features 355
 - differential diagnosis 355
 - laboratory and radiographic findings 355–56, 355t54.1
 - treatment and prophylaxis 355, 355t54.1
 - complications and admission criteria 355–56
 - pearls and pitfalls 364
- epiglottitis with thumb print sign 356f54.1
- epiglottitis abscess, pharyngitis 131
- see also* supraglottitis
- episiotomy site infection 410–11
- epidemiology and microbiology 410
 - clinical features 410
 - differential diagnosis 410
 - laboratory and radiographic findings 410
 - treatment and prophylaxis 410
 - infection control 411
 - pearls and pitfalls 411
- necrotizing fasciitis 410
- Epivir *see* lamivudine
- epizootic diseases 513
- Epstein–Barr virus (EBV)
- aseptic and viral meningitis 54
 - fever and rash differential diagnosis 100t14.1
 - focal signs and symptoms 38
 - keratitis 261t41.3, 262
 - monobactams 156
 - mononucleosis 100t14.1
 - myocarditis 11
 - parotitis 126
 - pericarditis 6
 - pharyngitis 130t20.1, 132t20.4, 134
 - solid organ transplants, late-phase infections 461
 - uveitis and retinitis 276t43.1
 - viral encephalitis 52–53
- Eraxis *see* anidulafungin
- ERCP intervention
- (endoscopic retrograde cholangiopancreatography)
 - acute bacterial cholangitis 150, 151–52
 - acute cholangitis 150, 151–52
 - bacterial exposures 150
 - parasitic cholangitis 153
- ertapenem (Invanz)
- properties and dosages 565
 - bite infections 372t56.1
 - diabetic foot infections, acute 230t34.1
 - ESBL-producing organisms and infections 554, 554t77.3

Index

- Lemierre's syndrome 138t21.2
 pyelonephritis, in adults 326t49.2
 pyelonephritis, in pregnancy 389t58.4
 secondary peritonitis 167t25.12
 erythema infectiosum, pediatric fever and rash 339–41
 erythema migrans associated with Lyme disease 106f14.8, 106t14.8
 erythema multiforme, clinical features 110
 erythema nodosum, clinical features 109–11
 erythromycin
 — activity spectrum 557–59
 — properties and dosages 570
 bacterial conjunctivitis 260t41.2
 blepharitis 267t42.2
 chalazia 268
 chancroid infections 218t31.6
 chlamydia 200t30.2
 conjunctivitis 260t41.2
H. influenzae, poor coverage 570
 hordeola 268
 MRSA susceptibilities 545t75.3
 non-gonococcal urethritis 202, 203t30.5
 pertussis 360–61, 360t54.5
 post-abortion prophylaxis 408
 erythromycin ethylsuccinate
 chlamydia 200t30.2
 non-gonococcal urethritis 203t30.5
 pertussis, pediatric 360–61, 360t54.5
 ESBL-producing organisms and infections (extended spectrum beta-lactamases) 552–54
 — microbiology 552
 — epidemiology 552–53
 — clinical features 553
 — laboratory and radiographic findings 553
 — treatment and prophylaxis 553–54
 — complications and admission criteria 554
 — infection control 554
 — pearls and pitfalls 554
 antibiotics commonly used 554t77.3
 carbapenems 554
 cephalosporin-beta-lactamase inhibitors 554
 cephalosporins,
 advanced-generation 564
 cephalosporins,
 third-generation 552
 children, antibiotics 554t77.3
E. coli 553, 553t77.1, 554
 fosfomycin 554, 554t77.3
 genotypic identification 553
 gram-negative bacteria 552
 multidrug-resistant organisms 552
 organism list 553t77.1
 screening methods 553
 transmission modes 552–53
 urinary tract infections 552–53, 554
 see also beta-lactams
 eschar 99
Escherichia coli
 0157:H7 diarrhea, HIV patients 182
 abscess 79
 acute bacterial cholangitis 150, 152t23.5
 acute bacterial meningitis, neonates 50, 58t8.9
 acute bacterial prostatitis 196–97
 acute calculous cholecystitis 146, 149t23.2
 acute cystitis 319, 321
 aminoglycosides 569
 appendicitis, viscus perforation 164t25.4
 bacteremia and sepsis, in sickle cell disease 475t66.1
 chorioamnionitis 393, 394t58.8
 CIED infections 14–15
 diarrhea, HIV patients 182, 182t27.1, 182t27.2, 183t27.3
 diverticulitis, viscus perforation 164t25.5
 emphysematous
 pyelonephritis 326
 epididymitis 195
 ESBL production 553, 553t77.1, 554
 ESBL screening 553
 febrile child 334–35
 fever in the newborn 328, 330t50.1
 health-care-associated CAP 280
 meningitis, shunt infections 61
 peripancreatic abscess 164
 peritonitis, liver abscess 165t25.6
 pyelonephritis, adults 324, 326
 sepsis 467
 septic arthritis and osteomyelitis, IDU-associated 435–36
 spinal epidural abscess 42
 spontaneous bacterial peritonitis 163, 163t25.1
 urinary tract infections, in pregnancy 387–88
 vertebral osteomyelitis 253, 254t40.1
 xanthogranulomatous
 pyelonephritis 326–27
Escherichia coli, antibacterials 557–59
 — drug spectra 558t78.1
 cephalosporins,
 advanced-generation 564
 cephalosporins, third- and fourth-generation 563
 fluoroquinolones, resistance 568
 fosfomycin 573
 nitrofurantoin 574
 penicillin-beta-lactamase inhibitor combinations 561
 piperacillin-tazobactam 561
 ESKAPE pathogens
 oncology patients, infections in 450
 VRE infections 548
 esophagectomy, anastomotic leak risks 455t63.3
 estrogens, hepatotoxicity 159t24.3
 ETEC diarrhea (enterotoxigenic *E. coli*) 170t26.1, 171, 173t26.4
 ethambutol
 MAC diarrhea, HIV patients 185t27.6
 Pott's disease (spinal tuberculosis) 255
 tuberculosis 313, 313t47.3, 314t47.5
 etiologies, non-infectious *see* non-infectious causes
 etravirine (Intelence, ETR)
 HIV PEP regimens, occupational 379t57.5, 380t57.6, 381t57.7
 side effects and toxicities 183t27.5, 381t57.7
 euglycemia, sepsis 470
 Europe, rickettsial infections 426t60.9
Eutrombicula alfreddugesi (chiggers) infestations 90, 90t13.4
 EVS (Endophthalmitis Vitrectomy Study) 278
 exotic animals, bite infections 369
 exposure management, blood or body fluid 375–83
 — laboratory testing 382
 — pearls and pitfalls 382
 additional interventions and prophylaxis 382
 exposure epidemiology and transmission risk 375–76
 exposure evaluation 376–78
 exposure wound management 376
 HBV PEP regimens 378, 382
 HBV risk levels 375–76, 377t57.3
 HCV risk levels 376, 377t57.3
 HIV PEP regimens 379–82
 HIV risk levels 376–77
 non-sexual exposures 375
 PEP for HBV and HIV 378–82
 PEP resources 383
 sexual exposures 375
 source testing 377–78
 status of source 377
 exposures
 cats, toxoplasmosis 274
 diarrhea, ova and parasite testing 175t26.8, 178
 rabbits, tularemia 94t13.7
 travel-related diseases 415t60.3
 VRE risks 549t76.1
 water (fresh, salt, fish tank),
 cellulitis risks 82t12.2
 see also post-exposure prophylaxis (PEP) resources
Exserohilum rostratum meningitis 59
 extended spectrum beta-lactamase
 see ESBL-producing organisms and infections
 extended spectrum penicillins,
 severe sepsis 471t65.8
 extrapulmonary tuberculosis
 — clinical features 310
 — microbiologic diagnosis 312
 — treatment 316
 deep neck space infections 136
 HIV patients 309
 eye anatomy 259f41.1, 275f43.1
 eye infections *see* conjunctival and corneal eye infections; conjunctivitis; keratitis; uvea, vitreous, and retina eye infections; uveitis and retinitis
 eyelashes, nits and lice 91
 eyelid infections *see* periocular infections
 facultative myiasis (maggot infestation) 93–95, 95t13.8, 96t13.9
 famciclovir (Famvir)
 herpes genitalis, mucocutaneous 211t31.2
 herpes virus infections 577–78
 varicella zoster, HIV patients 107–08
Fannia canicularis (lesser house fly), myiasis 95t13.8, 96t13.9
Fasciola, parasitic cholangitis 153
Fasciola gigantica, parasitic cholangitis 153
Fasciola hepatica, parasitic cholangitis 153, 153t23.6
 favipiravir antiviral, Ebola virus disease 523–24
 FCT *see* emtricitabine
 febrile child 334–37
 — general points 334
 — microbiology 334–35
 — epidemiology and microbiology 334–35
 — clinical features 335
 — differential diagnosis 335
 — laboratory and radiographic findings 335–36
 — treatment and prophylaxis 336–37
 — complications and admission criteria 336–37
 — infection control 337
 — pearls and pitfalls 337
 age stratification 334
 children 3 months plus 336
 hyperexia 335
 infants (1–2 months) 335, 336
 lumber puncture risks 335
 meningitis 336, 337t51.1
 neonates 335, 336–37
 older children 336
 pneumonia 336
 urinary tract infections 336
 febrile neutropenia
 cephalosporins, third- and fourth-generation dosage 563n.5
 immunocompromised patients 556
 febrile neutropenia, oncology patients 448–50
 aminoglycoside addition 450
 high risk patients 449–50
 low risk patients 449
 vancomycin addition 450

Index

- febrile post-transplant patients
 458–65
 — epidemiology 458
 — clinical features 458–61
 — differential diagnosis 461–62
 — laboratory and radiographic findings 462–63
 — prophylaxis 463
 — treatment 463
 — complications and admission criteria 463–65
 — infection control 465
 — pearls and pitfalls 465
 allograft rejection and GVHD 461
 biopsies 463
 children, treatment post-transplant 464t64.2
 drug interactions 465t64.3
 drug reaction and hypersensitivity 461–62
 hematopoietic stem cell transplants 461
 immunosuppressive agents 466t64.4
 mortality rates, transplants 458
 solid organ transplants 458–61
 thromboembolic disease and vascular events 462
 transfusion-related fever 462
 fecal ESBL carriage 552–53
 fecal microbiota transplant (FMT), *C. difficile* infection 189, 190
 fecal-oral infection exposure, associated illnesses 415t60.3
 feet *see* diabetic foot infections;
 plantar puncture wounds;
 plantar rash, secondary syphilis
 felon infection (volar pad of distal phalanx) 236–37
 — microbiology 236
 — clinical features 236
 — radiographic findings 237t35.3
 — treatment 236, 237t35.3
 — complications and admission criteria 237
 fingertip 236f35.4
 vs. herpetic whitlow 236, 237, 238
 female genitalia, condyloma lata 215f31.14
 femur, osteomyelitis, AP radiograph 244f37.2
 fever, definition 335
 fever, hemorrhagic, with renal syndrome *see* hemorrhagic fever with renal syndrome (HFRS)
 fever, injection drug users 432–33
 fever, typhoid *see* enteric fever
 fever, West Nile 75, 75t11.1
 fever and diarrhea, HIV patients 182
 fever and focal cerebral dysfunction 33–40
 — general points 33
 — pearls and pitfalls 40
 cerebral toxoplasmosis, AIDS patient 25
 herpes simplex encephalitis 37–40
 intracranial abscess 33–37
see also focal cerebral dysfunction, HIV patients
 fever and rash in adults 98–111
 — history and physical examination 98–99
 — clinical features 98–110
 — differential diagnosis 98
 — laboratory findings 110
 — complications and admission criteria 110
 — infection control 110–11
 — pearls and pitfalls 111
 AGEP (acute generalized exanthematous pustulosis) 100t14.1
 AIDS patients 106–08
 chlamydia 107
 chlamydia, infection control 111
 connective tissue diseases 100t14.1
 dermatologic conditions associated with systemic infection 109–10
 disseminated gonococcal infection 104
 DRESS (drug rash) 100t14.1
 erythema multiforme 110
 erythema nodosum 109–11
 HIV patients 100t14.1, 106–08
 Kawasaki disease 100t14.1
 measles (rubeola) 100t14.1, 104–06
 meningococcemia (meningococcal disease) 98–101, 100t14.1, 111
 mononucleosis (EBV) 100t14.1
 polyarteritis nodosa 100t14.1
 primary lesions 99
 purpura fulminans 100t14.1
 Rocky Mountain spotted fever 99–100, 100t14.1
 rubella 100t14.1, 106
 secondary lesions 99
 secondary syphilis 100t14.1
 selected causes 100t14.1
 severe drug reactions 100t14.1, 109
 sexually transmitted diseases 107, 111
 Stevens–Johnson syndrome 100t14.1, 108, 109
 syphilis, secondary 102–05, 111
 systemic lupus erythematosus 100t14.1, 108–09
 systemic viral infections 104
 thrombotic thrombocytopenic purpura 100t14.1
 toxic epidermal necrolysis 100t14.1, 108, 109
 toxic shock syndrome 100–02
 varicella zoster, HIV patients 107–08
 vasculitis 100t14.1
 fever and rash, pediatric *see* pediatric fever and rash
 fever in HIV *see* HIV fever and rash;
 HIV fever in pregnancy
 fever in the newborn (neonates) 328–32
 — microbiology 328
 — epidemiology 328
 — clinical features 328–30
 — differential diagnosis 329
 — laboratory and radiographic findings 329–31
 — treatment and prophylaxis 331–32
 — complications and admission criteria 332
 — pearls and pitfalls 332
 apnea risk 332
 chlamydia 332
 circumcised boys 329
 fontanelle appearance 329
 pneumonia 329, 332
 respiratory infections 329
 S-S-I-C-C-F-I-T mnemonic 331
 fever in pregnancy 385–404
 — unique considerations 386
 — laboratory considerations 386
 — radiologic considerations 386–87
 — treatment considerations 386–87
 — pearls and pitfalls 403–04
 appendicitis 391–93, 403–04
 chorioamnionitis 393–95, 403–04
 cytomegalovirus 396–97, 398t58.11
 hepatitis 398–401, 403–04
 herpes simplex virus 396–97
 HIV 401–02, 403–04
 imaging methods, fetal radiation doses 387t58.1
 malaria 402–04
 pyelonephritis 387–89
 respiratory infections 390–91
 rubella 395–97
 TORCH infections 395–98
 toxoplasmosis 395, 396–97
 urinary tract infections 387–89
 varicella 395, 396–97
 fever in the returning traveler 412–29
 — general points 412
 — clinical features 413
 — pearls and pitfalls 428–29
 altered mental status, cerebral malaria 413
 ARDS (acute respiratory distress syndrome) 413, 416
 chikungunya 417, 425
 dengue fever 413, 418–23, 422t60.7
 dengue hemorrhagic fever and shock 418, 421, 422t60.7
 endemic infectious diseases according to region of travel 414t60.1
 enteric fever 423–24
 exposures and associated febrile illnesses 415t60.3
 hemorrhagic manifestations 413
 incubation periods 415t60.2
 initial laboratory evaluation 416
 isolation, hospitalized patients 413
 leptospirosis 417, 427–28
 malaria 416–21
 MERS CoV 413
 mononucleosis 425–28
 neurologic abnormalities 413
 public health reporting 413
 rickettsial infections 413, 414t60.1, 415t60.2, 415t60.3, 424–25
 travel history 412–13
 viral hemorrhagic fever 417
see also dengue fever; Ebola virus disease; enteric fever; malaria
 fidaxomicin (Dificid)
 — properties and dosages 570
C. difficile infection 189
 field mouse (*Apodemus agrarius*), hantavirus 514
 fight bite infections (human bites) 233–35, 370
 — epidemiology and microbiology 233–34
 — clinical features 234
 — differential diagnosis 234
 — radiographic findings 234, 234t35.1
 — treatment and prophylaxis 234–35, 234t35.1
 — complications and admission criteria 235
 examples 234f35.1
 knuckle lacerations 238
 subcutaneous abscess, IDU-associated 433, 433t61.3
 uninfected fight bite 234, 234t35.1
Filoviridae viruses, Ebola virus disease 521
 fingertip, felon (volar pad of distal phalanx) 236f35.4
 fish tank owner or fish handler, cellulitis 82t12.2
 FK-506/tacrolimus (Prograf, Protopic)
 nephrotoxicity 465t64.3
 post-transplant patients 466t64.4
 flat-type smallpox (malignant smallpox) 500
Flaviviridae family, West Nile virus 74
 flaviviruses, aseptic and viral meningitis 54
 Flinders Island spotted fever 426t60.9
 fluconazole (Diflucan) 575–76
 candidiasis 223t32.6
 children, post-transplant, febrile 464t64.2
 cryptococcal meningitis, in HIV 24
 endophthalmitis 278t43.3
 febrile post-transplant patients 464t64.2
 flucytosine, altered mental status, HIV patients 24t4.6
 fluid replacement, diarrhea 175, 177, 186
 fluid resuscitation, sepsis 470
 fluoroquinolone allergy, acute cystitis 320t48.1
 fluoroquinolones
 — cross-reactivity 557

Index

- drug activity spectra 557–59
- properties and dosages 568–69
- QT interval prolongation 557
- C. difficile* colitis 172
- CAP warning 283
- community-acquired pneumonia 283, 568–69
- enteric fever 423, 424t60.8
- exposure, VRE risk 549t76.1
- fight bites 234
- gonorrhea 568–69
- health-care-associated CAP 284t44.3
- HIV pulmonary infections 294
- pyelonephritis and UTIs, in pregnancy 403–04
- TB (tuberculosis), warnings 313, 317
- see also specific drugs*
- fly larvae, myiasis 93–95
- FMT (fecal microbiota transplant), *C. difficile* infection 189, 190
- focal cerebral dysfunction, HIV patients 19–20
 - altered mental status, differential diagnosis 19t4.2
- focal encephalitis 37
- focal signs and symptoms, viruses 38
- focal weakness, infections presenting with 45t7.2
- fontanelle appearance, fever in the newborn 329
- food, undercooked or under pasteurized, associated illnesses 415t60.3
- foodborne botulism 26, 27–28, 28t5.1
- fosamprenavir (Lexiva, FOSAPV) 573–74
 - acute cystitis 573–74
 - HIV PEP regimens, occupational 381t57.7
 - side effects and toxicities 381t57.7
- foscarnet
 - herpes genitalis, antiviral resistant strains 211t31.2
 - herpes simplex virus meningitis 54
 - post-transplant patients, 464t64.2
- fosfomycin 573–74
 - properties and dosages 573–74
 - acute cystitis 320t48.1
 - cystitis, in pregnancy 389t58.4
 - ESBL-producing organisms and infections 554, 554t77.3
 - VRE infections 550t76.3
- fosphenytoin, intracranial abscess 37
- foul-smelling bite wounds 369
- fractures *see* open fractures
- Francisella tularensis*
 - (type A) (type B), tularemia 506
 - chronic meningitis 60
 - pharyngitis 130t20.1
 - ticks/tick-borne illnesses 93, 94t13.7
- fresh water exposure, cellulitis risks 82t12.2
- fulminant hepatic failure, HCV 158
- fungal infections
 - antifungal azoles 575–76
 - HIV invasive fungal rhinosinusitis 121
 - infective endocarditis, IDU-associated 431t61.1
 - influenza-like illnesses 301
 - keratitis 261t41.3, 262
 - meningitis 52, 57–59
 - myelitis, differential diagnosis 44, 45t7.2
 - natural disasters 239
 - neutropenic patients, meningitis 58–59
 - open fractures 239
 - persistent diarrhea in HIV 183t27.3
 - polyenes 577
 - rhinosinusitis, invasive 121, 122
 - septic arthritis and osteomyelitis, IDU-associated 435–36
 - sinusitis, allergic fungal 121
 - see also Aspergillus; Candida* infections
- furosemide, congestive heart failure, pericarditis/myocarditis 13t2.4
- furuncle (boil)
 - CA-MRSA 542, 543t75.2
 - cutaneous furuncle 80f12.3
 - ruptured and healing furuncle 80f12.4
 - skin and soft-tissue infections, bacterial 80t12.1
- furuncular cutaneous myiasis 95, 96
- furunculosis, in papule diagnosis 96t13.10
- Fusarium*, keratitis 261t41.3
- Fusobacterium*
 - acute necrotizing ulcerative gingivitis 145
 - cat bite infections 369
 - chorioamnionitis 394t58.8
 - deep neck space infections 135, 136t21.1
 - dental abscess 34t6.2
 - dentoalveolar infections 142t22.1
 - dog bite infections 369
 - intraparenchymal brain abscess 34t6.2
 - periapical abscess 140–41
 - periodontal infections 144t22.2
 - pharyngitis 138
 - subcutaneous abscess, IDU-associated 433, 433t61.3
- Fusobacterium necrophorum*
 - Lemierre's syndrome 138, 138t21.2, 139
 - peritonsillar abscess 132
 - pharyngitis 129, 131, 132, 138
- gallbladder, *A. lumbricoides* in parasitic cholangitis 153f23.3
- gallstones and gallbladder *see* acute calculous cholecystitis
- ganciclovir (Cytovene) 577–78
 - altered mental status, HIV patients 24t4.6
- children, post-transplant, febrile 464t64.2
- cytomegalovirus, HIV patients 185t27.6
- febrile post-transplant patients 464t64.2
- herpes simplex virus meningitis 54
- herpes virus infections 577–78
- viral encephalitis 52–53
- gangrenous cholecystitis 148, 149
- Gardnerella vaginalis*
 - bacterial vaginosis 220, 221t32.1
 - chorioamnionitis 393, 394t58.8
- GAS (group A beta-hemolytic *Streptococcus*), pharyngitis 129
 - laboratory and radiographic findings 131
 - treatment and prophylaxis 131–32
 - complications and admission criteria 132
 - pearls and pitfalls 134
- peritonsillar abscess 132
- sore throat infections 129
- GAS (group A beta-hemolytic *Streptococcus*), purulent tenosynovitis 235
- gastrectomy, anastomotic leak risks 455t63.3
- gastric bypass, anastomotic leak risks 455t63.3
- gastritis, abdominal pain differentiation 165–66
- gastroenteritis
 - acute infectious diarrhea 170, 171
 - febrile child 334–35
 - norovirus diarrhea 170
 - Salmonella* diarrhea 171
 - see also under* diarrhea
- gastroesophageal reflux, abdominal pain differentiation 165–66
- gastrointestinal anthrax 482–83, 484, 485
- gastrointestinal dysfunction, severe sepsis 468t65.2
- gastrointestinal surgical prophylaxis 563
- gastrointestinal tract infections, neutropenic oncology patients
 - clinical features 446
 - differential diagnosis 448
 - laboratory findings 446t62.5
 - treatment 446t62.5
- gastrointestinal tularemia 511
- gatifloxacin, bacterial keratitis 262
- GB virus (formerly hepatitis G (HGV)) 156
- GBS *see* Group B *Streptococcus*
- generalized vesicular or pustular rash, smallpox risk assessment 500–01
- Gengraf *see* cyclosporine
- genitalia, condyloma lata, female 215f31.14
- genitourinary infections, male 192–98
 - general points 192
 - pearls and pitfalls 198
- acute bacterial prostatitis 196–98, 324–25
- epididymitis 195–96, 198
- sterile urethritis 192
- urethritis 192–95, 198
- see also specific diseases*
- genotypic identification, ESBL-producing organisms and infections 553
- gentamicin (various brands)
 - activity spectrum 557–59
 - caution, pyelonephritis, in pregnancy 389t58.4
 - properties and dosages 569
- acute bacterial meningitis, neonates 58t8.9
- acute bacterial prostatitis 197t29.5
- chorioamnionitis 394t58.8
- gonorrhea 203t30.4
- health-care-associated CAP 284t44.3
- infective endocarditis 4t1.2
- MRSA susceptibilities 545t75.3
- musculoskeletal infections, pediatric 352t53.4
- neonates 58t8.9, 332, 364t54.8
- nephrotoxicity 332
- open fractures 241t36.1
- pelvic inflammatory disease, inpatient therapy 204t30.6
- plague 495t68.4
- pneumonia, neonates 332, 364t54.8
- postpartum endometritis 407t59.1, 408
- pyelonephritis in pregnancy, caution 389t58.4
- severe sepsis 471t65.8
- tularemia 94t13.7, 511–12
- Giardia lamblia* diarrhea
 - acute infectious 170t26.1, 173, 174t26.5, 178t26.12
 - HIV patients 181, 182t27.1, 182t27.2, 183t27.3, 183t27.4, 184
- giardiasis
 - acute infectious diarrhea 175t26.7
 - nitroimidazoles 573
- gingivitis periodontitis 143, 144t22.2
- glandular tularemia
 - clinical features 508–09
 - complications 512
 - differential diagnosis 510
- glucocorticoids, sinusitis 122
- glycerine, acute otitis media 118
- glycopeptides
 - properties and dosages 566–68
- C. difficile* 566–68
- infective endocarditis 566–68
- nephrotoxicity 566t78.18
- osteomyelitis 566–68
- see also specific drugs*
- glycylcyclines
 - properties and dosages 571
 - see also specific drugs*
- gonorrhea *see* *Neisseria gonorrhoeae*

Index

- graft-versus-host disease (GVHD), hematopoietic stem cell transplants 461
- gram-negative bacteria
- antibacterial drug spectra 558t78.1
 - antibacterials, commonly used 557–59
 - ESBL-producing organisms and infections 552
 - see also under* ESBL-producing organisms
- gram-positive bacteria
- antibacterial drug spectra 558t78.1
 - antibacterials, commonly used 557–59
- granulomatous disease 52
- group A beta-hemolytic *Streptococcus* *see* GAS
- group B *Streptococcus* (GBS)
- acute bacterial meningitis, neonates 50, 58t8.9
 - chorioamnionitis 393, 394t58.8
 - fever in the newborn 328, 330t50.1
 - group B and G, cellulitis 82
 - neonatal fever 328, 330t50.1
 - neonatal musculoskeletal infection 352
 - neonatal pneumonia 329, 364t54.8
 - neonatal sepsis 328
 - neonatal serious bacterial infection risk 334
 - neonates 404
 - pediatric urinary tract infections 367t55.2
 - postpartum endometritis 42, 406, 408
 - urinary tract infections, in pregnancy 387–88, 388t58.2
- GS-5734 antiviral, Ebola virus disease 523–24
- Guillain–Barré syndrome
- botulism differential diagnosis 29, 31
 - Campylobacter* diarrhea 171t26.3
 - Miller–Fisher syndrome, differential diagnosis 438–39
 - rabies paralysis similarity 65
 - spinal cord infections differential diagnosis 46
 - West Nile virus infections 75
 - Zika virus association 527
- gum disease 143
- Gustilo classification, open fractures 239–41
- GVHD (graft-versus-host disease), hematopoietic stem cell transplants 461
- H1N1pdm09 (swine influenza A virus)
- microbiology 299, 531, 532
 - epidemiology 531
 - vaccine updates 305
- H1N1v, H1N2v (swine influenza A virus)
- microbiology 532, 533
 - epidemiology 534t74.3
 - differential diagnosis 301, 302
- H3N2v (swine influenza A virus)
- microbiology 299, 531
 - epidemiology 534–36, 534t74.3, 540
 - differential diagnosis 301, 302
 - vaccine updates 305
- H5N1 (avian influenza A virus)
- microbiology 532
 - epidemiology and microbiology 533, 534–36, 534t74.2, 539
 - clinical features 535
 - laboratory and radiographic findings 536–37
 - antiviral treatment and chemoprophylaxis 537–39
 - complications and admission criteria 538
 - infection control 539
 - transmission and pathogenesis 534, 535, 540
 - vaccines 539
 - young adults 533
- H5N6 (avian influenza A virus)
- microbiology 531–32
 - epidemiology and microbiology 532, 533, 534t74.2
 - clinical features 535
 - laboratory and radiographic findings 536
 - complications and admission criteria 538
 - infection control 539
 - antiviral treatment and chemoprophylaxis 538
 - transmission and pathogenesis 534, 535
- H7N9 (avian influenza A virus)
- microbiology 531–32
 - epidemiology and microbiology 532–33, 534t74.2, 539
 - clinical features 533t74.1, 535
 - laboratory and radiographic findings 536
 - complications and admission criteria 538
 - infection control 539
 - antiviral treatment and chemoprophylaxis 538
 - incubation periods 535
 - transmission and pathogenesis 535
- H10N8 (avian influenza A virus) 532, 533t74.1, 534
- HACEK bacteria group 1, 2t1.1
- infective endocarditis, IDU-associated 431
- Haemophilus*
- deep neck space infections 135
 - intraparenchymal brain abscess 34t6.2
 - supraglottitis (epiglottitis) 123
- Haemophilus aphrophilus*, infective endocarditis 1
- Haemophilus ducreyi*, chancroid 216–17
- Haemophilus influenzae*
- antibacterial drug spectra 558t78.1
 - antibacterials, commonly used 557–59
 - acute otitis media 117
 - aminopenicillins 560
 - bacteremia and sepsis, sickle cell disease, children 474
 - cephalosporins, advanced-generation 564
 - community-acquired bacteria 301
 - community-acquired pneumonia 280
 - conjunctivitis 258, 260t41.1
 - erythromycin, poor coverage 570
 - ESBL production 553t77.1
 - parotitis 126
 - penicillin-beta-lactamase inhibitors 561
 - pneumonia 362
 - sinusitis 121t17.3
 - susceptibility, sickle cell disease 473
 - see also* influenza
- Haemophilus influenzae* B (Hib)
- acute bacterial meningitis, children 58t8.9
 - meningitis chemoprophylaxis 62t8.13
 - supraglottitis (epiglottitis) 123
 - vaccine 52, 123
- Haemophilus parainfluenzae*, infective endocarditis 1
- Haemophilus paraphrophilus*, infective endocarditis 1
- halofantrine contraindications, malaria, in pregnancy 403t58.17
- HA-MRSA (health-care-associated MRSA) 541, 542, 542t75.1
- hand infections 233–38
- general points 233
 - pearls and pitfalls 238
 - acute paronychia 236–37
 - Candida albicans* 236
 - children, herpetic whitlow 237
 - chronic paronychia 236
 - felon (volar pad of distal phalanx) 236–37, 238
 - fight bite examples 234f35.1
 - fight bite infections 233–35, 370
 - finger tip, felon 236f35.4
 - herpetic whitlow 237–38
 - herpetic whitlow vs. acute paronychia/felon 237, 238
 - human papilloma virus, HIV patient 207f30.3
 - index finger, purulent flexor tenosynovitis 235f35.2
 - Kanavel’s signs 236t35.2
 - knuckle lacerations 238
 - nail plate skin folds, acute paronychia 236f35.3
 - paronychia, acute 236–37
 - paronychia, chronic 236
- POCUS (point of care ultrasound) 235
- purulent tenosynovitis 235, 238
- uninfected fight bite 234, 234t35.1
- see also specific infections*
- hantavirus 514–19
- microbiology 514
 - epidemiology 514–15
 - clinical features 515–17
 - differential diagnoses 517
 - laboratory and radiographic findings 517
 - treatment 517–19
 - complications and admission criteria 518
 - infection control 518–19
 - pearls and pitfalls 519
- deer mouse (*P. maniculatus*) 514–15
- field mouse (*A. agrarius*) 514
- pneumonic plague 518
- Sin Nombre virus 514, 516t71.2, 519
- US occurrence 514–15
- see also* hantavirus
- cardiopulmonary syndrome; hemorrhagic fever with renal syndrome
- hantavirus cardiopulmonary syndrome (HCPS) 514
- clinical features 515–17
 - differential diagnosis in 517
 - laboratory and radiographic findings in 517
 - treatment 518–19
 - complications and admission criteria 518
 - pearls and pitfalls 519
- children, treatment 518t71.3, 519t71.4
- pneumonic plague 518
- harvest mite (*Trombicula autumnalis*) mite infestations 89, 90t13.4
- HAV *see* hepatitis A virus
- HBIG (hepatitis immunoglobulin) 378t57.4
- HBV *see* hepatitis B virus
- HCAP (health-care-associated CAP) 280, 283, 284t44.3, 286
- HCC (hepatocellular carcinoma) 156–57
- HCPS *see* hantavirus
- cardiopulmonary syndrome
- HCV *see* hepatitis C virus
- HDV *see* hepatitis D virus
- Head and Neck Surgery Guidelines, eardrop delivery 115
- head louse (*Pediculus humanus capitis*) 87, 88t13.1
- clinical features 91, 92
 - laboratory findings 92
 - treatment and prophylaxis 92–93
 - children, treatment 92–93
 - infants 92–93
 - life cycle and transmission 91
 - nits 91, 92

- non-insecticidal treatment 92–93
see also lice, human
- head trauma, penetrating 37
- health department notification
 requirements *see under*
 public health
- health-care-associated
 pneumonia 553
- health-care-associated CAP (HCAP)
 280, 283, 284t44.3, 286
- heart block, pericarditis/myocarditis
 13t2.4
- heart failure, myocarditis 12
- Helicobacter pylori*, peptic ulcers
 162, 163
- hematologic dysfunction, severe
 sepsis 468t65.2
- hematologic toxicity (penicillins
 ganciclovir, linezolid) 557
- hematopoietic stem cell transplants
 (HSCTs), infections in
 — epidemiology 458
 — clinical features 461
 — differential diagnosis 461–62
 — laboratory and radiographic
 findings 462–63
 — prophylaxis 463
 — treatment 463
 — complications and admission
 criteria 463–65
 — infection control 465
 — pearls and pitfalls 465
- allograft rejection 461
- biopsies 463
- children, treatment post-
 transplant 464t64.2
- drug interactions 465t64.3
- drug reaction and hypersensitivity
 461–62
- graft-versus-host disease 461
- immunosuppressive agents
 466t64.4
- infectious etiologies 462f64.2
- mortality rates 458
- phase 1: conditioning regimen
 461, 463
- phase 2: engraftment to day 100
 461, 463
- phase 3: >100 days post-
 engraftment 461, 463
- thromboembolic disease and
 vascular events 462
- transfusion-related fever 462
- hemodynamic failure, tetanus 71, 72
- hemolytic uremic syndrome, post-
 diarrheal 175t26.7
- hemorrhagic bullus, necrotizing soft-
 tissue infections 85f12.10
- hemorrhagic fever with renal
 syndrome (HFRS) 514
 — clinical features 515–16
 — differential diagnosis 517
 — laboratory and radiographic
 findings 517
 — treatment 517–18
 — complications and admission
 criteria 518
 — pearls and pitfalls 519
- hemorrhagic manifestations, fever in
 the returning traveler 413
- hemorrhagic smallpox 500
- hepatic abscess, secondary
 peritonitis 164
- hepatic dosage adjustments *see*
specific drug properties
- hepatitis
 — epidemiology and microbiology
 155–56, 156t24.1
 — clinical features 156–58
 — differential diagnosis 156t24.1,
 158
 — laboratory and radiographic
 findings 156t24.1, 158–59
 — treatment and prophylaxis
 156t24.1, 160–61
 — management and admission
 criteria 160
 — infection control 161
 — pearls and pitfalls 161
- abdominal pain differentiation
 165–66
- acute hepatitis 156, 160, 161
- acute liver failure 156–57, 160,
 161
- chronic hepatitis 156–57
- chronic liver disease 161
- chronic liver disease patients 158
- cirrhosis 156–57
- clinical courses (by virus) 157–58
- complete blood count 158
- cryptogenic hepatitis 155
- CT scans 159
- elderly patients, admission
 criteria 160
- hepatocellular carcinoma 156–57
- hepatotoxicity 159t24.3
- hepatotropic viruses 156
- immunocompromised patients
 156, 160
- liver transplants 156, 160
- myocarditis 11
- pericarditis 6
- public health reporting 160
- superinfection risk 158
- transmission modes 155
- ultrasound scans 159
- vaccines 160–61
- West Nile virus infections 75
see also acute liver failure,
 viral hepatitis; exposure
 management, blood or
 body fluid
- hepatitis, acute
 — clinical features 156
 — differential diagnosis 158
 — laboratory and radiographic
 findings 156t24.1, 158
 — treatment 156t24.1, 160
 — management and admission
 criteria 160
 — infection control 161
- and acute liver failure 156
- ALT and AST levels 158
- hepatitis B 157, 160
- hepatitis C 158, 159, 160
- hepatitis E 158
- immunocompromised patients 159
- liver biopsy 159
- non-microbial etiologies 158
- serologic assays 158
- hepatitis, chronic 156–57
 hepatitis B 155, 156–57
 hepatitis C 155–56, 158, 159, 160
 hepatitis D 156
- hepatitis, in pregnancy 398–401
 — epidemiology 398–400
 — clinical features 400
 — differential diagnosis 400
 — laboratory and radiographic
 findings 400
 — treatment 400–01
 — complications and admission
 criteria 401
 — infection control 401
 — pearls and pitfalls 403–04
- hepatitis A virus (HAV)
 — epidemiology 155
 — clinical course/chronology 157
 — treatment 160
- children, transmission 157
- diarrhea in HIV patients 181
- incubation periods 157
- mortality rates 157
- in pregnancy 401t58.14
- vaccines 160
- hepatitis B virus (HBV)
 — epidemiology 155, 375–76
 — clinical course/chronology
 157–58
 — laboratory and radiographic
 findings 158–59
 — treatment 160
- acute 157, 160
- acute liver failure 156, 157
- cesarean section 399
- chemotherapy patients 160
- chronic 156–57
- HBD co-infection 156, 158
- hematopoietic stem cell transplants,
 transfusion fever 462
- hepatitis, in pregnancy 401t58.14
- human bite infections 369
- immigrants 155
- immunosuppression patients 160
- incubation periods 157
- infants, transmission to 157
- neonates, infected 157
- PEP regimens, exposure
 management 378, 382
- risk levels, transmission 377t57.3
- screening recommendations 155
- serology testing 158–59, 159t24.4
- sexual transmission 155
- solid organ transplants 460t64.1,
 461
- vaccines 160
- viral serology 159t24.4
- hepatitis C virus (HCV)
 — epidemiology 155–56
 — clinical course/chronology
 158
 — laboratory and radiographic
 findings 159
 — treatment 160
- acute 158, 159, 160
- chronic 155–56, 158, 159, 160
- cirrhosis, HCV-associated 158
- direct acting antivirals 160
- fulminant hepatic failure 158
- hematopoietic stem cell
 transplants, transfusion
 fever 462
- hepatocellular carcinoma 158
- human bite infections 369
- immunizations 160
- injection drug users 155
- pregnant women 401t58.14
- risk levels, exposure management
 376, 377t57.3
- screening, CDC
 recommendations 155
- solid organ transplants 460t64.1,
 461
- updates, virus and treatments
 160
see also exposure management,
 blood or body fluid
- hepatitis D virus (HDV)
 acute liver failure 156
- chronic 156
- clinical course 158
- epidemiology 156
- immunization 160
- treatment 160
- hepatitis E virus (HEV)
 — epidemiology 156
 — clinical course 158
 — treatment 160
- acute 158
- children 158
- genotypes 156
- incubation periods 158
- mortality rates 156
- vaccines 160–61
- zoonic reservoirs and
 transmission 156
- hepatitis G virus (HGV) *see*
 GB virus
- hepatitis immunoglobulin (HBIG),
 hepatitis B post-exposure
 prophylaxis 378t57.4
- hepatocellular carcinoma (HCC)
 156–57
- hepatotoxic medications 155–61
 common 159t24.3
- hepatotoxicity 557
- hepatotropic viruses 155
 acute liver failure 156
- heroin users (black tar heroin)
 drug and paraphernalia
 435f61.2
- necrotizing soft-tissue infections
 84, 434–35
- wound botulism 438
- herpangina, pharyngitis 130t20.1
- herpes, anti-herpes-virus drugs
 — nephrotoxicity 578t78.44
 — properties 577–78
see also under herpes;
specific drugs
- herpes diarrhea, HIV-infected
 patients 183t27.3

Index

- herpes genitalis 208–12
 — epidemiology and microbiology 208
 — clinical features 208–10
 — differential diagnosis 210
 — laboratory and radiographic findings 210, 210t31.1
 — treatment and prophylaxis 210–11
 — complications and admission criteria 210–12
 — infection control 212
 — pearls and pitfalls 218
 young adults 208
 herpes simplex virus (HSV)
 cesarean section 399t58.12
 diarrhea, HIV-infected patients 181
 hematopoietic stem cell transplants 461
 keratitis 259, 262
 myocarditis 11
 neonates, fever 328, 330t50.1, 332
 non-gonococcal urethritis 202
 oral drug, typical 578
 solid organ transplants 460t64.1
 transmission, human bite infections 369
 urethritis (male infections) 192
 uveitis and retinitis 274, 276t43.1
 herpes simplex virus 1 (HSV-1) 37
 herpetic whitlow 237
 herpes simplex virus 1 and 2 (HSV-1 and HSV-2)
 aseptic and viral meningitis 54
 herpes genitalis 208
 herpetic whitlow 237
 pharyngitis 130t20.1
 herpes simplex virus encephalitis (HSV-1 encephalitis) 37–40
 — epidemiology 37–38
 — clinical features 38
 — differential diagnosis 38
 — laboratory and radiographic findings 38–39
 — treatment and prophylaxis 39–40
 — complications and admission criteria 40
 — infection control 40
 acyclovir notes 39, 40
 anti-herpes-virus drugs 577–78
 brain images 39f6.2
 children 38
 elderly patients 38
 gold standard, diagnosis 38
 viral encephalitis 52–53
 young adults 38
 herpes simplex virus (HSV), fever in pregnancy
 — epidemiology and microbiology 396
 — clinical features 396–97
 — laboratory tests 398t58.11
 — treatment and prophylaxis 396
 — complications and admission criteria 396–97
 — infection control 397
 — pearls and pitfalls 404
 herpes viruses
 aseptic and viral meningitis 54
 otitis externa 115t15.1
 herpes zoster, anti-herpes-virus drugs 577–78
 herpes zoster oticus (Ramsey-Hunt Syndrome), otitis externa 114, 115
 herpes virus infections, anti-herpes-virus drugs 577–78
 Herpesvirus simiae (monkey B virus), bite infections 369
 herpetic whitlow (herpes simplex infection, finger) 237–38
 — epidemiology and microbiology 237
 — clinical features 237
 — differential diagnosis 237, 238
 — laboratory and radiographic findings 238t35.4
 — treatment 238, 238t35.4
 — complications 238
 vs. acute paronychia/felon 236, 237, 238
 children 237
 herpes genitalis 210f31.4
 HEV *see* hepatitis E virus
 HFRS (hemorrhagic fever with renal syndrome) 514
 — clinical features 515–16
 — differential diagnosis in 517
 — laboratory and radiographic findings in 517
 — treatment 517–18
 — complications and admission criteria 518
 — pearls and pitfalls 519
 HGE (human granulocytic ehrlichiosis) 94t13.7
 HGV (hepatitis G virus) *see* GB virus
 HHV-6 (human herpes virus-6)
 hematopoietic stem cell transplants, phase 2 infections 461
 HSV-1 encephalitis differential diagnosis 38
 meningitis 54
 viral encephalitis 52–53
 Hib (*Haemophilus influenzae* B)
 acute bacterial meningitis, children 58t8.9
 meningitis chemoprophylaxis 62t8.13
 supraglottitis (epiglottitis) 123
 vaccine 52, 123
 HICPAC (Hospital Infection Control Practices Advisory Committee)
 anthrax 488
 botulism 31
 tularemia 512
 hidradenitis suppurativa (abscesses) 80–81
 hip replacements *see* prosthetic joint infections
Histoplasma
 fungal causes, influenza-like illnesses 301
 uveitis and retinitis 276t43.1
Histoplasma capsulatum
 fungal meningitis 59
 HIV pulmonary infections 289t45.1, 290, 293–94, 294t45.4
 solid organ transplants 460t64.1
 vertebral osteomyelitis 254t40.1
 histoplasmosis
 diarrhea, HIV patients 183t27.3
 pericarditis 7
 history taking *see* patient history taking
 HIV (human immunodeficiency virus)
 acute infection, differential diagnosis 100t14.1
 risk levels, exposure management 376–77
 solid organ transplants 460t64.1
 testing, uveitis and retinitis 274
 transmission and acquisition risk, chancroid 217
 uveitis and retinitis 276t43.1
 virus transmission, human bite infections 369
see also exposure management, blood or body fluid
 HIV, PEP regimens 379–82
 additional interventions and prophylaxis 382
 discontinuation 379–80
 expert consultation 381–82
 failure of PEP 380–81
 HIV altered mental status *see* altered mental status, HIV patients
 HIV ANUG (Vincent's angina) 145
 HIV aseptic and viral meningitis 54, 61
 HIV brain disorders, neuroimaging 22t4.5
 HIV cesarean section 402
 HIV chancroid 218t31.6
 HIV death predictor 181
 HIV dementia
 ART therapy impact 18
 CD4 counts 18
 diffuse cerebral dysfunction 21t4.4
 neuroimaging 22t4.5
 HIV diarrhea *see* diarrhea, in HIV patients
 HIV enteropathy 183t27.3, 186
 HIV fever and rash 106–08
 acute HIV infection 107
 adverse drug reactions 108
 post-herpetic neuralgia, treatment 107
S. aureus 107
 sexually transmitted diseases 107
 skin and soft-tissue infections, bacterial 107
 varicella zoster 107–08
 HIV fever in pregnancy 401–02
 — epidemiology 401
 — clinical features 401
 — differential diagnosis 401
 — laboratory and radiographic findings 401–02
 — treatment and prophylaxis 402
 — complications and admission criteria 402
 — infection control 402
 — pearls and pitfalls 403–04
 HIV invasive fungal rhinosinusitis 121
 HIV IRIS (immune reconstitution inflammatory syndrome) 19–20, 22t4.5
 HIV meningitis, CSF evaluation 56
 HIV myocarditis 11
 HIV osteomyelitis 242
 HIV parasitic diarrhea 174, 178t26.12
 HIV parotitis 126–27, 127t19.1
 HIV pericarditis 6
 HIV pharyngitis 130t20.1, 134
 HIV pulmonary disease list 288
 HIV pulmonary infections 288–96
 — microbiology 288
 — epidemiology 288
 — clinical features 288–90
 — differential diagnosis 291–94
 — laboratory and radiographic findings 290, 291t45.2
 — treatment 294–95
 — admission criteria 295–96
 — isolation and infection control 295
 — pearls and pitfalls 295–96
 ARG (room-air arterial blood gas) 290
 ART therapy timing 293
Aspergillus 289t45.1, 293–94, 294t45.4
 ATS/IDSA guidelines on treatment 290, 294
 atypical bacteria 289t45.1
C. neoformans 289, 289t45.1, 290, 293–94, 294t45.4
 CD4 count 290, 293–94
 chest computed tomography (CT) 291
 chest imaging 290–91
 CURB-65 severity scores 295, 296t45.7
 cytomegalovirus 289, 289t45.1, 294t45.4
H. capsulatum 289t45.1, 290, 293–94, 294t45.4
 HIV-associated disease list 288
 ICU treatment 294
 IDSA guidelines 290
 influenza viruses 289t45.1
 Kaposi's sarcoma 289t45.1, 292–93, 294t45.4
 MAC (*M. avium* complex) 289t45.1, 294t45.4
 mortality rates 288
 MRSA coverage 294, 296t45.6
 oropharyngeal thrush, HIV-identifying illnesses 290
P. aeruginosa 290, 293–94, 294t45.4, 296t45.6
 pneumonia severity index 295, 296t45.7

Index

- recurrent bacterial pneumonia 294
T. gondii 289, 289t45.1, 293–94, 294t45.4
- HIV respiratory infections, bacterial pneumonia
 — microbiology 288, 291t45.2
 — clinical features 289
 — differential diagnosis 293–94, 294t45.4
 — laboratory and radiographic findings 291t45.2
 — treatment 294–95, 296t45.6
 — admission criteria 295
- atypical bacteria 289t45.1
 gram-negative bacteria 289t45.1, 291t45.2
H. influenzae 289t45.1, 291t45.2, 294t45.4
L. pneumophila 289t45.1, 294
 radiographic findings 291
 recurrent bacterial pneumonia 294
S. aureus 289t45.1
S. pneumoniae 288, 290, 291t45.2, 294, 294t45.4
- HIV respiratory infections, PCP (*Pneumocystis pneumonia*)
 — microbiology 288
 — clinical features 289
 — differential diagnosis 294t45.4
 — laboratory and radiographic findings 290, 291t45.2
 — treatment 294–95, 296t45.6
 — admission criteria 295
- P. jiroveci* pneumonia 289t45.1, 290
 radiographic findings 291
- HIV respiratory infections, tuberculosis (*M. tuberculosis*)
 — microbiology 288
 — clinical features 289
 — differential diagnosis 293, 294t45.4
 — laboratory and radiographic findings 290, 291t45.2
 — treatment 296t45.6
 — admission criteria 295
- fluoroquinolone resistance 294
 multidrug-resistant TB 294
 radiographic findings 291–93
- HIV syphilis, treatment regimens 105t14.6, 107, 216t31.4
- HIV TEN (toxic epidermal necrolysis) 109
- HIV TMP-SMX cautions 572
- HIV tuberculosis
 CDC TB treatment guidelines 316
 radiographic findings 311
- HME (human monocytotropic ehrlichiosis) 94t13.7
- holidaymakers *see* fever in the returning traveler
- home remedies
 acute otitis media 118
 BRAT diet 175
- homeless persons, TB transmission 309
- homosexually active men *see* men who have sex with men
- hordeola (eyelid infection) 268
- hospital diarrhea epidemics, astrovirus 170
- Hospital Infection Control Practices Advisory Committee (HICPAC)
 anthrax 488
 botulism 31
 tularemia 512
- hospital onset infections *see* nosocomial infections
- house fly (*Musca domestica*), myiasis 95t13.8, 96t13.9
- HPAI (highly pathogenic avian influenza) *see under* avian influenza A
- HPV *see* human papilloma virus
- HRIG vaccine, rabies 66
- HSV *see under* herpes simplex virus
- HTIG vaccine (human tetanus immune globulin) 71–72
- human bite infections
 — microbiology 369
 — epidemiology 370
 — treatment and prophylaxis 371–73, 372t56.1
 cellulitis risks 82t12.2
see also bite infections
- human granulocytic ehrlichiosis (HGE) 94t13.7
- human herpes virus-6 (HHV-6), meningitis 54
- human immunodeficiency virus *see under* HIV
- human lice *see* head louse; lice, human
- human metapneumovirus 301
- human monocytotropic ehrlichiosis (HME) 94t13.7
- human papilloma virus (HPV) 205
 — clinical features 205
 — differential diagnosis 205
 — laboratory and radiographic findings 205, 206t30.7
 — treatment and admissions criteria 205, 206t30.7
 — complications 205
 — infection control 205
 — prevention 205
 — pearls and pitfalls 206–07
- condyloma accuminata (genital wart) 205
- condyloma accuminata, on the penis 207f30.2
- hands, HIV patient 207f30.3
- incubation periods 206t30.7
- solid organ transplants 461
- urethritis (male infections) 192
- vaccines 205
- human t-cell leukemia virus, uveitis and retinitis 276t43.1
- human tetanus immune globulin (HTIG vaccine) 71–72
- HUS (hemolytic-uremic syndrome), acute infectious bacterial diarrhea 172
- hydrocortisone therapy, septic shock 470
- hydroxychloroquine sulfate (Plaquenil and generic)
 antimalarial regimens 420t60.6
Plasmodium malaria 419t60.5
- hydroxyiminodiacetic acid (HIDA) scan, acute calculous cholecystitis 147–48
- hypercalcemia, abdominal pain differentiation 165–66
- hyperemesis gravidarum, botulism differential diagnosis 29
- hyperexia, febrile child 335
- hypothyroidism, botulism differential diagnosis 29
- iatrogenic botulism 26, 28t5.1, 29
- ibuprofen
 acute otitis media 118
 pericarditis 10t2.3
- ICU (intensive care unit)
 acute liver failure, viral hepatitis 160, 161
 community-acquired pneumonia 284t44.3
 HIV pulmonary infections 294
- IDSA guidelines (Infectious Diseases Society of America)
 acute bacterial meningitis 61
 cellulitis recommendations 83, 84
 dexamethasone, acute bacterial meningitis 57
 diabetic foot infection classification 228–29
 diabetic foot infections 230, 231
 febrile neutropenia definition 448
 HCV updates 160
 HIV pulmonary infections 290, 294
- imaging (prior to lumbar puncture, adults), acute bacterial meningitis 56t8.5
- influenza, virus and treatment updates 306
- meningitis, acute bacterial 56t8.5, 57, 61
- shunt infections, acute bacterial meningitis 61
- SSTI treatment, VRE infections 551
- tuberculosis treatment 312
- ventriculitis 61
- VRE infections 548
- IDU (injection drug use) *see under* injection drug use
- IE *see* infective endocarditis
- imipenem (Primaxin)
 — activity spectrum 557–59
 — properties and dosages 565
- anthrax 486t67.3
- ESBL-producing organisms and infections 554, 554t77.3
- imipenem-cilastatin, oncology patients 449–50
- imiquimod, human papilloma virus 206t30.7
- immigrants
Entamoeba histolytica diarrhea 174
 hepatitis B virus 155
see also fever in the returning traveler; pregnant women, malaria
- immune antibody therapy, West Nile virus 77
- immune reconstitution
 inflammatory syndrome (IRIS) 19–20, 22t4.5
- immunization therapies
 AIG (anthrax immune globulin) 488
 Ebola virus disease 523–24
 hepatitis C virus 160
 hepatitis D virus 160
 tetanus, D'TaP 71
- immunocompromised patients
 abscess 33, 82
 acute viral hepatitis 159
 admission criteria, viral hepatitis 160
 aseptic and viral meningitis 61
 bacteriostatic vs. bactericidal drug activity 556
 deep neck space infections 135
 endocarditis 556
 enteric fever, vaccines 424
 febrile neutropenia 556
 infective endocarditis 4t1.2, 5t1.3
 intracranial abscess/brain abscess 33
 invasive fungal rhinosinusitis, sinusitis 121
Isospora diarrhea 174
 keratitis, treatment 262
 lower urinary tract infection, susceptibilities 322
 meningitis 556
 meningitis CSF studies 56t8.6
 myocarditis 11
 osteomyelitis 556
 parotitis 127
 pericarditis 10t2.3
 septic shock 556
 sinusitis, invasive fungal rhinosinusitis 121
 spinal epidural abscess, IDU-associated 438t61.10
 spine infections, epidural abscesses 256t40.2
 subcutaneous abscess, IDU-associated 434t61.4
 treatment, periorbital and orbital cellulitis 272t42.7
 viral hepatitis 156
- immunosuppressed patients
 hepatitis B virus 160
 herpes genitalis, treatment 211t31.2
 MOE (malignant otitis externa) 115
 septic arthritis, adults 227
 severe drug reactions 109
 tetanus 72
 West Nile virus infections 74, 76, 77
- immunosuppressive agents, nephrotoxicity 465t64.3, 466t64.4
- impetigo 88
- incarcerated hernia, abdominal pain differentiation 165–66

Index

- index finger, purulent flexor 235f35.2
 Indian subcontinent, rickettsial infections 426t60.9
 indinavir, skin reactions 108
 indomethacin, pericarditis 10t2.3
 infants
 acute bacterial meningitis 50–52, 55, 58t8.9
 acute otitis media 118, 118t16.2
 botulism 26, 28–29, 28t5.1, 29f5.1
 Campylobacter diarrhea, antibiotics 176–77
 CSF evaluation, meningitis 56
 febrile 335, 336
 head louse (*P. humanus capitis*) 92–93
 hepatitis B virus, from mother 157
 influenza 300, 301t46.1, 302t46.3
 meningitis, acute bacterial, presentation 55
 meningitis chemoprophylaxis 62t8.13
 musculoskeletal infections, pediatric 352t53.4
 ocular toxoplasmosis, uveitis and retinitis 274
 pericarditis, signs and symptoms 8t2.2
 peritonsillar abscess 133, 134
 pharyngitis 129
 plague 495t68.4
 severe diarrhea, rotavirus 170, 170t26.2
 sudden infant death syndrome 29
 tetracyclines, cautions 571
 urinary tract infections, differential diagnosis 366–67
 West Nile virus infections 77
 Zika virus 528
 see also children; meningitis, acute bacterial; *under* pediatric
 infants with diarrhea, exposure to ova and parasite testing 175t26.8, 178
 infections with a high CA-MRSA prevalence 543t75.2
 Infectious Diseases Society of America *see under* IDSA
 infectious mononucleosis, pharyngitis 130t20.1
 infective endocarditis (IE) 1–5
 — epidemiology and microbiology 1, 2t1.1
 — clinical features 1–2
 — laboratory and radiographic findings 3–4
 — treatment and prophylaxis 4–5
 — complications and admission criteria 4–5
 — pearls and pitfalls 5
 aminoglycosides 569
 antistaphylococcal penicillins 560t78.3
 CA-MRSA coverage 545t75.4
 cefazolin 562
 cephalosporins, third- and fourth-generation 563
 children, treatment 4t1.2, 5t1.3
 classic examination findings 3f1.1
 differential diagnosis 2–3
 echocardiography 4
Enterococcus endocarditis 551
 glycopeptides 566–68
 immunocompromised patients 4t1.2, 5t1.3
 intracranial abscess 34, 37
 intraparenchymal brain abscess, microbiology 34t6.2
 Janeway lesions 2
 lipopeptide 574–75
 MRSA coverage 545t75.4
 MRSA screening 544
 Osler nodes 2
 polymicrobial, IDU-associated 431
 pregnant women, treatment 4t1.2, 5t1.3
 prevention 143, 544, 546
 Roth spots 2
 VRE endocarditis 548–49, 551
see also infective endocarditis
 infective endocarditis, IDU-associated 431–33
 — epidemiology and microbiology 431, 431t61.1
 — clinical features 431
 — differential diagnosis 431–32, 433
 — laboratory and radiographic findings 431t61.1, 432
 — treatment and prophylaxis 432
 — complications and admission criteria 432
 — pearls and pitfalls 440–41
 CA-MRSA 431
 MRSA 431t61.1
 MSSA 431t61.1
 opioid users 431
 polymicrobial endocarditis 431
 inflammatory bowel disease
 abdominal pain differentiation 165–66
 patients with 190
 inflammatory diarrhea 169
 inflammatory myopathy, botulism differential diagnosis 29
 influenza 299–306
 — microbiology 299, 306
 — epidemiology 300
 — clinical features 300–02
 — differential diagnosis 301–02
 — laboratory and radiographic findings 301t46.2, 302–03
 — treatment 303–04
 — complications and admission criteria 302t46.3, 304–05
 — infection prevention and control 305
 — pearls and pitfalls 305–06
 A virus (uncomplex) 299, 302, 304, 304t46.5
see also under avian influenza
 A viruses; novel influenza A viruses
 ACIP viruses/treatment updates 306
 annual vaccinations 305
 antigenic drift 299
 antigenic shift 299
 antivirals 304t46.5, 578–79
 aspirin risks 304, 305
 B virus 299, 302, 304t46.5
 C virus 299
 chest X-rays 302, 304
 children 300, 301, 301t46.1, 302t46.3, 304
 co-infection pathogens, common 304
 community-acquired bacteria 301
 community-acquired pneumonia 300
 cruise ships 300
 elderly patients 301t46.1, 302t46.3, 305
 hematopoietic stem cell transplants, phase 3 infections 461
 high-risk people 300
 immunocompromised and immunosuppressed patients 300, 302, 302t46.3, 305
 incubation periods 300, 301t46.2
 infants 300, 301t46.1, 302t46.3
 LAIV vaccine 303
 mortality rates and risks 299, 300, 305
 MRSA coverage 305
 neonates 328
 nursing home residents 300, 305
 patient follow-up 305
 pharyngitis 129, 130t20.1
 pneumonia patients 300
 post-influenza CAP 543t75.2
 pregnant women, complications risks 300, 302t46.3, 305, 403
 rare infections, differential diagnosis 301
 Reye syndrome 304, 305
 school-age children 300, 301, 301t46.1, 302t46.3
 suspected 284t44.3
 travelers, returning 300
 types 531
 uncomplicated 301, 302t46.3
 unpredictability, consequences 306
 updates on viruses and treatments 306
 vaccination effectiveness 305
 viral pneumonia development 304
 influenza epidemics 299, 300
 influenza pandemics 299, 531
 influenza-like illnesses, differential diagnosis 301–02
 ingestions when traveling, associated illnesses 415t60.3
 INH (isoniazid), hepatotoxicity 159t24.3
 inhalational anthrax 481–82, 484, 485, 488
 inhalational botulism 26, 27, 28, 28t5.1
 injection drug use, black tar heroin drug and paraphernalia 435f61.2
 necrotizing soft-tissue infections 84, 434–35
 wound botulism 438
 injection drug use, infectious complications 430–41
 — microbiology 430–31
 — special considerations 432–33
 — pearls and pitfalls 440–41
 abscess 79
 altered mental status, differential diagnosis 19t4.2
 AMS, HIV patients 20
 deep neck space infections 135
 febrile but well-appearing 433
 fever 432–33
 hepatitis C virus 155
 infective endocarditis 431–33, 440–41
 necrotizing soft-tissue infections 434–35, 440–41
 osteomyelitis 244, 435–37, 440–41
 paralysis 431
 related NSTI, necrotizing soft-tissue infections 84
 septic arthritis 227, 435–37, 440–41
 spinal epidural abscess 437–38, 440–41
 subcutaneous abscess 433–34, 440–41
 tetanus 439–40
 wound botulism, IDU-associated 438–39
see also infective endocarditis, IDU-associated; injection drug use, black tar heroin; necrotizing soft tissue infections, IDU-associated; osteomyelitis, IDU-associated; spinal epidural abscess, IDU-associated; wound botulism, IDU-associated
 Intence *see* etravirine
 interferon gamma release assay, tuberculosis 311, 317
 interferon-alpha
 acute viral hepatitis 160
 West Nile virus infections 77
 interferon-based therapies
 viral hepatitis C 160
 viral hepatitis D 160
 internal jugular vein, septic thrombophlebitis *see* Lemierre's syndrome
 intestinal toxemia botulism 26, 28t5.1, 29
 intra-abdominal infections
 carbapenems and monobactams 565
 cephalosporins, advanced-generation 564
 cephalosporins, second-generation 562–63
 cephalosporins, third- and fourth-generation 564
 ESBL-producing organisms and infections 553
 nitroimidazoles 573
 penicillin-beta-lactamase inhibitor combinations 561–62
 tetracyclines and glycolines 571

Index

- intracranial abscess
 (intraparenchymal brain abscess) 33–37
 — epidemiology and microbiology 34
 — clinical features 34
 — differential diagnosis 34–35
 — laboratory and radiographic findings 35–36
 — treatment and prophylaxis 36–37
 — complications and admission criteria 37
 antibiotic therapy, initial 37
 cardiac disease patient (congenital) 37
 children, contiguous otitis 33
 elderly patients 33
 epidural brain abscesses 34
 infective endocarditis 34, 37
 intraparenchymal brain abscess 34–35
 lumbar puncture risks 35–36, 40
 mildly immunocompromised patients 33
 sinusitis, young adults 33
 subdural empyema 34
 intracranial pressure, elevation
 symptoms, meningitis 62
 intraparenchymal brain abscess 34–35
 intraperitoneal infections 162
 intrarenal abscess 326
 intraretinal hemorrhages, West Nile encephalitis 75
 Invanz *see* ertapenem
 invasive fungal rhinosinusitis 121, 122
 IRIS (immune reconstitution inflammatory syndrome)
 19–20, 22t4.5
 iritis, West Nile encephalitis virus 75
 irritable bowel syndrome, patients with 190
 isavuconazole (Cresemba) 575–76
 ischemic bowel, abdominal pain
 differentiation 165–66
 Isentress *see* raltegravir
 isolation, hospitalized patients
 C. difficile diarrhea 178
 fever in the returning traveler 413
 isoniazid
 Pott's disease (spinal tuberculosis) 255
 tuberculosis, drug-susceptible disease treatment 313
 tuberculosis, first-line antituberculosis drugs 313t47.3, 314t47.5
 tuberculosis, latent tuberculosis 314t47.4
Isospora diarrhea
 parasitic diarrhea, acute infectious 174, 174t26.5
 TMP-SMX 178t26.12
 itraconazole (Sporanox) 575–76
 children, post-transplant, febrile 464t64.2
 ivermectin (Mectizan, Stomectol)
 human lice 92–93, 93t13.6, 97
 scabies 89, 89t13.3, 97
 Janeway lesions, infective endocarditis 2
 Japan, rickettsial infections 426t60.9
 Japanese encephalitis complex 54
 joint aspiration
 complications from 225
 prosthetic joint infections 251
 septic arthritis, adults 225, 226, 226t33.1, 227
 joint replacements *see* prosthetic joint infections
 jugular vein, internal, septic thrombophlebitis *see* Lemierre's syndrome
 juvenile recurrent parotitis 126
 Kaletra *see* lopinavir
 Kanavel's signs of purulent tenosynovitis 236t35.2
 Kaposi's sarcoma
 diarrhea in HIV patients 182, 183t27.3, 186
 HIV pulmonary infections 289t45.1, 292–93, 294t45.4
 kava kava, hepatotoxicity 159t24.3
 Kawasaki disease (mucocutaneous lymph node syndrome)
 fever and rash differential diagnosis 100t14.1
 pediatric fever and rash 344–46
 Keflex *see* cephalexin
 Kefzol *see* cefazolin
 keratitis 259–62
 — epidemiology and microbiology 259, 261t41.3
 — clinical features 259–60
 — differential diagnosis 261
 — laboratory and radiographic findings 261–62, 261t41.3
 — treatment and prophylaxis 262–63
 — complications and admission criteria 262
 — pearls and pitfalls 262
 onchocerciasis (river blindness) 261, 414t60.1
 ketoacidosis, abdominal pain
 differentiation 165–66
 ketoconazole, hepatotoxicity 159t24.3
 ketolides
 — properties and dosages 570
 C. difficile 570
 see also specific drugs
Kingella kingae, infective endocarditis 1
Klebsiella
 — antibacterial drug spectra 558t78.1
 — antibacterials, commonly used 557–59
 acute bacterial cholangitis 150, 152t23.5
 acute bacterial prostatitis 196–97
 acute calculous cholecystitis 146
 acute calculous cholecystitis, resuscitation 149t23.2
 acute cystitis 319
 aminoglycosides 569
 bacteremia and sepsis, in sickle cell disease 474
 cephalosporins, advanced-generation 565
 cephalosporins, third- and fourth-generation 563
 cephalosporins, third-generation, cautions 564
 deep neck space infections 135
 emphysematous pyelonephritis 326
 ESBL production 552, 553
 ESBL screening 553
 fosfomycin 573
 meningitis, shunt infections 61
 neonates, fever 328, 330t50.1
 penicillin-beta-lactamase inhibitor combinations 561
 piperacillin-tazobactam 561
 pyelonephritis, adults 324, 326
 sepsis 467
 septic arthritis and osteomyelitis, IDU-associated 435–36
 shunt infections, meningitis 61
 spontaneous bacterial peritonitis 163, 163t25.1
 supraglottitis (epiglottitis) 124t18.1
 urinary tract infections, in pregnancy 387–88
Klebsiella oxytoca
 antibiotic-associated diarrhea 456
 ESBL production 553t77.1
Klebsiella pneumoniae
 ESBL production 553t77.1
 health-care-associated CAP 280
 oncology patients 450
 parotitis 126
 peritonitis, liver abscess 165t25.6
 knee effusion, septic arthritis, adults 226f33.1
 knee replacements *see* prosthetic joint infections
 knuckle lacerations 238
 Koplik's spots 108f14.11
 Korea, rickettsial infections 426t60.9
 labetalol, tetanus, IDU-associated 440t61.14
Lactobacilis
 bacterial vaginosis 221t32.1
 deep neck space infections 135
 lagomorph bite infections *see* bite infections
 LAIV (live attenuated influenza virus) vaccine 303
 Lambert-Eaton syndrome, botulism differential diagnosis 29
 lamivudine (Epivir, 3TC)
 hepatitis B virus, in pregnancy 401t58.14
 HIV PEP regimens, occupational 379t57.5, 380t57.6, 381t57.7
 side effects and toxicities 183t27.5, 381t57.7
 lamotrigine, severe drug reactions 109
 large bowel diarrhea, HIV patients 182t27.1
 laryngeal trauma, botulism differential diagnosis 29
 laryngotracheobronchitis *see* croup
 latent syphilis, treatment 105t14.6, 216t31.4
 latent tuberculosis
 — clinical features 310
 — laboratory and radiographic findings 311
 — treatment 313–14
 CDC guidelines, TB tests 312t47.2
 left-ventricular assist devices (LVADs) 14
Legionella, antibacterials, commonly used 557–59
Legionella pneumophila
 community-acquired pneumonia 280, 282
 influenza-like illnesses 301
 leishmaniasis, in papule diagnosis 96t13.10
 Lemierre's syndrome (septic jugular venous thrombophlebitis) 135, 137–39
 — epidemiology and microbiology 138
 — clinical features 138
 — differential diagnosis 138
 — laboratory and radiographic findings 138–39
 — treatment 139
 — complications and admission criteria 139
 — pearls and pitfalls 139–38
 anticoagulation 139
 catheter-associated 138, 138t21.2, 139
 deep mandibular space infections 143
 peritonsillar abscess 134
 pharyngitis 129, 130t20.1, 131, 132
 trismus, severe (lockjaw) 138
 young adults 129, 138
 leptomeningeal carcinomatosis 46, 52
 Leptospirosis
 chronic meningitis 60
 diarrhea, acute infectious 175t26.7
 fever in the returning traveler 417, 427–28
 lesion classification 99, 340t52.1
 lesions
 CA-MRSA 543, 543t75.2
 fever in the newborn 330t50.1
 Janeway, infective endocarditis 2
 mite lesions, superinfection risk 89
 primary 99
 primary, on penis 209f31.2
 primary syphilis 212
 recurrent, on penile shaft 209f31.3
 secondary 99
 smallpox 502

Index

- lesions (*cont.*)
 “spider bite” lesion (necrotic furuncle) 543, 543t75.2
 varicella skin lesions 342
see also sexually transmitted diseases, ulcerative
- lesser house fly (*Fannia canicularis*), myiasis 95t13.8, 96t13.9
- leucovarin, altered mental status, HIV patients 24t4.6
- leukocytosis, CIED infections 15
- levofloxacin (Levaquin) 568–69
 — activity spectrum 557–59
 acute bacterial cholangitis 152t23.5
 acute bacterial prostatitis 197t29.5
 acute calculous cholecystitis, resuscitation 149t23.2
 acute chest syndrome, in sickle cell disease 476t66.2
 acute cystitis 320t48.1
 anthrax 486t67.3
 bacteremia and sepsis, in sickle cell disease 475t66.1
 bacterial keratitis 262
 chlamydia 200t30.2
 community-acquired pneumonia 283t44.2, 284t44.3
 epididymitis 196t29.4
 HIV pulmonary infections 294
 MRSA susceptibilities 545t75.3
 non-gonococcal urethritis 202, 203t30.5
 oncology patients 449–50
 osteomyelitis 243t37.1
 postpartum endometritis 407t59.1
 pyelonephritis, adults 326t49.2
Shigella diarrhea 177t26.10
 urethritis (male infections) 194t29.2
- Lexiva *see* fosamprenavir
- lice, human 89–90, 91–93
 — clinical features 92
 — laboratory findings 92
 — treatment and prophylaxis 92–93
 — infection control 96–97
- body lice (*P. humanus corporis*) 91–92
 CDC guidelines, pubic lice 91
 human louse (pediculosis) 88t13.1
 infants 92–93
 infestation types 91
 non-insecticidal treatment 92–93
 pubic lice (*P. pubis*) 91, 92
 sexual abuse, suspected 91, 92t13.5
 treatment failures 97
see also head louse
- lidocaine
 acute necrotizing ulcerative gingivitis 145
 acute otitis media 118
 periapical abscess 143
 peritonsillar abscess 133
- lincosamides 571–72
 — properties and dosages 571–72
see also specific drugs
- lindane (Kwell), scabies 89t13.3
- linezolid (Zyvox) 574–75
 — activity spectrum 557–59
 — interactions 575
 anthrax 486t67.3
 HIV pulmonary infections, MRSA coverage 296t45.6
 MRSA susceptibilities 545t75.3
 toxic shock syndrome 102t14.4
 VRE infections 550t76.3, 551
- lipopeptides
 — properties and dosages 574–75
 infective endocarditis 574–75
see also specific drugs
- liposomal, altered mental status, HIV patients 24t4.6
- liposomal amphotericin B (AmBisome), properties and dosages 577
- Listeria*
 — antibacterial drug spectra 558t78.1
 — antibacterials, commonly used 557–59
 chorioamnionitis 394t58.8, 395
 penicillin allergic patients 572
 TMP-SMX 572
- Listeria monocytogenes*
 acute bacterial meningitis, adults 50 plus 58t8.9
 acute bacterial meningitis, neonates 50, 52, 58t8.9
 CNS infections, HIV/AIDS patients, initial treatment 24t4.6
 CSF evaluation, meningitis 56
 diffuse cerebral dysfunction in HIV/AIDS 21t4.4
 febrile child 334–35, 336
 neonates, fever in 328, 330t50.1, 332
 solid organ transplants 459, 460
- live attenuated influenza virus (LAIV) vaccine 303
- liver abscess classification 164
- liver abscess, secondary peritonitis 164
- liver biopsy, viral hepatitis 159
- liver disease, adults with, *Campylobacter* diarrhea 171t26.3
- liver failure, acute *see* acute liver failure, viral hepatitis
- liver transplants, viral hepatitis 156, 160
- livestock exposure, associated illnesses 415t60.3
- loop drain procedure, abscess 81f12.6
- loperamide (antimotility agent) 175–76, 186
- lopinavir (Kaletra, LPV)
 diarrhea effect 183t27.5, 381t57.7
 HIV PEP regimens, occupational 379t57.5, 380t57.6, 381t57.7
- louse bites while traveling associated illnesses 415t60.3
 rickettsial infections 426t60.9
- lower urinary tract infection, in adults (acute cystitis) 319–22
 — microbiology 319
 — epidemiology 319
 — clinical features 319–20
 — differential diagnosis 320–21
 — laboratory and radiographic findings 320t48.1, 321
 — treatment 320t48.1, 321–22
 — complications and admission criteria 322
 — pearls and pitfalls 322
- asymptomatic bacteriuria 321, 322
- catheter-associated susceptibilities 322
- complicated lower urinary tract infection 320t48.1, 322
- elderly patients, susceptibilities 322
- fluoroquinolone allergy 320t48.1
- fosamprenavir 573–74
- immunocompromised patients, susceptibilities 322
- pregnant women 320t48.1, 322
- TMP-SMX guidance 572
- uncomplicated lower UTI 320t48.1, 321–22
- urine collection methods 321
- urine culture 321
- urine dipstick 321
- urine microscopy 321
- LPAI (low pathogenic avian influenza) virus subtypes 532
- LPV *see* lopinavir
- Ludwig’s angina 124
- deep neck space infections 135, 136, 137
- mortality rates 140
- trismus, severe (lockjaw) 136, 141
- lumbar puncture risks
 febrile child 335
 intracranial abscess/brain abscess 35–36, 40
- lumbar spine, lateral plane radiograph, osteomyelitis 245f37.3
- lung infection, intracranial abscess 34t6.2, 37
- LVADs (left-ventricular assist devices) 14
- Lyme arthritis, pediatric orthopedic infections 352
- Lyme disease (spirochetes) 103–06
 acute necrotizing ulcerative gingivitis 145
 arthritis 106t14.8
 Bell’s palsy 94t13.7, 105, 106t14.8
Borrelia burgdorferi 103–06
 cardiac first-degree block 106t14.8
 cardiac second- or third-degree block 106t14.8
 carditis 12
 cefuroxime (Ceftin) 106t14.8
 deer tick bite 94t13.7, 103
 erythema migrans associated with Lyme disease 106f14.8, 106t14.8
 fever and rash differential diagnosis 100t14.1
 LymeRix vaccine 94t13.7
 myocarditis 11
- periodontal infections 143, 144t22.2
- spinal cord infections differential diagnosis 44
- ticks/tick-borne illnesses 93, 94t13.7
- uveitis and retinitis 274
- LymeRix vaccine 94t13.7
- lymphangitis, cellulitis 83f12.8
- lymphocytic choriomeningitis virus (LCMV)
 aseptic and viral meningitis 54
 solid organ transplants 460t64.1
- lymphoma, abdominal pain differentiation 165–66
- lymphomatous meningitis, diffuse cerebral dysfunction, HIV/AIDS patients 21t4.4
- Lyssavirus*, rabies 64
- macaque monkeys, monkey B virus 369
- Macrobid *see* nitrofurantoin
- Macrochantin *see* nitrofurantoin
- macrolides
 — drug activity spectra 557–59
 — hepatotoxicity 159t24.3, 557
 — properties and dosages 570
- C. difficile* 570
- cellulitis 83
- chlamydia, neonates 332
- HIV pulmonary infections 294
see also specific drugs
- macules 99, 340t52.1
- maculopapular rash, secondary syphilis 214f31.10
- maggot infestation (facultative myiasis) 93–95, 95t13.8, 96t13.9
- magic mouthwash 144t22.2, 145
- magnesium sulfate, muscle spasms, tetanus 71, 440t61.14
- magnetic resonance cholangiopancreatography (MRCP)
 acute bacterial cholangitis 150
- malaria 416–21
 — epidemiology and microbiology 416
 — clinical features 416–17, 417t60.4
 — differential diagnosis 417
 — laboratory and radiographic findings 417–18, 417t60.4
 — prophylactic antimalarial regimens 420t60.6
 — treatment 417t60.4, 418, 419t60.5
 — complications and admission criteria 418
 — pearls and pitfalls 428–29
- acute malaria treatment 419t60.5
- Anopheles* mosquito 416
- ARDS, *P. vivax* 416
- CDC guidelines 418
- cerebral malaria 416–17
- children, acute malaria treatment 419t60.5

Index

- children, antimalarial regimens 420t60.6
- co-infection, Ebola virus disease 524
- incubation period 417t60.4
- mortality rates, cerebral malaria 416
- P. falciparum* malaria 416, 418, 419t60.5
- P. malariae* malaria 416, 419t60.5
- P. ovale* malaria 416, 419t60.5
- P. vivax* malaria 416, 419t60.5
- see also pregnant women, malaria
- Malarone see atovaquone-proguanil
- malathion (Ovide), human lice 92, 93t13.6
- male genitourinary infections see genitourinary infections, male
- malignant otitis externa (MOE) 114
- malignant smallpox (flat-type smallpox) 500
- mandibular space infections, deep see deep mandibular space abscess/infections
- maraviroc
- diarrhea effect 183t27.5, 381t57.7
- HIV PEP regimens, occupational 381t57.7
- Marburg virus diarrhea 175t26.7
- mass casualty setting
- anthrax 485–87
- plague 494
- tularemia 511–12
- mastitis (lactation mastitis) 409–10
- epidemiology and microbiology 409
- clinical features 409
- differential diagnosis 409
- laboratory and radiographic findings 409, 410t59.4
- treatment and prophylaxis 409–10
- pearls and pitfalls 411
- breast abscess 410t59.4, 410t59.5
- MDROs see drug-resistant organisms
- MDR-TB (multidrug-resistant tuberculosis) 308–09, 316
- measles (rubeola)
- clinical features 104–06
- differential diagnosis 100t14.1
- otitis externa 115t15.1
- mebendazole, parasitic cholangitis 153t23.6
- mechanical diarrhea 169
- medications, altered mental status 19t4.2
- see also under drug
- Mediterranean spotted fever 426t60.9
- mefloquine (Lariam and generic)
- antimalarial regimens 420t60.6
- with caution, malaria, in pregnancy 403t58.17
- P. falciparum* malaria 419t60.5
- Mefoxin see cefoxitin
- men who have sex with men (MSM) CA-MRSA 542
- diarrhea, acute infectious 175t26.8, 178
- epidemic syphilis 102
- hepatitis A virus, prophylaxis 382
- hepatitis B virus 155
- herpes simplex proctitis 212
- Kaposi's sarcoma 293
- oral chancres 212
- ova and parasite testing 175t26.8, 178
- perineal ulcers 212, 213
- S. flexneri* 171
- stool tests 178
- syphilis 59–60, 102, 212, 213
- syphilis chancres 213
- urethritis 192–93
- meningitis 50–62
- microbiology 52
- epidemiology 50
- clinical features 54
- differential diagnosis 52, 55, 60–61
- laboratory and radiographic findings 55–57
- prophylaxis 61
- complications and admission criteria 61–62
- infection control 62
- special considerations 61
- pearls and pitfalls 62
- acute bacterial vs. viral vs. chronic 52, 60–61
- acute otitis media, complication 119
- acute VRE infections 548–49
- anthrax 483, 484, 485
- atypical bacterial 52
- cephalosporins, third- and fourth-generation 564
- chemoprophylaxis 62, 62t8.13
- eosinophilic meningitis, CSF studies 56t8.6
- febrile child 336, 337t51.1
- fungal meningitis 57–59
- glycopeptides 566–68
- immunocompromised patients 61
- intracranial pressure symptoms 62
- lymphomatous, HIV/AIDS patients 21t4.4
- MSSA 562
- mumps parotitis complication 128
- N. meningitidis* coverage 566
- neonates, fever in 330t50.1
- neurosurgical procedure history 61
- non-infectious causes 60–61
- parasitic 57, 60
- penetrating trauma prophylaxis 61
- penicillin resistance 560
- plague, clinical features 493
- shunt infections 61
- steroid treatments 56–57
- syphilitic 57, 59–60
- syphilitic, HIV/AIDS patients 21t4.4, 22t4.5
- tuberculous 57, 59, 62
- tuberculous, HIV/AIDS patients 21t4.4, 22t4.5, 24t4.6
- West Nile see West Nile meningitis
- meningitis, acute bacterial
- microbiology 50–52
- clinical features 54–55
- differential diagnosis 55, 60–61
- treatment, age dependent 56–57
- complications and admission criteria 61–62
- infection control 62
- age-dependent differences 50
- age-dependent treatments 58t8.9
- babies and young children (1 month to 5 years) 50–52, 55, 58t8.9
- carbapenems and monobactams 565
- cephalosporins, third- and fourth-generation 563
- children, presentation 55
- children and adults (6–50) 52, 58t8.9
- CNS infections, HIV/AIDS patients, initial treatment 24t4.6
- CSF evaluation 56–57
- dexamethasone, IDSA guidelines 57
- dexamethasone effect, pediatric population 57
- dexamethasone study 56
- diffuse cerebral dysfunction, HIV/AIDS 21t4.4
- Haemophilus influenzae* B (HIB) 52, 58t8.9
- IDSA guidelines 56t8.5, 57, 61
- infants, presentation 55
- lumbar punctures 56t8.5
- neonates 50, 52, 55, 58t8.9
- pathogens and risk factors 51t8.1
- sinusitis, differential diagnosis 55t8.4
- steroid treatment 56–57
- meningitis, aseptic and viral
- microbiology 52–54
- clinical features 55
- differential diagnosis 55
- complications and admission criteria 61–62
- infection control 62
- acute bacterial vs. viral or chronic meningitis 52, 60–61
- Japanese encephalitis complex 54
- lymphocytic choriomeningitis virus 54
- mumps 54
- pathogen table 54
- polio virus 54
- St. Louis encephalitis virus 54
- tick-borne encephalitis virus 54
- types of aseptic meningitis 52
- varicella-zoster virus 54
- viral encephalitis 52–53
- meningitis, chronic 60
- clinical features and presentation 55, 57
- CSF evaluation 56–57
- differential diagnosis 52, 55, 60–61
- meningitis, cryptococcal amphotericin B 577
- CNS infections, HIV/AIDS patients, initial treatment 24t4.6
- diffuse cerebral dysfunction in HIV/AIDS 21t4.4
- echinocandins caution 577
- HIV-related brain disorders, neuroimaging 22t4.5
- meningococcal infections febrile child 334–35
- pediatric fever and rash 343–44
- meningococcemia
- infection control 111
- childcare contacts 111
- fever and rash differential diagnosis 100t14.1
- fever and rash, in adults 98–101
- meningoencephalitis complication, Zika virus 530
- meningovascular syphilis, focal cerebral dysfunction, HIV/AIDS patients 20t4.3
- meropenem (Merrem)
- activity spectrum 557–59
- properties and dosages 565
- anthrax 486t67.3
- children, post-transplant, febrile 464t64.2
- ESBL-producing organisms and infections 554, 554t77.3
- oncology patients 449–50
- severe sepsis 471t65.8
- shunt infections, meningitis 61
- MERS-CoV (Middle East respiratory syndrome coronavirus) 301, 413
- metabolic encephalopathies, HIV/AIDS patients 21t4.4
- metastasis, HIV pulmonary infections 289t45.1
- methamphetamine, altered mental status, differential diagnosis 19t4.2
- methicillin-susceptible *Staphylococcus aureus* see MSSA
- metronidazole (Flagyl)
- activity spectrum 557–59
- exposure, VRE risk 549t76.1
- properties and dosages 573
- acute bacterial cholangitis 152t23.5
- acute calculous cholecystitis, resuscitation 149t23.2
- acute necrotizing ulcerative gingivitis 145
- bacterial vaginosis, nonpregnant women 221
- bacterial vaginosis, pregnant women 221
- bite infections 372t56.1
- C. difficile* diarrhea 177t26.10
- C. difficile* diarrhea, HIV patients 185t27.6
- E. histolytica* diarrhea 178t26.12
- E. histolytica* diarrhea, HIV patients 185t27.6
- febrile post-transplant patients 464t64.2

Index

- metronidazole (Flagyl) (*cont.*)
 G. diarrhea, HIV patients 185t27.6
 intracranial abscess 37t6.4
 lactation, postpartum
 endometritis 40t759.1
 Lemierre's syndrome 138t21.2, 139
 non-gonococcal urethritis,
 persistent or recurrent 202,
 203t30.5
 pelvic inflammatory disease
 204t30.6
 post-abortion prophylaxis 408
 postpartum endometritis 40t759.1,
 408
 purulent tenosynovitis 236t35.2
 secondary peritonitis 167t25.12
 tetanus, IDU-associated 440t61.14
 urethritis (male infections)
 194t29.2
 Mexico, rickettsial infections
 426t60.9
 micafungin (Mycamine) 576–77
 miconazole, candidiasis 223t32.6
 microsporidium diarrhea, HIV
 patients 182t27.1, 183t27.3,
 185t27.6, 186
 midazolam
 muscle spasms, tetanus 71
 peritonitis abscess 133
 Middle East respiratory syndrome
 coronavirus (MERS-CoV) 301,
 413
 Middle East, rickettsial infections
 426t60.9
 migrants, arriving *see* fever in the
 returning traveler
 Entamoeba histolytica
 diarrhea 174
 hepatitis B virus 155
 Miller–Fisher syndrome
 (polyradiculopathy), botulism
 differential diagnosis 31
 misdiagnosis rates, necrotizing
 soft-tissue infections 85
 mite bites while traveling, associated
 illnesses 415t60.3
 mite infestations 88t13.1, 89–90
 — clinical features 89–90,
 90t13.4
 — differential diagnosis 90,
 90t13.4
 — laboratory and radiographic
 findings 90, 90t13.4
 — treatment and prophylaxis 90,
 90t13.4
 bird mite (*Ornithonyssus*) 90,
 90t13.4
 chiggers (*E. alfreddugesi*) 90,
 90t13.4
 dog, cat, and rabbit mite
 (*Cheyletiella*) 90
 dust and bed mite
 (*Dermatophagoides*) 89, 90,
 90t13.4
 harvest mite (*T. autumnalis*) 89,
 90t13.4
 superinfected excoriations 90
 mite lesions, superinfection risk 89
 MMR vaccine (measles, mumps, and
 rubella vaccine), parotitis 126,
 127–28
Mobiluncus species, bacterial
 vaginosis 220, 221t32.1
 modified smallpox 500
 MOE (malignant otitis externa) 114
 Mollaret's meningitis complication,
 herpes genitalis 210
 Mongolia, rickettsial infections
 426t60.9
 monkey B virus (Herpesvirus
 simiae) 369
 monobactams
 — properties and dosages 565
 sepsis 565
 monomicrobial (type II) necrotizing
 soft-tissue infections 85t12.4
 mononucleosis
 Epstein-Barr virus (EBV) 100t14.1
 fever in the returning traveler
 425–28
Moraxella (*Brahamella*)
 conjunctivitis 258
 ESBL production 553t77.1
 penicillin-beta-lactamase inhibitor
 combinations 561
Moraxella catarrhalis
 acute otitis media 117
 community-acquired
 pneumonia 280
 conjunctivitis 258, 260t41.1
 sinusitis 121t17.3
 morsus humanus *see* fight bite
 infections
 mortality rates
 acute bacterial cholangitis 150
 acute calculous cholecystitis 150
 acute infectious diarrhea 169
 acute liver failure, viral
 hepatitis 156
 CA-MRSA CAP 546
 cerebral malaria 416
 CIED infections 16
 community-acquired pneumonia
 281, 285, 285t44.5
 deep mandibular space
 infections 143
 dental and odontogenic
 infections 143
 diabetic foot infections 228
 hepatitis A virus 157
 hepatitis E virus 156
 HIV pulmonary infections 288
 Ludwig's angina 140
 necrotizing soft-tissue infections
 84, 85
 parapharyngeal space
 infections 143
 plague 491
 rabies 65
 rotavirus diarrhea, acute
 infectious 170
 sepsis 467, 468
 septic arthritis, adults 227
 sickle cell disease, infections
 in 478
 smallpox 498
 tetanus 72
 toxic epidermal necrolysis 109
 tuberculosis 308, 316
 viral hepatitis, acute liver
 failure 156
 mosquito bites while traveling,
 associated illnesses 415t60.3
 mosquito inoculation effects, West
 Nile virus infections 74
 mosquito transmissions, West Nile
 virus 74
 moxifloxacin (Avelox) 568–69
 — activity spectrum 557–59
 bacterial keratitis 262
 community-acquired pneumonia
 283t44.2, 284t44.3
 HIV pulmonary infections 294
 secondary peritonitis 167t25.12
 urethritis (male infections) 194t29.2
 MRCP (magnetic resonance
 cholangiopancreatography),
 acute bacterial cholangitis 150
 MRSA (methicillin-resistant
 Staphylococcus aureus) 541–47
 — microbiology 541
 — epidemiology 541–42
 — clinical features 542–44
 — differential diagnosis 544
 — laboratory and radiographic
 findings 544–45
 — treatment and prophylaxis
 544–46
 — complications and admission
 criteria 546
 — infection control 546
 — pearls and pitfalls 546–47
 acute care antibiotics 546t75.5
 antimicrobial susceptibilities
 545t75.3
 categorization of infection
 542t75.1
 cephalosporins,
 advanced-generation 564
 community-onset MRSA 542,
 542t75.1, 543
 coverage 544–46, 545t75.4
 genotypic identification 541
 glycopeptides 566
 health-care-associated 541, 542,
 542t75.1
 hospital onset (nosocomial) 542,
 542t75.1, 543
 invasive infections 544, 545, 546
 metastatic infections 543, 544,
 546, 547
 screening 544
 Staphylococcus genus 541
 USA 300 CA-MRSA clone 542–44
 vancomycin 545, 547
 see also CA-MRSA; community-
 acquired pneumonia,
 CA-MRSA
 MRSA considerations
 bacteremia and sepsis, in sickle
 cell disease 474
 bite infections 374
 bone and joint infections,
 pediatric 348–49
 cellulitis 83–84
 chronic diabetic foot wounds
 228, 231
 CIED infections 16
 diabetic foot infections, treatment
 230, 230t34.1
 HIV pulmonary infections 294,
 296t45.6
 infective endocarditis, IDU-
 associated 431t61.1
 mite infestations 90t13.4
 musculoskeletal infections,
 pediatric 352t53.4
 necrotizing soft-tissue infections
 86, 545
 necrotizing soft-tissue infections,
 IDU-associated 435t61.5
 open fractures 239
 osteomyelitis 242
 osteomyelitis, pediatric 350
 parotitis 126, 127
 pediatric orthopedic
 infections 348
 plantar puncture wounds 246
 purulent tenosynovitis 235,
 236t35.2
 septic arthritis, adults 225,
 226t33.1, 227
 septic arthritis and osteomyelitis,
 IDU-associated 435–36
 spinal epidural abscess 42, 47
 spinal epidural abscess, IDU-
 associated 437, 438t61.9
 subcutaneous abscess, IDU-
 associated 433, 433t61.3
 surgical site infections 453
 toxic shock syndrome 102t14.4
 MSM *see* men who have sex
 with men
 MSSA (methicillin-susceptible
 Staphylococcus aureus)
 — antibacterial drug spectra
 558t78.1
 abscesses 79, 433t61.3
 beta-lactamase inhibitors 161
 cefazolin 562
 cephalosporins, third- and
 fourth-generation 563
 diabetic foot infections 230t34.1
 glycopeptides 566
 infective endocarditis, IDU-
 associated 431t61.1
 influenza complications 302t46.3
 meningitis 562
 musculoskeletal infections,
 pediatric 352t53.4
 nafcillin 561, 562
 osteomyelitis 243t37.1, 561
 osteomyelitis, pediatric 350
 Pantón–Valentine leukocidin 79
 subcutaneous abscess,
 IDU-associated 433t61.3
 mucocutaneous herpes genitalis
 211t31.2
 mucormycosis (mucorales fungi)
 invasive fungal rhinosinusitis
 121
 open fractures 239

Index

- mucous patches, secondary syphilis 214f31.9
 multidrug-resistant organisms (MDROs) *see* drug-resistant organisms
 multifocal brain disease, diffuse cerebral dysfunction, HIV/AIDS patients 21t4.4
 multisystem diseases *see* systemic diseases
 mumps virus and disease
 aseptic and viral meningitis 54
 parotitis 53, 54, 126, 127t19.1, 128
 pericarditis 6
 uveitis and retinitis 276t43.1
 young adults 54
 mupirocin, MRSA susceptibilities 545t75.3
 murine typhus (ricketsial infections) 426t60.9
 Murphy's sign
 acute calculous cholecystitis 146, 147, 147t23.1
 hepatic abscess 164
Musca domestica (house fly), myiasis 95t13.8, 96t13.9
 muscle spasm sedative, tetanus 70–71
 IDU-associated 440t61.14
 musculoskeletal infections
 CA-MRSA 543t75.2
 pediatric 352t53.4
 myasthenia gravis, botulism
 differential diagnosis 29
 myasthenic crisis (myasthenia gravis acute exacerbation) 46
 Mycamine *see* micafungin
 mycobacterial infections, persistent diarrhea, HIV patients 183t27.3
Mycobacterium africanum, tuberculosis 308
Mycobacterium avium complex (MAC)
 HIV diarrhea 182t27.1, 185t27.6, 186
 HIV pulmonary infections 289t45.1, 294t45.4
Mycobacterium bovis, tuberculosis 308
Mycobacterium chelonae
 keratitis 261
 solid organ transplants 460t64.1
Mycobacterium fortuitum, keratitis 261
Mycobacterium leprae (leprosy), uveitis and retinitis 276t43.1
Mycobacterium microti, tuberculosis 308
Mycobacterium tuberculosis 256t40.2
 diarrhea, HIV patients 183t27.3, 183t27.4
 keratitis 261
 osteomyelitis, IDU-associated 436
 pericarditis 6
 solid organ transplants 460t64.1
 spine infections, epidural abscesses 256t40.2
 tuberculosis 308
 uveitis and retinitis 276t43.1
 vertebral osteomyelitis 254t40.1
Mycobacterium tuberculosis complex 308
 mycophenolate mofetil (CellCept, Myfortic), post-transplant patients 466t64.4
Mycoplasma
 pelvic inflammatory disease 202–03
 pharyngitis 129
 pneumonia 362
Mycoplasma genitalium, non-gonococcal urethritis 192, 194t29.2, 202, 203t30.5
Mycoplasma hominis
 bacterial vaginosis 220, 221t32.1
 chorioamnionitis 394t58.8
 urethritis (male infections) 192
Mycoplasma pneumoniae
 — antibacterials, commonly used 557–59
 acute chest syndrome, in sickle cell disease 476
 atypical bacteria, influenza-like illnesses 301
 community-acquired pneumonia 280, 281
 pharyngitis 130t20.1
 susceptibility, sickle cell disease 473
 myiasis (ectoparasites) 88t13.1, 93–97
 — clinical features 95–96, 96t13.9
 — differential diagnosis 95, 96t13.9
 — laboratory and radiographic findings 95–96
 — treatment and prophylaxis 96, 96t13.9
 accidental myiasis 93, 95t13.8, 96t13.9
 facultative myiasis (maggot infestation) 93–95, 95t13.8, 96t13.9
 fly larvae 93–95
 furuncular cutaneous myiasis 95, 96
 infestation subtypes 95t13.8
 obligatory myiasis 95t13.8, 96, 96t13.9, 97
 subtypes of infestation 93–95
 wound care 96
 myocardial depression complication, sepsis 471
 myocarditis 6, 11–13
 — epidemiology and microbiology 11
 — clinical features table 8t2.2
 — differential diagnosis 7–8, 11–12
 — laboratory and radiographic findings 12
 — treatment and prophylaxis 12
 — complications and admission criteria 12–13
 — pearls and pitfalls 13
 bacterial myocarditis 11
 beta-blockers, contraindication 12
 cardiac tamponade 12
 cardiogenic shock 12
 chest X-ray findings 9f2.1
 children 11, 12–13
 clinical findings 11
 congestive heart failure 12
 dysrhythmias 12
 echocardiography 12
 heart block and tachydysrhythmias 13t2.4
 heart failure 12
 immunocompromised patients 11
 important causes 7t2.1
 non-infectious causes 11
 pulmonary edema and respiratory failure 12
 respiratory failure and pulmonary edema 12
 tachydysrhythmias and heart block 13t2.4
 viral myocarditis 11
 West Nile virus infections 75
 myopathy, inflammatory, botulism
 differential diagnosis 29
 myopericarditis 6
 complications and admission criteria 12
 differential diagnosis 7–8
 laboratory and radiographic findings 8
 military personnel, smallpox vaccination 2002/3 504
 see also myocarditis; pericarditis
N,N-diethyl-*m*-toluamide (DEET)-containing pesticides, protection against mites 90
 NAAT testing (nucleic acid amplification test)
 chlamydia 194
 epididymitis 196
 gonorrhea 194, 196, 201, 202t30.3
 non-gonococcal urethritis 194, 196, 200t30.1
 urethritis (male infections) 193–94
 West Nile virus infections 75t11.1
Naegleria fowleri, parasitic meningitis 57, 60t8.11
 nafcillin 560–61
 — activity spectrum 557–59
 MSSA 243t37.1, 561, 562
 MSSA osteomyelitis 243t37.1
 vertebral osteomyelitis 254t40.1
 nail plate skin folds, acute paronychia 236f35.3
 NAP1/BI/027 epidemic strain (*C. difficile*) 188
 nasal polyposis, sinusitis 120
 natamycin, fungal keratitis 262
 Nationally Notifiable Disease list 175t26.7
 natural disasters, open fractures, fungi 239
 natural penicillins, properties and dosages 560t78.2
 natural reservoirs
 anthrax 480
 avian influenza A 531
 plague 490
 smallpox 498
 tuberculosis 308
 tularemia 506
 naxprofen, pericarditis 10t2.3
 NEAS (Neuroviruses Emerging in the Americans Study), Zika virus 527
 neck and oropharynx, spaces 135–36
 neck space infections, deep *see* deep neck space infections
 necrotizing fasciitis
 episiotomy site infection 410
 initial therapy 86t12.5
 upper extremity, NSTIs, IDU-associated 435f61.3
 necrotizing periodontitis 143
 young adults 143
 necrotizing soft-tissue infections (NSTIs) 84–86
 — epidemiology and microbiology 84
 — clinical features 84–85
 — laboratory and radiographic findings 85
 — treatment and prophylaxis 85–86
 — complications and admission criteria 86
 — infection control 86
 brackish water, emersion in 84
 CA-MRSA 543t75.2
 CA-MRSA NSTI 84, 86
 children, varicella infection 84
 hemorrhagic bullus 85f12.10
 injection drug use, related NSTI 84
 misdiagnosis rates 85
 monomicrobial (type II) infections 85t12.4
 mortality, major determinant 85
 mortality rates, injection drug users 84
 MRSA coverage 86
 necrotizing fasciitis, initial therapy 86t12.5
 Streptococcus toxic shock syndrome 84
 surgical approach 85
 necrotizing soft-tissue infections, IDU-associated 434–35
 — epidemiology and microbiology 434–35, 435t61.5
 — clinical features 434–35
 — laboratory and radiographic findings 435, 435t61.5
 — treatment and prophylaxis 435
 — complications and admission criteria 435
 — pearls and pitfalls 440–41
 fasciitis, upper extremity 435f61.3

Index

- heroin users 434–35
 MRSA 435t61.5
- Neisseria*
 — antibacterial drug spectra 558t78.1
 — antibacterials, commonly used 557–59
- Neisseria gonorrhoeae* (gonorrhea)
 200–02
 — epidemiology and microbiology 200
 — clinical features 200–02
 — differential diagnosis 201
 — laboratory and radiographic findings 201, 202t30.3
 — treatment 201–03
 — complications and admission criteria 202
 — pearls and pitfalls 206–07
 acute bacterial prostatitis 196–97
 CDC guidelines 199
 cervicitis, acute 200–02
 conjunctivitis 259, 260t41.1, 261f41.3, 262
 conjunctivitis, adult 201, 203t30.4
 epididymitis 195, 195t29.3
 ESBL production 553t77.1
 fluoroquinolones 568–69
 gonococcus, neonates, cefotaxime 260t41.2
 incubation periods 202t30.3
 NAAT testing (nucleic acid amplification test) 196, 201, 202t30.3
 neonates, conjunctivitis 260t41.2
 neonates, osteomyelitis 349
 pelvic inflammatory disease 202–03
 pharyngitis 130t20.1, 132t20.4, 134
 purulent urethral discharge 201f30.1
 pyelonephritis, adults 324
 quinolone-resistant (QRNG) 201
 septic arthritis, adults 225, 226t33.1
 urethritis (male infections) 192, 193t29.1
- Neisseria meningitidis* (meningococcus)
 acute bacterial meningitis (1 month–5 years) 50, 51–52, 58t8.9
 acute bacterial meningitis (age 6 plus, including adults) 58t8.9
 acute bacterial meningitis (neonates) 50, 52, 55, 58t8.9
 carbapenems and monobactams 566
 chemoprophylaxis 62t8.13
 meningococcemia 98–101
 suspected meningitis 566
 young adults 51, 51t8.1
 see also acute bacterial meningitis neonates (newborn babies) 260t41.2
 acute bacterial meningitis 50, 52, 55, 58t8.9
 acute otitis media 118
- Campylobacter* diarrhea, antibiotics 176–77
 congenital herpes infection 212
 conjunctivitis 260t41.2, 260t41.1, 262
 CSF evaluation, meningitis 56
 febrile child 335, 336–37
 fungal meningitis 58–59
 HBV-infected 157
 meningitis, CSF evaluation 56
 meningitis chemoprophylaxis 62t8.13
 musculoskeletal infections 352, 352t53.4
 osteomyelitis, gonorrhea 349
 pneumonia, treatment 364t54.8
 suspected HSV, keratitis 262
 tetanus 70
 Zika virus 527
 see also febrile child; fever in the newborn
- Neoral see cyclosporine
 nephrotoxicity 557
 acyclovir crystallization 578
 aminoglycosides 388, 450, 557, 569t78.22
 amphotericin 577, 577t78.43
 amphotericin B caution 577
 acyclovir caution 578
 anti-herpes-virus drugs 578t78.44
 common immunosuppressive agents 465t64.3
 cyclosporine 465t64.3
 elvitegravir 381t57.7
 gentamicin 332
 glycopeptides 566t78.18
 HIV PEP regimens 332
 immunosuppressive agents 465t64.3, 466t64.4
 polyenes 577t78.42
 sirolimus 465t64.3
 tacrolimus 465t64.3
 telavancin warning 567
 tenofovir 381t57.7
 vancomycin 546t75.5
- nerve gas, botulism differential diagnosis 29
 neuraminidase inhibitors — activity 578
 novel influenza A virus 537, 579
 oseltamivir 537–39, 578–79
 peramivir 537, 538, 578–79
 zanamivir 537, 578–79
- neurologic abnormalities, fever in the returning traveler 413
 neuropathic arthropathy, diabetic foot infections 231
 neurosurgery, intracranial abscess 34t6.2, 37
 neurosyphilis
 HIV/AIDS patients, initial treatment 24t4.6
 treatment 105t14.6, 216t31.4
- Neuroviruses Emerging in the Americans Study (NEAS), Zika virus 527
 neutropenia 561
 chemotherapeutic agents 443
 linezolid caution 575
 see also under febrile neutropenia; gastrointestinal tract infections, neutropenic oncology patients
 neutropenic patients, fungal meningitis 58–59
 nevirapine, diarrhea effect 183t27.5
 newborn babies see fever in the newborn; neonates
 nitazoxanide
Cryptosporidium diarrhea 178t26.12
Cryptosporidium diarrhea, HIV patients 185t27.6
G. lamblia diarrhea 178t26.12
 parasitic cholangitis, *F. hepatica* 153t23.6
 nitrofurans, antimicrobial properties 573–74
 see also specific drugs
 nitrofurantoin (Macrochantin, Macrobid)
 — properties and dosages 573–74
 acute cystitis 320t48.1
 cystitis, in pregnancy 388, 389t58.4
 ESBL-producing organisms and infections 554t77.3
 nitroglycerin
 congestive heart failure, myocarditis 13t2.4
 congestive heart failure, pericarditis 13t2.4
 nitroimidazoles
 — properties and dosages 573
 see also specific drugs
 nits 91
- Nocardia*
 HIV pulmonary infections 289t45.1
 intraparenchymal brain abscess 34t6.2
 oncology patients 445, 450
 spinal epidural abscess 42
 trimethoprim-sulfamethoxazole (TMP-SMX) 572
- Nocardia asteroides* 256t40.2
 solid organ transplants 459, 460
 spine infections, epidural abscesses 256t40.2
 nodules 99, 340t52.1
 non SARS coronaviruses
 influenza-like illnesses 301
 noncholera *Vibrio* strains, acute diarrhea 172
 non-gonococcal urethritis (NGU) 192, 202
 — microbiology 192, 193f29.2, 193t29.1, 202
 — epidemiology and microbiology 192, 202
 — clinical features 193f29.2, 193t29.1, 202–03
 — differential diagnosis 202
 — laboratory findings 193f29.2, 193t29.1, 202, 203t30.5
 — treatment 194t29.2, 202, 203t30.5
 — complications and admission criteria 202
 — pearls and pitfalls 206–07
 incubation periods 193t29.1, 203t30.5
- non-group D alpha-hemolytic *Streptococcus*
 fever in the newborn 328, 330t50.1
 non-infected wounds, bite infections 373
 non-infectious causes
 acute viral hepatitis 158
 chronic meningitis 60–61
 diarrhea, in HIV patients 181
 fever and rash 98
 keratitis 259
 myocarditis 11
 parotitis 126–27, 127t19.1
 pericarditis 7
 pregnant women, respiratory complaints 390
 West Nile encephalitis, differential diagnosis 76
 see also drug reactions, severe; drug toxicity and allergy principles
- non-inflammatory diarrhea 169
 acute infectious viral 170t26.1, 170t26.2
 non-insecticidal treatment, human lice 92–93
 non-palpable purpura 99, 340t52.1
 non-purulent cellulitis 82f12.7, 84t12.3
 non-sexual exposures, exposure management
 blood or body fluid, for HBV and HIV 375
- non-specific viral exanthems, pediatric fever and rash 340–42
 non-typhi *Salmonella*, acute infectious diarrhea 170t26.1
 non-ulcerative sexually transmitted diseases see sexually transmitted diseases, non-ulcerative
- norovirus, acute infectious viral diarrhea 170, 170t26.2
 norovirus diarrhea, HIV patients 182t27.2
 north Asian tick typhus 94t13.7, 426t60.9
- Norvir see ritonavir
 Norwalk virus, acute infectious viral diarrhea 170, 170t26.1, 170t26.2
 Norwegian/crusted scabies 88, 88t13.2
- nosocomial infections (hospital onset)
 aminoglycosides 569
C. difficile, exposure risk 172
 carbapenems and monobactams 565
 cephalosporins, third- and fourth-generation 563
 fluoroquinolones 568–69
 glycopeptides 566–68
Isospora diarrhea 174
 MRSA 542, 542t75.1, 543

Index

- oxazolidinones 574–75
 penicillin-beta-lactamase inhibitor combinations 561–62
 notifiable disease list 175t26.7
 novel influenza A viruses (zoonotic influenza) 299, 531–40
 — microbiology 531–32
 — epidemiology 532–34
 — clinical features 535
 — differential diagnosis 536
 — laboratory and radiographic findings 535t74.4, 536–37
 — antiviral treatment and chemoprophylaxis 537–39
 — complications and admission criteria 535t74.4, 538
 — infection control 538–39
 — infection prevention 539
 — pearls and pitfalls 539–40
 airborne infection isolation room (AIIR) 539
 antigenic drift 299
 antigenic shift 299
 antivirals, neuraminidase inhibitor 537, 578, 579
 children, avian influenza A 532, 533
 children, treatment 539t74.7
 elderly patients 533t74.1
 H1N1pdm09 299, 305, 531, 532
 H1N1v, H1N2v, H3N2v 301, 302, 532, 533, 534t74.3
 high pathogenic viruses 531–32, 533
 immunocompromised patients, treatment 539t74.7
 incubation periods 535t74.4
 influenza virus types 531
 low pathogenic viruses 531–33
 pandemics 531
 parotitis 126, 127t19.1
 pathogenesis 535
 peramivir 537, 538
 pregnant women, treatment 539t74.7
 rare infections, differential diagnosis 301
 vaccines 539
 viral pneumonia 535, 536t74.5, 538
 young adults, LPAI 533t74.1
see also under avian influenza A viruses; H3N2v; H5N1; H5N6; H7N9; swine influenza A viruses
 Noxafil *see* posaconazole
 NSAIDs (non-steroidal anti-inflammatories)
 dengue fever 422
 epididymitis 196t29.4
 fever and rash, in adults 109
 otitis externa 115
 peptic ulcer perforation 163
 periapical abscess 142t22.1
 pericarditis 10t2.3
 pharyngitis 132, 132t20.4
 pulpitis 142–43, 142t22.1
 rubella 109t14.11
 sinusitis 122
 Stevens-Johnson syndrome 109
 toxic epidermal necrolysis 109
 NSTI *see* necrotizing soft-tissue infections
 nursing home residents
 community-acquired pneumonia 286
G. lamblia diarrhea 173
Shigella diarrhea 171
 obligatory myiasis 95t13.8, 96, 96t13.9, 97
 occult bacteremia, febrile child 334–35
 ocular findings, West Nile virus infections 75
 ocular toxoplasmosis 274
 oculoglandular tularemia
 clinical features 512
 differential diagnosis 510–11
 odontogenic infections 135, 140
see also dental and odontogenic infections; deep neck space infections
 OE *see* otitis externa
 ofloxacin
 bacterial keratitis 262
 chlamydia 200t30.2
 epididymitis 196t29.4
 non-gonococcal urethritis 202, 203t30.5
 post-abortion prophylaxis 408
 urethritis (male infections) 194t29.2
 OM *see* acute otitis media
 OME (otitis media with effusion) 117
 omphalitis, fever in the newborn 330t50.1
 onchocerciasis (river blindness) 259, 261
 onchocerciasis, uveitis and retinitis 276t43.1
 oncology patients, infections in 442–51
 — general points 442
 — pathophysiology and epidemiology 442–43
 — clinical features 443–46
 — differential diagnosis 446–47
 — laboratory and radiographic findings 447
 — treatment and prophylaxis 447–50
 — pearls and pitfalls 450–51
 aminoglycoside addition 450
 bacteremia and fungemia 443, 443t62.1, 447, 448–50
 central nervous system infections 446, 446t62.6, 448
 chemotherapeutic agent effects 442, 443
 gastrointestinal tract infections 446, 446t62.5, 448
 high-risk patients, treatment 449–50
 Infectious Diseases Society of America 448
 low-risk patients, treatment 449
 multidrug-resistant organisms 450
 neutropenia 443, 447, 448–50
 oral therapy risk assessment 449
 oropharyngeal infections 444, 444t62.2, 447
 other considerations 450
 prophylaxis patient 447–50
 respiratory tract infections 445, 445t62.4, 448
 sepsis syndrome, differential diagnosis 447
 skin and soft tissue infections 444–45, 445t62.3, 447
 urinary tract infections 446
 vancomycin addition 450
 oophoritis, mumps parotitis complication 128
 open fractures 239–41
 — microbiology 239
 — epidemiology 239
 — clinical features 239–41
 — differential diagnosis 239
 — treatment and prophylaxis 239–41, 241t36.1
 — complications and admission criteria 241
 — pearls and pitfalls 241
 contaminated environments 240
 distal tibia grade II 240f36.2
 elbow grade I 240f36.1
 grade III 240, 241t36.1
 grades I and II 240, 241t36.1
 Gustilo classification 239–41
 mucormycosis (mucorales fungi) 239
 natural disasters, fungi 239
 planar puncture wounds 239
 poke-hole 239
 tibia grade III 240f36.3
 operation sterility classification 454t63.2
 ophthalmologist involvement
 endophthalmitis 278t43.3
 keratitis 260, 262, 263n.‡
 uveitis and retinitis 276
 opioid effects, acute calculous cholecystitis 148
 opioid users, infective endocarditis, IDU-associated 431
 opioids
 acute otitis media 118
 otitis externa 115
 pharyngitis 132
Opisthorchis, parasitic cholangitis 153
 optic neuritis, West Nile virus infection, complications 75
 oral anaerobes
 fight bites 234t35.1
 necrotizing soft-tissue infections, IDU-associated 434–35, 435t61.5
 oral chancre, syphilis 213f31.7
 Orbactiv *see* oritavancin
 orbital and periorbital cellulitis 269–73
 — epidemiology and microbiology 269–70, 270t42.6
 — clinical features 270
 — differential diagnosis 270–71
 — laboratory and radiographic findings 271
 — treatment 271–72
 — complications and admission criteria 272–73
 — pearls and pitfalls 273
 children, treatment 272t42.7
 immunocompromised patients, treatment 272t42.7
 pregnant women, treatment 272t42.7
 orchitis complications
 mumps parotitis 128
 West Nile virus infections 75
 organisms, resistant *see* drug-resistant organisms
 oriental spotted fever (rickettsial infections) 426t60.9
Orientia tsutsugamushi (rickettsial infections) 426t60.9
 oritavancin (Orbactiv) 566–68
Ornithonyssus (bird mite) infestations 90, 90t13.4
 oropharyngeal infections, neutropenic oncology patients
 — clinical features 444
 — differential diagnosis 447
 — laboratory findings 444t62.2
 — treatment and prophylaxis 444t62.2
 oropharyngeal thrush, HIV pulmonary infections 290
 oropharyngeal tularemia
 clinical features 512
 differential diagnosis 511
 pharyngitis 130t20.1
 oropharynx and neck, spaces 135–36
 oropharynx view, peritonsillar abscess 133f20.2
 Orthomyxoviridae family, influenza 299
Orthopoxvirus genus, smallpox 498
 oseltamivir (Tamiflu)
 — properties and dosages 578–79
 community-acquired pneumonia 284t44.3
 health-care-associated CAP 284t44.3
 influenza 304t46.5, 390t58.6, 578–79
 novel influenza A 537–39, 579
 pregnant women 390t58.6
 Osler nodes, infective endocarditis 2
 osmotic diarrhea 169
 osteomyelitis 242–45
 — microbiology 242
 — epidemiology 242
 — clinical features 242–43
 — differential diagnosis 242
 — laboratory and radiographic findings 242–43, 243t37.1
 — treatment 243–44, 243t37.1

Index

- osteomyelitis (*cont.*)
 — complications and admission criteria 16t3.2, 143, 244
 — special considerations 244
 — pearls and pitfalls 245
 acute osteomyelitis 242, 243–44
 AIDS infections 242
 ankle, AP radiograph 244f37.1
 bone scan, distal lower extremities 245f37.4
 CA-MRSA 543, 543t75.2, 545t75.4
 cefazolin 562
 cephalosporins, third- and fourth-generation dosage 563
 chronic diabetic foot ulcers 242
 chronic osteomyelitis 242, 244
 CIED complications 16t3.2
 deep mandibular space infections, complication 143
 diabetic foot infections 228, 229, 231, 242
 diabetic plantar puncture wounds 247t38.1
 femur, AP radiograph 244f37.2
 glycopeptides 566–68
 HIV patients 242
 injection drug users 244
 lateral plane radiograph, lumbar spine 245f37.3
 MRSA 242
 MRSA screening 544, 546
 MSSA 243t37.1
 plantar puncture wounds 247t38.1
 pressure ulcers 244
 refractory acute osteomyelitis, treatment 244
Salmonella osteomyelitis 242, 244
 sickle cell disease, infections in 242, 244
see also vertebral osteomyelitis
 osteomyelitis, IDU-associated 435–37
 — epidemiology and microbiology 435–36, 436t61.7
 — clinical features 436
 — differential diagnosis 436
 — laboratory and radiographic findings 436–37, 436t61.7
 — treatment 437
 — pearls and pitfalls 440–41
 MRSA 435–36
 osteomyelitis, pediatric orthopedic infections 348–50
 — epidemiology and microbiology 348–49
 — clinical features 349–50
 — differential diagnosis 350
 — laboratory and radiographic findings 350, 350t53.1
 — treatment 350
 — complications and admission criteria 350
 — pearls and pitfalls 353
 cat exposure 348
 neonates 349
 tibial osteomyelitis 349f53.1
 osteomyelitis and septic arthritis, in sickle cell disease 477–78
 — epidemiology and microbiology 477
 — clinical features 477
 — differential diagnosis 477
 — laboratory and radiographic findings 477–78
 — treatment 478
 — complications and admission criteria 478
 — pearls and pitfalls 478–79
 acute bone infarct differentiation 244
 susceptibility 242
 otitis externa (OE) (swimmer's ear) 114–16
 — microbiology 114
 — clinical features 114
 — differential diagnosis 114–15
 — laboratory and radiographic findings 115, 115t15.1
 — treatment and prophylaxis 115–16, 115t15.1
 — complications and admission criteria 116
 — pearls and pitfalls 116
 AIDS patients 114
 children 114
 diabetic patients 114, 115
 eardrop delivery 115
 elderly patients 114, 115
 herpes virus 115t15.1
 immunosuppressed patients, MOE 115
 instructions for patients 116
 malignant 114
 Ramsey–Hunt syndrome 114, 115
 otitis media *see* acute otitis media
 fever in the newborn 330t50.1
 otitis media with effusion (OME) 117
 ova and parasite testing 175t26.8, 178, 186
see also stool tests
 ovarian vein thrombosis 408t59.3
 over-exertion, botulism differential diagnosis 29
Ovide see malathion
 oxazolidinones and lipopeptides
 — properties and dosages 574–75
see also specific drugs
 painful joint arthroplasty *see* prosthetic joint infections
 palivizumab (Synagis), bronchiolitis, pediatric 362
 palmar rash, secondary syphilis 214f31.11
 palpable purpura 99, 340t52.1
 pancreas resection, anastomotic leak risks 455t63.3
 pancreatitis
 abdominal pain differentiation 165–66
 mumps parotitis complication 128
 West Nile virus infections 75
 pandemics, influenza 531
 Pantón–Valentine leukocidin (PVL) 79
 papules
 definition 99
 pediatric patients 340t52.1
 persistent pruritic papule, differential diagnosis 96t13.10
Paracoccidioides brasiliensis, solid organ transplants 460t64.1
 parainfluenza
 acute otitis media 117
 hematopoietic stem cell transplants, phase 3 infections 461
 influenza-like illnesses 301
 parotitis 126, 127t19.1
 pharyngitis 130t20.1
 paralysis
 ascending paralysis 66
 botulism 28t5.1, 29, 31, 438–39
 conversion paralysis (psychiatric) 29
 cranial nerves, AOE 116
 descending 28t5.1, 438–39
 epidural abscess 136, 256, 437
 facial 343
 flaccid 29, 44, 75
 injection drug users 431
 poliomyelitis 44, 53t8.2
 pseudoparalysis, septic arthritis, children 350
 rabies 65, 66
 spinal cord infections 44
 tick-paralysis 93–94, 94t13.7
 West Nile virus infections 29, 44, 75
 wound botulism, IDU-associated 438, 439
see also Guillain-Barré syndrome
 paramyxovirus
 measles (rubeola) 104–06
 parotitis 126
 parapharyngeal space infections
 deep mandibular space infections 143
 mortality rates 143
 neck infections 137
 trismus, severe (lockjaw) 135–36
 parasite and ova testing 175t26.8
 parasitic cholangitis 152–53
 — differential diagnosis 153
 ERCP intervention 153
 medical therapy 153t23.6
 ultrasound, *Ascaris* in the gallbladder 153
 parasitic diarrhea, acute infectious
see diarrhea, acute infectious
 parasitic
 parasitic meningitis 57, 60
 parasitic myelitis, spinal cord infections differential diagnosis 44, 45t7.2
 paromomycin, *Cryptosporidium* diarrhea, HIV patients 185t27.6
 paronychia, acute *see* acute paronychia
 parotitis 126–28
 — microbiology 126, 127t19.1
 — epidemiology and microbiology 126
 — clinical features 126
 — differential diagnosis 126–27
 — laboratory and radiographic findings 127
 — treatment and prophylaxis 127–28
 — complications and admission criteria 128
 — infection control 128
 — pearls and pitfalls 128
 abscess formation 128
 acute suppurative parotitis 126
 aseptic meningitis 128
 at-risk patients, treatment 127
 bacterial parotitis, complications 128
 chronic/recurrent parotitis 126
 elderly patients 126, 128
 encephalitis complication 128
 HIV patients 126–27, 127t19.1
 immunocompromised patients 127
 juvenile recurrent parotitis 126
 MMR vaccine 126, 127–28
 mumps parotitis 126, 128
 mumps virus 53, 54, 126, 127t19.1
 non-infectious causes 126–27, 127t19.1
 parotid swelling 126–27
 perinatal transmission 128
 Sjögren's Syndrome 126–27, 127t19.1
 paroxysmal coughing in pregnancy, membrane rupture 391
 parvovirus B19
 differentiation, fever in pregnancy 396
 myocarditis 11
Pasteurella multocida
 cat bite cellulitis 82t12.2
 cat bite infections 369
 cephalosporins, first-generation, cautions 562
 dog bite infections 369
 ESB production 553t77.1
 patient history taking
 fever and rash, adults 98–99
 fever and rash, pediatric 340t52.1
 neurosurgical procedures, meningitis 61
 penicillin allergies 557
 prior antimicrobial use 556–57
 sexual history, HIV patients 181–82
 smallpox vaccinations 503
 tetanus toxoid containing vaccine 70
 tetanus vaccinations 70, 71, 72
 travel history 412–13
 patient instructions, CA-MRSA infection control 547
 PCN G *see* penicillin G
 pediatric fever and rash 339–47
 — general points 339
 — epidemiology 339
 — clinical features 339–46
 — differential diagnosis 346

Index

- laboratory and radiographic findings 346
- complications and admission criteria 346
- infection control 346
- pearls and pitfalls 347
- enteric fever 424t60.8
- erythema infectiosum 339–41
- focused history and physical exam 340t52.1
- Kawasaki disease 344–46
- lesion classification 340t52.1
- meningococcal infection 343–44
- non-specific viral exanthems 340–42
- roseola infantum 339–40
- staphylococcal scalded skin syndrome 344
- varicella zoster 342–43
 - see also specific diseases*
- pediatric malaria, antimalarial regimens 420t60.6
- pediatric orthopedic infections 348–53
 - general points 348
 - special considerations 352–53
- diskitis, special considerations 352
- Lyme arthritis, special considerations 352
- MRSA 348
- neonatal musculoskeletal infection 352
- osteomyelitis 348–50, 353
- septic arthritis 350–52, 353
- sickle cell disease 348, 352–53
 - see also specific diseases*
- pediatric respiratory infections 354
 - general points 354
 - pearls and pitfalls 364
- bacterial tracheitis 357–58, 364
- bronchiolitis 361–62, 364
- croup 356–57, 364
- epiglottitis 354–56, 364
- pertussis (whooping cough) 360–61, 364
- pneumonia 359, 362–64
- retropharyngeal abscess 358–60, 364
 - see also specific diseases*
- pediatric urinary tract infections 366–68
 - microbiology 366, 367t55.2
 - epidemiology 366
 - clinical features 366–67
 - differential diagnosis 366–67
 - laboratory and radiographic findings 367–68, 367t55.2
 - treatment and prophylaxis 367t55.2, 368
 - complications and admission criteria 368
 - pearls and pitfalls 368
- children aged 2 plus, differential diagnosis 367
- infants and children younger than 2 years, differential diagnosis 366–67
- prevalence table by age 367t55.1
- pediculosis *see* lice, human
- Pediculus humanus capitis* *see* head louse
- pelvic inflammatory disease (PID) 202–05
 - epidemiology and microbiology 202–03
 - clinical features 203–04
 - differential diagnosis 203–04
 - laboratory and radiographic findings 204, 204t30.6
 - treatment 204, 204t30.6
 - complications and admission criteria 205
 - pearls and pitfalls 206–07
- abdominal pain, differentiation 165–66, 203
- incubation periods 204t30.6
- inpatient therapy 204t30.6
- lower abdominal pain, differentiation 203
- outpatient therapy 204t30.6
- penetrating head trauma 34t6.2, 37
- penicillin
 - properties and dosages 560t562t78.2
 - drug activity spectra 557–59
 - toxicity 557
- fight bites 234
- MRSA susceptibilities 545t75.3
- syphilis, pregnant women 216t31.4
- toxic epidermal necrolysis 109
 - see also specific penicillins*
- penicillin, antistaphylococcal, properties and dosages 560–61
- penicillin G (PNG)
 - activity spectrum 557–59
 - properties and dosages 560t78.2
- altered mental status, HIV patients 24t4.6
- deep mandibular space infections 142t22.1, 143
- intracranial abscess 37t6.4
- Lyme disease, cardiac second- or third-degree block 106t14.8
- neurosyphilis, treatment 216t31.4
- pharyngitis 132t20.4
- wound botulism, IDU-associated 439t61.12
- penicillin G benzathine (Bicillin-LA, BPG)
 - properties and dosages 560t78.2
- pharyngitis 132t20.4, 560t78.2
- syphilis 105t14.6, 215–16, 216t31.4
- penicillin VK
 - properties and dosages 560t78.2
- cellulitis 84t12.3
- pharyngitis 132t20.4
- pulpitis 142–43, 142t22.1
- penicillin-allergic patients
 - acute otitis media 118
 - cellulitis 83
 - deep mandibular space infections 143
 - hand infections, purulent tenosynovitis 236t35.2
 - patient history taking 557
 - purulent tenosynovitis 236t35.2
- secondary peritonitis 167
- penicillin-beta-lactamase inhibitor combinations
 - properties and dosages 561–62
- diabetic foot infections 561–62
- necrotizing soft-tissue infections 86
- sepsis 561–62
- Penicillium marneffe*, fungal meningitis 59
- penile chancre, primary syphilis 213f31.5
- penile shaft, recurrent lesions 209f31.3
- penis, primary lesions 209f31.2
- pentamidine, post-transplant, febrile child 464t64.2
- PEPline (Post-Exposure Prophylaxis Hotline) 383
 - see also under* post-exposure prophylaxis; *specific infections*
- peptic ulcer perforation
 - NSAID use causing 163
 - viscus perforation, secondary peritonitis 162, 163
- Peptostreptococcus*
 - abscess 80t12.1
 - cat bite infections 369
 - chorioamnionitis 393, 394t58.8
 - deep neck space infections 135, 136t21.1
 - dog bite infections 369
 - Lemierre's syndrome 138t21.2
 - necrotizing soft-tissue infections, IDU-associated 434–35
 - subcutaneous abscess, IDU-associated 433, 433t61.3
- peramivir (Rapivab), influenza antiviral
 - properties and dosages 578–79
- influenza 304t46.5, 578–79
- novel influenza A 537, 538
- perforated tympanic membrane
 - complication, acute otitis media (AOM) 118
- periapical abscess
 - epidemiology, pathophysiology, and microbiology 140–41
 - clinical features 141, 142t22.1
 - differential diagnosis 141
 - treatment and prophylaxis 142t22.1, 143
 - complications and admission criteria 143
- pericardiocentesis 8
- pericarditis 6–11
 - epidemiology and microbiology 6–7
 - clinical features 7–8
 - differential diagnosis 7–8
 - laboratory and radiographic findings 8, 8t2.2
 - treatment and prophylaxis 9–10
 - complications and admission criteria 10–11, 13t2.4
- cardiac tamponade 10f2.3, 13t2.4
- cardiogenic shock 13t2.4
- children, treatment 10t2.3
- congestive heart failure 13t2.4
- echocardiography 10
- electrocardiography 8
- heart block and tachydyssrhythmias 13t2.4
- immunocompromised patients 10t2.3
- important causes 7t2.1
- infants, signs and symptoms 8t2.2
- non-infectious causes 7
- pericardiocentesis 8
- pregnant women, treatment 10t2.3
- purulent pericarditis 6, 8
- STEMI (ST segment elevation myocardial infarction)
 - misdiagnosis 13t2.4
- pericarditis/myocarditis, comparison 8t2.2
- pericardium 6
- pericoronitis 144
 - epidemiology and microbiology 144
 - clinical features 144
 - differential diagnosis 144
 - laboratory and radiographic findings 144
 - treatment 144
 - complications and admission criteria 144
 - pearls and pitfalls 145
- children 144
- deep neck space infections 144
- systemic toxicity 144, 145
- trismus, severe (lockjaw) 144
- perinatal transmission, parotitis 128
- perinephric abscess, pyelonephritis 326
- periocular infections (eyelid infections) 265–73
 - general points 265–66
 - pearls and pitfalls 273
- blepharitis 266–67, 273
- chalazia 268
- dacryocystitis 266f42.3, 268–69
- eyelid anatomy 265–66
- eyelid edema, sinusitis 122
- hordeola 268
- periobital and orbital cellulitis 269–73
- periodontal infections 143–44
 - epidemiology and microbiology 143
 - clinical features 143, 144t22.2
 - laboratory and radiographic findings 144, 144t22.2
 - treatment, abscess 144, 144t22.2
 - pearls and pitfalls 145
- adolescents 143
- dental plaque 143
- gingivitis periodontis 143, 144t22.2
- gum disease 143
- necrotizing periodontitis 143
- periodontitis, necrotizing 143
- young adults 143

Index

- periorbital and orbital cellulitis
 269–73
 — epidemiology and microbiology
 269–70, 270t42.6
 — clinical features 270
 — differential diagnosis 270–71
 — laboratory and radiographic findings 271
 — treatment 271–72
 — complications and admission criteria 272–73
 — pearls and pitfalls 273
 children, treatment 272t42.7
 immunocompromised patients, treatment 272t42.7
 pregnant women, treatment 272t42.7
 peripancreatic abscess, secondary peritonitis 164–65
 peritonitis 162–68
 — epidemiology 162
 — clinical features 162–65
 — differential diagnosis 165–66
 — laboratory and radiographic findings 165–67
 — treatment and prophylaxis 167
 — infection control 167
 — pearls and pitfalls 167–68
 abdominal pain 162, 163–64, 165–66, 166t25.10
 classification 162
 imaging, acute abdominal pain 166t25.10
 patterns of referred abdominal pain 163t25.2
 shifting pain 168
 tertiary 162
see also peritonitis, primary; peritonitis, secondary
 peritonitis, primary 162
 — epidemiology and microbiology 162
 — clinical features 162–63
 — laboratory and radiographic findings 163t25.1
 — treatment and prophylaxis 167t25.11
 antibiotics for 167t25.11
 catheter-associated 162–63, 163t25.1, 167t25.11
 spontaneous bacterial (SBP) 162–63, 167t25.11
 peritonitis, secondary 162
 — epidemiology 162
 — clinical features 163–64
 — treatment and prophylaxis 167
 abdominal pain 163–64
 anastomotic leaks 164
 appendicitis 162, 164
 diverticulitis 162, 164
 hepatic abscess 164
 liver abscess 164
 liver abscess classification 164
 NSAID use causing 163
 patterns of referred abdominal pain 163t25.2
 penicillin-allergic patients 167
 peptic ulcer perforation 162, 163
 peripancreatic abscess 164–65
 solid organ abscess 164–65
 splenic abscess 165
 viscus perforation 163–64
 peritonsillar abscess (PTA) (quincy)
 129, 132–34
 — epidemiology and microbiology 132
 — clinical features 133, 134t20.5
 — differential diagnosis 133
 — laboratory and radiographic findings 133, 134t20.5
 — treatment and prophylaxis 133–34, 134t20.5
 — complications and admission criteria 134
 — pearls and pitfalls 134
 abscess aspiration 133
 adolescents 132, 134
 bedside ultrasound 133
 infants and children 133, 134
 Lemierre's syndrome 134
 oropharynx view 133f20.2
 peritonsillar cellulitis, young children 133
 pharyngitis 130t20.1
 sore throat 132, 134
 trismus, severe (lockjaw) 133
 young adults 132, 135
see also pharyngitis
 peritonsillar cellulitis, young children 133
 permanent pacemakers 14
 permethrin (Elimite)
 human lice 92, 93t13.6
 mites 90
 scabies 89, 89t13.3
 persistent diarrhea, definition 182
 persistent diarrhea in HIV, causes 183t27.3
 pertussis (whooping cough), pediatric 360–61
 — epidemiology and microbiology 360, 360t54.5
 — clinical features 360, 360t54.5
 — differential diagnosis 360
 — laboratory and radiographic findings 360, 360t54.5
 — treatment and prophylaxis 360–61, 360t54.5
 — complications and admission criteria 361
 — infection control 361
 — pearls and pitfalls 364
 pestis minor, clinical features 493
 petechiae 99, 340t52.1
 petroleum jelly, human lice, eyelashes 92–93
 pharmacokinetics and pharmacodynamics, antimicrobials 556
 pharyngeal infection, gonorrhea, treatment 203t30.4
 pharyngeal space infections 135–36
 pharyngitis 129–32
 — epidemiology and microbiology 129–30
 — clinical features 130, 132t20.4
 — differential diagnosis 130–31
 — laboratory and radiographic findings 131, 132t20.4
 — treatment and prophylaxis 131–32, 132t20.4
 — pearls and pitfalls 132, 134
 children 129, 132
 deep neck space infections 131
 epiglottitis abscess 131
 etiologies 130t20.1
F. necrophorum 129, 131, 132
 GAS pharyngitis 129, 131–32
 infants 129
 Lemierre's syndrome 131, 132
 retropharyngeal abscess 131
 tonsillectomy 132
 young adults 131, 135
see also peritonsillar abscess
 pharyngitis, streptococcal
 penicillin G benzathine 132t20.4, 560t78.3
 phenothiazines, hepatotoxicity 159t24.3
 phenytoin
 intracranial abscess 37
 severe drug reactions 109
 toxic epidermal necrolysis 109
 PID *see* pelvic inflammatory disease
 piperacillin–tazobactam (Zosyn)
 — activity spectrum 557–59
 — properties and dosages 561–62
 acute bacterial cholangitis 152t23.5
 acute calculous cholecystitis 148
 acute calculous cholecystitis, resuscitation 149t23.2
 appendectomy in pregnancy 392t58.7
 deep neck space infections 137
 diabetic foot infections, acute 230t34.1
 health-care-associated CAP 284t44.3
 Lemierre's syndrome 138t21.2, 139
 necrotizing soft-tissue infections 86
 oncology patients 449–50
 osteomyelitis 243t37.1
 plantar puncture wounds 248t38.2
 postpartum endometritis 407t59.1
 pyelonephritis, adults 326t49.2
 pyelonephritis, in pregnancy 389t58.4
 secondary peritonitis 167t25.12
 severe sepsis 471t65.8
 spine infections, epidural abscesses 256t40.2
 spontaneous bacterial peritonitis 167t25.11
 piperazine citrate, parasitic cholangitis, *A. lumbricoides* 153t23.6
 plague 490–96
 — microbiology 490
 — epidemiology 490–91
 — clinical features 491–93
 — differential diagnosis 493–94
 — laboratory and radiographic findings 494
 — treatment and prophylaxis 494–95
 — complications and admission criteria 495–96
 — infection control 496
 — pearls and pitfalls 496
 as a biological weapon 491
 bubonic plague 492, 493–94
 children 495t68.4
 contained casualty setting, treatment 494
 decontamination 496
 infants 495t68.4
 mass casualty setting, treatment 494
 meningitis 493
 mortality rates 491
 natural reservoirs 490
 pestis minor, clinical features 493
 pharyngitis 130t20.1, 493
 pneumonic plague 491, 493
 post-exposure prophylaxis 494, 495t68.4
 pregnant women 495t68.4
 septicemic plague 492–93, 494
 transmission modes 490
 US occurrence 491
 vaccination 495
 Working Group for Civilian Biodefense 490
 worldwide occurrence 490–91
Y. pestis and biovars 490, 496
 plague meningitis 493
 plague pharyngitis 130t20.1, 493
 plantar puncture wounds 246–48
 — microbiology 246
 — epidemiology 246
 — clinical features 246–47
 — laboratory and radiographic findings 247, 247t38.1
 — treatment and prophylaxis 247–48
 — complications and admission criteria 248
 — pearls and pitfalls 248
 cellulitis 247, 247t38.1, 248t38.2
 children, treatment 248
 diabetic neuropathy 246
 diabetic patients, osteomyelitis 247t38.1
 foreign body detection 246–47, 248
 foreign body removal 247, 248t38.2
 osteomyelitis 239, 247t38.1
 prophylactic antibiotics 248, 248t38.2
 seasonality 246
 spectrum of infection 247
 tetanus immunization 247
 wound care 247
see also diabetic foot infections
 plantar rash, secondary syphilis 104f14.6
 AIDS setting 104f14.7
 plaque, dental 140, 143

- plaques 99, 340t52.1
Plasmodium, hematopoietic stem cell transplants
 transfusion fever 462
Plasmodium falciparum malaria 416, 418, 419t60.5
Plasmodium malariae malaria 416, 419t60.5
Plasmodium ovale malaria 416, 419t60.5
Plasmodium vivax malaria 416, 419t60.5
PML (progressive multifocal leukoencephalopathy)
 CNS infections, HIV/AIDS patients, initial treatment 24t4.6
 focal cerebral dysfunction, HIV/AIDS patients 20t4.3
 neuroimaging 22t4.5
pneumococcal pneumonia, penicillin resistance 560
Pneumococcus meningitis, penicillin resistance 560
Pneumocystis, focal cerebral dysfunction
 HIV/AIDS patients 20t4.3
Pneumocystis carinii, uveitis and retinitis 27t43.1
Pneumocystis jiroveci pneumonia
 neutropenic oncology patients 445, 450
 solid organ transplants 460
Pneumocystis pneumonia (PCP)
 hematopoietic stem cell transplants, phase 3 infections 461
 HIV-associated 288, 291t45.2
 TMP-SMX 572
pneumonectomy, anastomotic leak risks 455t63.3
pneumonia
 abdominal pain differentiation 165–66
 CA-MRSA coverage 545t75.4
 causes, unusual 282
 MRSA screening 544, 546
 oxazolidinones 574–75
 pneumonia, pediatric respiratory infections 362–64
 — epidemiology and microbiology 362, 363t54.7
 — clinical features 362
 — differential diagnosis 362–63
 — laboratory and radiographic findings 363, 363t54.7
 — treatment and prophylaxis 363–64
 — complications and admission criteria 363–64
 — infection control 364
 — pearls and pitfalls 359, 364
 age/organism treatment table 364t54.8
 bronchiolitis with right upper lobe atelectasis 363f54.5
 febrile child 336
 lingular infiltrate 363f54.6
 neonates 329, 330t50.1, 332, 364t54.8
 pneumonia, *Pneumocystis jiroveci* neutropenic oncology patients 445
 solid organ transplants 460
 pneumonia, *Pneumocystis* (PCP)
 hematopoietic stem cell transplants, phase 3 infections 461
 HIV-associated 288, 291t45.2
 TMP-SMX 572
 pneumonia severity index (PSI)
 community-acquired pneumonia 285, 285f44.1, 285t44.5
 HIV pulmonary infections 295, 296t45.7
 pneumonic plague
 — clinical features 491
 — differential diagnosis 493
 septicemic plague 492
 pneumonic tularemia
 — clinical features 512
 — differential diagnosis 510
 bioterrorism risk assessment 513
 pneumonitis, pharyngitis 130t20.1
 POCUS (point of care ultrasound), purulent tenosynovitis 235
 podofilox, human papilloma virus 206t30.7
 podophyllin resin, human papilloma virus 206t30.7
 poke-hole, open fractures 239
 polio virus, aseptic and viral meningitis 54
 poliomyelitis 44, 53t8.2
 poliomyelitis-like syndrome (flaccid paralysis) 29, 75
 polyarteritis nodosa, fever and rash
 differential diagnosis 100t14.1
 polyenes (amphotericin)
 — properties and dosages 577
 nephrotoxicity 577t78.42
see also specific drugs
 polymicrobial endocarditis,
 IDU-associated 431
 polymixin B, otitis externa 115
 polyradiculopathies, Miller-Fisher syndrome 31
see also Guillain-Barré syndrome
 porphyria, abdominal pain
 differentiation 165–66
Porphyromonas, deep neck space
 infections 136t21.1
Porteus mirabilis, antibacterial drug
 spectra 558t78.1
 posaconazole (Noxafil) 575–76
 post-abortion endometritis 408t59.2
 post-abortion prophylaxis,
 endometritis 408
 post-antibiotic era 135
 Post-Exposure Prophylaxis Hotline (PEpline) 383
 post-exposure prophylaxis (PEP)
 resources
 CDC guidelines 383
 HBV and HIV 383
 New York exposures 383
 PEpline 383
 post-herpetic neuralgia, treatment,
 HIV patients 107
 post-influenza CA-MRSA CAP
 543t75.2
 post-operative infections 453–56
 — general points 453–54
 — infection control 456
 — pearls and pitfalls 456
 anastomotic leak risks 455t63.3
 antibiotic-associated diarrhea 456
 CA-MRSA 453
 catheter-associated urinary tract
 infections 454t63.1, 456
 cellulitis 453
 MRSA 453
 operation sterility classification
 454t63.2
 pneumonia 456
 post-operative infection types
 454t63.1
 surgical site infections 453–56
 vertebral osteomyelitis 255–56
see also surgical site infections
 postpartum and post-abortion
 infections 406–11
 — general points 406
 — pearls and pitfalls 411
 breast abscess 410t59.4, 410t59.5
 endometritis 406–08, 411
 mastitis 409–10, 411
 post-abortion endometritis
 408t59.2
 postpartum endometritis 407t59.1
 septic pelvic thrombophlebitis
 408–09, 411
 spinal epidural abscess 42
see also specific diseases
 post-transplant infections *see* febrile
 post-transplant patients;
 hematopoietic stem cell
 transplants, infections in; solid
 organ transplants, infections in
 post-WNV infection syndrome
 75t11.1
 Pott's disease (spinal tuberculosis)
 spinal cord infections differential
 diagnosis 44–45
 vertebral osteomyelitis 255
 PPROM (preterm premature rupture
 of the membranes)
 paroxysmal coughing in
 pregnancy 391
 praziquantel, parasitic cholangitis, *C. sinensis* 153t23.6
 prednisone, *Pneumocystis*
 pneumonia (PCP), HIV
 296t45.6
 pregnant women
 acute calculous cholecystitis
 149–50
 acute cystitis 320t48.1, 322
 bacterial vaginosis, treatment 221
 candidiasis, treatment 223t32.6
 chancroid 218t31.6
 chest x-ray 403–04
 community-acquired pneumonia
 283t44.2
 enteric fever, vaccines 424
 infective endocarditis, treatment
 4t1.2, 5t1.3
 influenza, complication risks 300,
 302t46.3, 305, 403
 keratitis, treatment 262
 parotitis 128
 pericarditis, treatment 10t2.3
 periorbital and orbital cellulitis,
 treatment 272t42.7
 spinal epidural abscess, IDU-
 associated 438t61.10
 syphilis 105t14.6, 216t31.4
 tetanus, prophylaxis 72
 tetracyclines, cautions 571
 trichomoniasis 222, 222t32.4
 tularemia, treatment and PEP
 512t70.4
 viral pneumonia 304
 West Nile virus infections 76
 pregnant women, malaria 402–03
 — epidemiology 403
 — clinical features 403
 — differential diagnosis 403
 — laboratory and radiographic
 findings 403
 — treatment and prophylaxis 403
 — complications and admission
 criteria 403
 — infection control 403
 — pearls and pitfalls 404
 pregnant women, pyelonephritis and
 urinary tract infections 387–89
 — epidemiology and microbiology
 387–88
 — clinical features 388
 — differential diagnosis 388
 — laboratory and radiographic
 findings 388
 — treatment and prophylaxis
 388–89
 — complications and admission
 criteria 389
 — pearls and pitfalls 403–04
 asymptomatic bacteriuria 387–88
 cephalosporins 388
 chest X-ray, pregnant women
 403–04
 cystitis 387–88, 389t58.4, 389t58.5
 cystitis vs. pyelonephritis 388,
 388t58.2
 fluoroquinolones 403–04
 quinolones 388
 sulfonamides 388
 tetracyclines 388
 pregnant women, Zika virus
 — clinical features 527–28
 — complications 530
 screening 529
 transmission to fetus 527–28
 traveling partner 529
 women wishing to get
 pregnant 530
 pressure ulcers, osteomyelitis 244
 preterm premature rupture of the
 membranes (PPROM) 391
 prevertebral space infections 136
Prevotella
 acute necrotizing ulcerative
 gingivitis 145
 bacterial vaginosis 220, 221t32.1

Index

- Prevotella* (*cont.*)
 cat bite infections 369
 deep neck space infections 135, 136t21.1
 dentoalveolar infections 142t22.1
 dog bite infections 369
 Lemierre's syndrome 138t21.2
 periapical abscess 140–41
Prevotella intermedia
 deep mandibular space infections 141
 pericoronitis 144
 periodontal infections 143, 144t22.2
 Prezista *see* darunavir
 primaquine
 antimalarial regimens 420t60.6
 contraindications, pregnancy 403t58.17
 PCP (*Pneumocystis pneumonia*), HIV 296t45.6
 primaquine phosphate
Plasmodium ovale malaria 419t60.5
Plasmodium vivax malaria 419t60.5
 primary central nervous system lymphoma, HIV/AIDS patients CT scan, head 23f4.2
 focal cerebral dysfunction features 20t4.3
 HIV-related brain disorders, neuroimaging 22t4.5
 primary infection sites, sepsis 467
 primary lesions, fever and rash, adults 99
 primary peritonitis *see* peritonitis, primary
 primary pneumonic plague 491, 493
 primary septicemic plague 492–93, 494
 primary syphilis *see* syphilis, primary
 Primaxin *see* imipenem
 probenecid
 altered mental status, HIV patients 24t4.6
 neurosyphilis 216t31.4
 probiotics, acute infectious diarrhea 176
 procaine penicillin
 altered mental status, HIV patients 24t4.6
 neurosyphilis 216t31.4
 progressive multifocal leukoencephalopathy (PML) CNS infections, HIV/AIDS patients, initial treatment 24t4.6
 focal cerebral dysfunction in HIV/AIDS patients 20t4.3
 HIV-related brain disorders, neuroimaging 22t4.5
Propionibacterium
 Lemierre's syndrome 138t21.2
 uveitis and retinitis 276t43.1
Propionibacterium acnes
 endophthalmitis 277
 prosthetic joint infections 250
 shunt infections, meningitis 61
 propofol, muscle spasms, tetanus 71 IDU-associated 440t61.14
 prostatitis, acute bacterial *see* acute bacterial prostatitis
 prosthetic joint infections 250–51
 — microbiology 250
 — epidemiology 250
 — clinical features 250
 — differential diagnosis 250–51
 — laboratory and radiographic findings 251, 251t39.1
 — treatment and prophylaxis 251, 251t39.1
 — complications and admission criteria 251
 — pearls and pitfalls 251
 enterococci 250
 joint aspiration 251
P. acnes 250
 revision arthroplasty 251
S. aureus 250
 staphylococci 250
 protease inhibitors
 HIV patients 108, 183
 HIV PEP, side effects and toxicities 381t57.7
see also specific drugs
Proteus
 acute bacterial cholangitis 152t23.5
 acute bacterial prostatitis 196–97
 acute calculous cholecystitis 146
 cephalosporins, third- and fourth-generation 563
 CIED infections 15t3.1
 emphysematous pyelonephritis 326
 keratitis 261t41.3
 meningitis, shunt infections 61
 urinary tract infections, in pregnancy 387–88
 vertebral osteomyelitis 253, 254t40.1
 xanthogranulomatous pyelonephritis 326–27
Proteus mirabilis
 — antibacterials, commonly used 557–59
 acute cystitis 319, 321
 ESBL production 553t77.1
 ESBL screening 553
 pyelonephritis, adults 324
 septic arthritis and osteomyelitis, IDU-associated 435–36
 protozoal infections, HIV patients 182t27.2, 183t27.3
Pseudallescheria boydii, fungal meningitis 59
Pseudomonas
 — antibacterial drug spectra 558t78.1
 — antibacterials, commonly used 557–59
 acute bacterial cholangitis 152t23.5
 aminoglycosides 569
 cephalosporins, advanced-generation 564
 cephalosporins, third- and fourth-generation 563
 CIED infections 14–15
 contact lens wearers 260t41.2
 endophthalmitis 278t43.2
 epididymitis 195
 ertapenem, clinical issues 554t77.3
 fluoroquinolones, resistance 568
 infective endocarditis, IDU-associated 431
 intraparenchymal brain abscess 34t6.2
 keratitis 259
 penetrating head trauma 34t6.2
 peripancreatic abscess 164
 piperacillin–tazobactam 561
 plantar puncture wounds 246
 post neurosurgery 34t6.2
 septic arthritis and osteomyelitis, IDU-associated 435–36
 supraglottitis (epiglottitis) 124t18.1
 urinary tract infections, in pregnancy 387–88
 vertebral osteomyelitis, injection drug users 253, 254t40.1
Pseudomonas aeruginosa
 acute bacterial prostatitis 196–97, 198
 acute cystitis 319
 bacteremia and fungemia, neutropenic oncology patients 443t62.1
 catheter-associated peritonitis 163
 chronic diabetic foot wounds 228, 230, 231
 CIED infections 14–15
 community-acquired pneumonia 281t44.1
 deep neck space infections 135
 ESBL production 553t77.1
 health-care-associated CAP 280
 hematopoietic stem cell transplants, phase 1 infections 461
 HIV pulmonary infections 290, 293–94, 294t45.4, 296t45.6
 keratitis 261t41.3
 malignant otitis externa 114
 neutropenic oncology patients 443
 oncology patients 450
 open fractures 239
 osteomyelitis 242
 osteomyelitis, non-diabetic patients 247
 otitis externa 114
 plantar puncture wounds 246, 247, 247t38.1
 pyelonephritis, adults 324
 shunt infections, meningitis 61
 solid organ transplants 460t64.1
Pseudomonas putida, ESBL production 553t77.1
 pseudoparalysis, septic arthritis 350, 352
 PSI (pneumonia severity index) community-acquired pneumonia 285, 285f44.1, 285t44.5
 HIV pulmonary infections 295, 296t45.7
 psitticosis, pharyngitis 130t20.1
 psychiatric illness (conversion paralysis), botulism differential diagnosis 29
 PTA *see* peritonsillar abscess
 pubic lice (*Phthirus pubis*) lice, human 91, 92
 sexual abuse, suspected 91, 92t13.5
 public health reporting acute infections diarrhea 175t26.7, 178
 anthrax meningitis 483
 diarrhea in HIV patients 184
 fever in the returning traveler 413
 viral hepatitis 160
 public health risk action, tuberculosis 316, 317
 pulmonary adverse effects, nitrofurantoin caution 574
 pulmonary dysfunction, severe sepsis 468t65.2
 pulmonary edema and respiratory failure myocarditis 12
 pulmonary tuberculosis — clinical features 310
 — microbiologic diagnosis 311–12
 — treatment 312–13
 CDC guidelines, TB tests 311
 drug-susceptible, treatment algorithm 315f47.1
 fluoroquinolones, warning 313, 317
 HIV-related 311
 pulpitis — clinical features 140, 141, 142t22.1
 — differential diagnosis 141
 — radiographic findings 142
 — treatment and prophylaxis 142–43, 142t22.1
 — complications and admission criteria 143
 purpura fulminans, fever and rash differential diagnosis 100t14.1
 purulent cellulitis around abscess 80, 81f12.5
 CA-MRSA 543t75.2, 544, 545
 cellulitis 80, 81f12.5, 83, 84t12.3
 purulent pericarditis 6, 8
 purulent tenosynovitis (hand infections) 235, 238
 — microbiology 235
 — clinical features 235
 — differential diagnosis 235
 — radiographic findings 235, 236t35.2
 — treatment 235, 236t35.2
 index finger, purulent flexor 235f35.2
 Kanavel's signs 236t35.2
 penicillin allergic patients 236t35.2
 POCUS (point of care ultrasound) 235

Index

- purulent urethral discharge,
 gonorrhea 193f29.1, 201f30.1
 pustules 99, 340t52.1
 pyelonephritis, in adults 324–27
 — microbiology 324
 — epidemiology 324
 — clinical features 324–25
 — differential diagnosis 325
 — laboratory findings 325,
 325t49.1
 — treatment 325–26
 — complications and admission
 criteria 326–27
 — pearls and pitfalls 327
 abdominal pain differentiation
 165–66
 emphysematous
 pyelonephritis 326
 inpatient therapy 326t49.2
 intrarenal abscess 326
 outpatient therapy 326t49.2
 perinephric abscess 326
 xanthogranulomatous
 pyelonephritis 326–27
 pyelonephritis, in pregnancy
 see pregnant women,
 pyelonephritis and urinary tract
 infections
 pyomyositis
 CA-MRSA 543, 543t75.2,
 545t75.4
 MRSA screening 544, 546
 spinal cord infections differential
 diagnosis 44
 pyomyositis, CA-MRSA coverage
 545t75.4
 pyrantel pamoate, parasitic
 cholangitis, *A. lumbricoides*
 153t23.6
 pyrazinamide
 Pott's disease 255
 tuberculosis 313, 313t47.3,
 314t47.5
 pyrethrin–piperonyl butoxide,
 human lice 93t13.6
 pyrimethamine, altered mental
 status, HIV patients 24t4.6
 pyrimethamine–sulfadoxine,
 malaria, in pregnancy
 403t58.17
 Q fever (ricketsial infections)
 426t60.9
 QT interval prolongation
 (macrolides, fluoroquinolones,
 azoles) 557
 Queensland tick typhus (ricketsial
 infections) 426t60.9
 quinidine, malaria, in pregnancy
 403t58.17
 quinidine gluconate, *P. vivax* malaria
 419t60.5
 quinine, malaria, in pregnancy
 403t58.17
 quinine sulphate, *P. falciparum*
 malaria 419t60.5
 quinolone-resistant *Neisseria*
gonorrhoeae (QRNG) 104, 201
 quinolones
 otitis externa 115
 plantar puncture wounds 248
 in pregnancy 388
 rabbit fever 94t13.7
 see also tularemia
 rabbit mite (*Cheyletiella*)
 infestations 90
 rabies 64–66
 — microbiology 64
 — epidemiology 64
 — clinical features 64–65
 — differential diagnosis 65
 — laboratory diagnosis 65
 — treatment 65
 — post-exposure prophylaxis
 64, 66
 — infection control 66
 — pearls and pitfalls 66
 complications 65
 HRIG vaccine 66
Lyssavirus 64
 mortality rates 65
 paralysis 65, 66
 RIB vaccine 66
 solid organ transplants 460t64.1
 US occurrence 64, 66
 wound care 66
 racemic epinephrine
 bronchiolitis, pediatric 361t54.6
 croup 356t54.2, 357
 raltegravir (Isentress, RAL)
 HIV PEP regimens, non-
 occupational 381t57.8
 HIV PEP regimens, occupational
 379t57.5, 380t57.6, 381t57.7
 side effects and toxicities 183t27.5,
 381t57.7
 Ramsey–Hunt Syndrome (herpes
 zoster oticus) 114, 115, 343
 rape, blood or body fluid
 exposures 375
 rapidly progressive outer retinal
 necrosis (RPORN) 277f43.5
 Rapivab see peramivir
 rare infections, influenza differential
 diagnosis 301
 rash
 drug reactions, severe 100t14.1,
 109
 with fever, selected causes
 100t14.1
 fever in the newborn 330t50.1
 TMP-SMX cautions 572
 see also fever and rash in adults;
 lesions; pediatric fever and rash;
 sexually transmitted diseases,
 ulcerative; *specific infections*
 rat bite fever, bite infections 369
 rat flea bite infections 492
 rats and rodents see plague
 raxibacumab (ABthrax) 488
 reactivation tuberculosis,
 radiographic findings 311
 rectal resection, anastomotic leak
 risks 455t63.3
 recurrent acute sinusitis 120
 Red man's or Red neck syndrome,
 vancomycin reaction 567
 reduviid bug bite illnesses 415t60.3
 refractory acute osteomyelitis,
 treatment 244
 rehydration therapy, HIV diarrhea
 184–86
 relapsing fever (tick-borne illness)
 94t13.7
 Relenza see zanamivir
 renal adjustments see *specific drug*
properties
 renal dysfunction
 amphotericin B caution 577
 severe sepsis 468t65.2
 renal failure in sepsis 471
 resistant organisms see drug-resistant
 organisms
 respiratory failure and pulmonary
 edema, myocarditis 12
 respiratory flora, deep neck space
 infections 135
 respiratory infections
 exposure to while traveling,
 associated illnesses 415t60.3
 fever in the newborn 329
 HIV-associated see under HIV
 human immunodeficiency virus
 288–96
 pediatric 354 see pediatric
 respiratory infections
 respiratory infections, fever in
 pregnancy 390–91
 — epidemiology and
 microbiology 390
 — clinical features 390
 — differential diagnosis 390
 — laboratory and radiographic
 findings 390
 — treatment 390–91
 — complications and admission
 criteria 391
 — infection control 391
 bronchitis, viral 390t58.6
 influenza 390t58.6, 391
 mortality rates 391
 pneumonia 390t58.6
 preterm membrane rupture 391
 Tdap vaccine 391
 respiratory pathogens, atypical,
 antibacterial drugs 557–59
 respiratory support, sepsis 470
 respiratory syncytial virus (RSV)
 acute otitis media 117
 influenza-like illnesses 301
 Respiratory Syndrome coronavirus
 (MERS CoV) 413
 respiratory tract infections,
 neutropenic oncology patients
 — clinical features 445
 — differential diagnosis 448
 — laboratory 445t62.4
 — treatment 445t62.4
 Restasis see cyclosporine
 resuscitation, acute calculous
 cholecystitis 149t23.2
 retinal artery occlusions, West Nile
 virus 75
 retinitis see uveitis and retinitis
 retropharyngeal abscess 131, 135, 136
 retropharyngeal abscess, pediatric
 358–60
 — epidemiology and microbiology
 358, 359t54.4
 — clinical features 358–59
 — differential diagnosis 359
 — laboratory and radiographic
 findings 359, 359t54.4
 — treatment and prophylaxis 359,
 359t54.4
 — complications and admission
 criteria 359
 — pearls and pitfalls 359, 364
 ampicillin-sulbactam 359t54.4
 clindamycin 359t54.4
 with widened prevertebral space
 362t54.4
 Retrovir see zidovudine
 returning traveler
 cruise ship diarrhea, norovirus 170
 EAEC diarrhea 171–72
 ETEC diarrhea 171
 West Africa, Ebola virus disease
 523–22
 see also fever in the returning
 traveler
 revision arthroplasty, prosthetic joint
 infections 251
 Reyataz see atazanavir
 Reye syndrome risk, aspirin 304
 Reynold's pentad, acute bacterial
 cholangitis 150
 rhabdomyolysis, West Nile virus 75
 rhinosinusitis 120, 121t17.2
 rhinovirus
 acute chest syndrome, in sickle
 cell disease 476t66.2
 acute otitis media 117
 community-acquired
 pneumonia 280
 influenza-like illnesses 301
 pharyngitis 129
 ribavirin, West Nile virus infections 77
 Rickettsia 93
 Rickettsia prowazekii 426t60.9
 Rickettsia rickettsii 94t13.7, 99–100,
 424–25, 426t60.9
 see also Rocky Mountain
 spotted fever
 Rickettsia sibirica 96
 Rickettsia typhi 426t60.9
 Rickettsiae 424–25
 rickettsial infections 424–25
 in clinical evaluation 413
 exposure to while traveling,
 associated illnesses 415t60.3
 glycyclus 571
 incubation periods 415t60.2
 meningitis 60
 myocarditis 11
 regions of travel 414t60.1
 rickettsial pox 426t60.9
 specific infections 426t60.9
 tetracyclines 571
 see also Rocky Mountain
 spotted fever

Index

- rifabutin
 MAC diarrhea, HIV patients 185t27.6
 tuberculosis, first-line drugs 313t47.3, 314t47.5
- rifampin
 anthrax 486t67.3
 hepatotoxicity 159t24.3
 infective endocarditis 4t1.2
 meningitis chemoprophylaxis 62t8.13
 meningococcemia 101t14.2
 MRSA susceptibilities 545t75.3
 musculoskeletal infections, pediatric 352t53.4
 Pott's disease 255
 tuberculosis, drug-susceptible disease treatment 313
 tuberculosis, first-line antituberculosis drugs 313t47.3, 314t47.5
 tuberculosis, latent tuberculosis 314t47.4
- rifapentine, latent tuberculosis 314t47.4
- RIG (rabies immunoglobulin) vaccine 66
- right-ventricular assist devices (RVADs) 14
- rilpivirine (Edurant, RPV)
 HIV PEP regimens, occupational 379t57.5, 380t57.6, 381t57.7
 side effects and toxicities 183t27.5, 381t57.7
- ritonavir (Norvir, RTV)
 diarrhea effect 183t27.5
 HIV PEP regimens, non-occupational 381t57.8
 HIV PEP regimens, occupational 379t57.5, 380t57.6, 381t57.7
- Rocephin *see* ceftriaxone
- rocker-bottom foot with associated plantar ulcer
 diabetic foot infections 231f34.2
- Rocky Mountain spotted fever (RMSF) 94t13.7, 426t60.9
 admission criteria 96
 children, exposure 93
 children, treatment 101t14.3
 differential diagnosis 100t14.1
 fever and rash, in adults 99–100, 100t14.1
Rickettsia rickettsii 99–100, 424–25, 426t60.9
- rodent bite infections 369
see also bite infections
- rodent contact while traveling, illnesses 415t60.3
- rodent flea bite infections 492
- rodents, hantavirus 514–15
- roseola infantum, pediatric fever and rash 339–40
- rotavirus diarrhea
 acute infectious 170, 170t26.2
 HIV patients 182t27.2
- Roth spots, infective endocarditis 2
- RPORN (rapidly progressive outer retinal necrosis) 277f43.5
- RPV *see* rilpivirine
- RSV (respiratory syncytial virus)
 acute chest syndrome, in sickle cell disease 476t66.2
 community-acquired pneumonia 280
 hematopoietic stem cell transplants, phase 3 infections 461
- RTV *see* ritonavir
- rubella (German measles) 100t14.1, 106
- rubella (German measles), fever in pregnancy
 — epidemiology and microbiology 395–96
 — clinical features 396–97
 — laboratory tests 398t58.11
 — treatment and prophylaxis 396
 — complications and admission criteria 396–97
 — infection control 397
- rubeola virus, uveitis and retinitis 276t43.1
- Russia, rickettsial infections 426t60.9
- Salmonella*
 bacteremia and sepsis, in sickle cell disease 475t66.1
 febrile child 334–35, 337
 osteomyelitis 242, 244
 osteomyelitis, pediatric 348
 osteomyelitis, sickle cell patients 244, 253, 254t40.1, 479
 solid organ transplants 459, 460–61
- Salmonella* diarrhea
 — microbiology 171
 — clinical features 170t26.1, 171, 173
 — treatment 170t26.1, 171, 173, 176
 — complications 171
 — infection control 178
 antibiotic therapy 177t26.10
 transmission modes 171, 173t26.4
- Salmonella* diarrhea, HIV patients
 — microbiology 181
 — clinical features 181, 182, 185t27.6
 — treatment 184, 185t27.6
 — pearls and pitfalls 186
 acute diarrhea 182t27.2
 bacteremia and septicemia risks 186
 CD4 counts 183t27.4
 persistent diarrhea 183t27.3
 small bowel diarrhea 182t27.1
- Salmonella enterica*, enteric fever 423
- Salmonella enteritidis*, ESBL production 553t77.1
- Salmonella typhi* and *paratyphi*, enteric fever 423
- Salmonella typhimurium*, ESBL production 553t77.1
- salmonellosis, acute infectious
 bacterial diarrhea 171, 175t26.7, 178
- salt water exposure, cellulitis 82t12.2
- sand fly bites, associated illnesses 415t60.3
- Sandimmune *see* cyclosporine
- The Sanford Guide to Antimicrobial Therapy* 550t76.3
- saquinavir
 HIV PEP regimens, occupational 381t57.7
 side effects and toxicities 381t57.7
 skin reactions 108
- Sarcoptes scabiei* mite (scabies) 87
- SARS-associated Coronavirus, influenza differential diagnosis 301
- saxitoxin (paralytic shellfish poisoning)
 botulism differential diagnosis 29
- scabies mites 87–89
 — clinical features 87–88
 — differential diagnosis 88
 — laboratory and radiographic findings 89
 — treatment and prophylaxis 89
 — infection control 96
- crusted/Norwegian scabies 88, 88t13.2
- impetigo 88
- incubation periods 88t13.2
- in papule diagnosis 96t13.10
- patient bedding and towels 89
- scabies rash 88
- transmission modes 88t13.2
- treatment failures 97
- scarlatiniform rash, pharyngitis 130t20.1
- scarlet fever, pharyngitis 130t20.1
- SCCM (Society of Critical Care Medicine), sepsis diagnostic criteria 467–68
- screening
 Ebola virus disease algorithm 523
 ESBL-producing organisms and infections 553
 hepatitis B virus 155
 hepatitis C virus 155
 MRSA 544
 pregnant women, Zika virus 529
 tuberculosis 309
- screw worm infestations, myiasis 93, 96t13.9
- scrotum, condyloma lata, syphilis 215f31.13
- scrub typhus (rickettsial infections) 426t60.9
- secondary lesions, fever and rash in adults 99
- secondary peritonitis 162, 164–65 *see* peritonitis, secondary
 — epidemiology 162
 — clinical features 163–64
 — treatment and prophylaxis 167
- abdominal pain 163–64
- hepatic abscess 164
- liver abscess 164
- liver abscess classification 164
- patterns of referred abdominal pain 163t25.2
- penicillin-allergic patients 167
- peripancreatic abscess 164–65
- solid organ abscess 164–65
- splenic abscess 165
- secondary peritonitis, viscous perforation 163–64
- anastomotic leaks 164
- appendicitis 164
- diverticulitis 162, 164
- NSAID use causing peptic ulcer 163
- peptic ulcer perforation 162, 163
- secondary pneumonic plague 491, 493
- secondary septicemic plague 492–93
- secondary syphilis
 — clinical features 102–03
 — treatment 212–13, 216t31.4
- fever and rash differential diagnosis 100t14.1, 111
- secretory diarrhea 169
- SEN virus, viral hepatitis 156
- sepsis 467–71
 — microbiology 467
 — epidemiology 467
 — clinical features 467–68
 — differential diagnosis 468–69
 — laboratory and radiographic findings 468–69
 — treatment 468–70
 — complications and admission criteria 470–71
 — infection control 471
 — pearls and pitfalls 471
- ACCP standardized diagnostic criteria 467–68
- antibiotics 470–71
- ARDS complication 470–71
- carbapenems and monobactams 565
- cephalosporins, third- and fourth-generation 563
- in children *see* septic arthritis, pediatric
- CIED complications 16t3.2
- community-acquired pneumonia 281t44.1
- definitions (diagnostic criteria) 468t65.1
- early goal-directed therapy 468–69
- euglycemia 470
- fluid resuscitation 470
- major organ dysfunction 468t65.2, 470–71
- mortality rates 467, 468
- myocardial depression complication 471
- penicillin-beta-lactamase inhibitor combinations 561–62
- physiologic steroid therapy for relative adrenal insufficiency 470
- primary infection sites 467
- renal failure in sepsis 471
- respiratory support 470
- SCCM standardized diagnostic criteria 467–68

Index

- sepsis definitions/diagnostic criteria 468t65.1
 SIRS 468t65.1
 SIRS + hypoperfusion differential diagnosis 469t65.3
 Surviving Sepsis Campaign guidelines 470–71
 vasopressors 470
see also bacteremia and sepsis, in sickle cell disease; sepsis, severe; *under* septic
- sepsis, severe
 — differential diagnosis 468–69
 — infection control 471
 antibiotic regimens 471, 471t65.8
 definition 468
 diagnostic criteria 468t65.1
 ICU admission 470–71
 lactate measurement 468
 major organ dysfunction 468t65.2
 myocardial depression complication 471
 renal failure 471
see also sepsis; septic shock
- septic arthritis
 CA-MRSA 543, 543t75.2, 544
 CA-MRSA coverage 545t75.4
 MRSA screening 544, 546
- septic arthritis, adults 225–27
 — microbiology 225, 226t33.1
 — epidemiology 225
 — clinical features 225–26
 — differential diagnosis 225–26, 226t33.1
 — laboratory and radiographic findings 226–27, 226t33.1
 — treatment and prophylaxis 226t33.1, 227
 — complications and admission criteria 227
 — pearls and pitfalls 227
 CIED complications 16t3.2
- immunosuppressed individuals 227
 joint aspiration 225, 226, 226t33.1, 227
 mortality rates 227
 right knee effusion 226t33.1
 standard evaluation 227
 trauma patients, treatment 227
- septic arthritis and osteomyelitis, in sickle cell disease 477–78
 — epidemiology and microbiology 477
 — clinical features 477
 — differential diagnosis 477
 — laboratory and radiographic findings 477–78
 — treatment 478
 — complications and admission criteria 478
 — pearls and pitfalls 478–79
- acute bone infarct differentiation 244
 susceptibility 242
- septic arthritis, IDU-associated 435–37
 — epidemiology and microbiology 435–36, 436t61.7
 — clinical features 436
 — differential diagnosis 436
 — laboratory and radiographic findings 436–37, 436t61.7
 — treatment 227, 437
 — pearls and pitfalls 440–41
 MRSA 435–36
- septic arthritis, pediatric 350–52
 — epidemiology and microbiology 350
 — clinical features 350–51
 — differential diagnosis 351
 — laboratory and radiographic findings 351–52
 — treatment 352
 — complications and admission criteria 352
 — pearls and pitfalls 353
- septic emboli, CIED complications 16t3.2
- septic jugular venous thrombophlebitis *see* Lemierre's syndrome
- septic knee joint, gonorrhea 201
- septic pelvic thrombophlebitis 408–09
 — epidemiology and microbiology 408
 — clinical features 408
 — differential diagnosis 408–09
 — laboratory and radiographic findings 408t59.3, 409
 — treatment and prophylaxis 409
 — pearls and pitfalls 411
 cesarean section risk level 408
 incubation periods 408t59.3
- septic shock
 — clinical features 467–68
 — pearls and pitfalls 471
 antibiotics 471
 community-acquired pneumonia 281t44.1
 definition 468, 468t65.1
 diagnostic criteria 467–68, 468t65.1
 euglycemia 470
 hydrocortisone therapy 470
 respiratory support/ventilation 470
 steroid treatments 470
 vasopressors 470
 ventilation 470
see also sepsis
- septic thrombophlebitis, internal jugular vein *see* Lemierre's syndrome
- septicemic plague 492–93, 494
- septicemic tularemia 511
- Septra *see* TMP-SMX
- serology testing
 acute viral hepatitis 158
 hepatitis B virus 158–59, 159t24.4
- serotonergic agents, linezolid interaction 575
- serotonin syndrome, linezolid guidance 575
- Serratia*
 — antibiotic drug spectra 558t78.1
 — antibacterials, commonly used 557–59
 aminoglycosides 569
 cephalosporins, third- and fourth-generation 563
 CIED infections 15t3.1
 keratitis 261t41.3
- Serratia marcescens*, ESBL production 553t77.1
- severe complicated infections, *C. difficile* 189–90, 189t28.1, 190t28.2
- severe drug reactions *see* drug reactions, severe; nephrotoxicity; penicillin-allergic patients; toxic epidermal necrolysis
- severe sepsis *see* sepsis, severe
- sexual abuse or assault, exposures 375
- sexual abuse, suspected conjunctivitis 260t41.1
 pubic lice (*P. pubis*) 91, 92t13.5
- sexual contact/body fluids, returning traveler 415t60.3
- sexual history, diarrhea in HIV patients 181–82
- sexually transmitted diseases (STDs) 199
 — infection control 111
 CDC guidelines 199
 fever and rash in adults 107, 111
 groupings 199, 208
 hepatitis B virus 155
 HIV patients 107
 macrolides and ketolides 570
 pubic lice 91
 urethritis risk factors 192–93
 Zika virus 527, 529
see also genitourinary infections, male; sexually transmitted diseases, nonulcerative; sexually transmitted diseases, ulcerative
- sexually transmitted diseases, non-ulcerative 199–207
 — pearls and pitfalls 206–07
 chlamydia 107, 199–200, 206–07
 gonorrhea 200–02, 206–07
 human papilloma virus 205, 206–07
 non-gonococcal urethritis 202, 206–07
 pelvic inflammatory disease 202–05, 206–07
 purulent urethral discharge 201f30.1
- sexually transmitted diseases, ulcerative 208–18
 — pearls and pitfalls 218
 chancroid 216–18
 herpes genitalis 208–12, 218
 lymphogranuloma venereum, chancroid and granuloma inguinale 208, 210, 213, 217
 suspected (fever and rash) 107
- syphilis 212–16, 218
- shellfish, acute infectious bacterial diarrhea 172
- Shiga toxin-producing *Escherichia coli* (STEC), diarrhea 175t26.7
- Shigella* diarrhea
 — microbiology 170t26.1, 171
 — clinical features 171, 173t26.4
 — treatment 173t26.4
 — infection control 178
 antibiotic therapy 177t26.10
 transmission modes 173t26.4
- Shigella* diarrhea, HIV patients
 — microbiology 181
 — clinical features 181, 182, 185t27.6
 — treatment 184, 185t27.6
- acute bacterial diarrhea 182t27.2
- persistent bacterial diarrhea 183t27.3
- Shigella dysenteriae* diarrhea 171
- Shigella flexneri*, men who have sex with men 171
- Shigella sonnei* diarrhea 171
- Shigellosis diarrhea 175t26.7, 178
- shunt infections, meningitis 61
- sickle cell crisis, abdominal pain differentiation 165–66
- sickle cell disease, infections in 473–79
 — general points 473–74
 — microbial susceptibilities 473
 — complications and admission criteria 478
 — pearls and pitfalls 478–79
 acute chest syndrome 474–77, 478–79
 bacteremia and sepsis 474, 478–79
 cholecystitis and cholangitis 478–79
 mortality rates 478
 osteomyelitis and septic arthritis 477–79
 pediatric orthopedic infections 348, 352–53
 vertebral osteomyelitis 253
- Sin Nombre virus (SNV) 514, 516t71.2, 519
- sinecatechins, human papilloma virus 206t30.7
- sinusitis 120–22
 — microbiology 120, 121t17.3
 — epidemiology and microbiology 120
 — clinical features 120
 — differential diagnosis 120–21
 — laboratory and radiographic findings 121–22, 121t17.3
 — treatment and prophylaxis 121t17.3, 122
 — complications and admission criteria 122
 — pearls and pitfalls 122
 acute bacterial meningitis, differential diagnosis 55t8.4
 acute sinusitis definition 120
 allergic fungal sinusitis 121
Aspergillus sensitivity 121

Index

- sinusitis (*cont.*)
 bacterial 120, 568–69, 570
 bacterial rhinosinusitis 120
 categorization 120
 cephalosporins, second-generation 562–63
 children with cystic fibrosis, risks 120
 chronic sinusitis 120
 cranial nerve involvement 122
 dental infections 120, 121
 eyelid edema 122
 immunocompromised patients, invasive fungal rhinosinusitis 121
 intracranial abscess, initial antibiotic therapy 37
 intraparenchymal brain abscess, microbiology 34t6.2
 invasive fungal rhinosinusitis 121, 122
 minor sinusitis factors 121t17.1
 nasal polyposis 120
 recurrent acute 120
 rhinosinusitis 120, 121t17.2
 unilateral maxillary sinusitis 120, 121
 vasomotor rhinitis 120
 viral rhinosinusitis 120
 vision changes 122
 sirolimus (Rapamune) nephrotoxicity 465t64.3
 post-transplant patients 466t64.4
 SIRS (systemic inflammatory response syndrome)
 acute liver failure, in viral hepatitis 156
 and hypoperfusion differential diagnosis 469t65.3
 in sepsis definitions 468t65.1
 Sjogren's Syndrome, parotitis 126–27, 127t19.1
 SJS *see* Stevens–Johnson syndrome
 skin and skin structure infections, complex
 cephalosporins, advanced-generation 564
 skin and soft tissue infections, neutropenic oncology patients
 — clinical features 444–45
 — differential diagnosis 447
 — laboratory findings 445t62.3
 — treatment 445t62.3
 skin and soft-tissue infections (SSTIs) 79–86
 — definitions and terminology 79
 — pearls and pitfalls 86
 abscess 79–82
 anti-staphylococcal penicillins 560t78.3
 CA-MRSA 86, 543t75.2, 544, 546, 547
 carbuncle 80t12.1
 cellulitis 80t12.1, 82–84
 furuncle 80t12.1
 glycopeptides 566–68
 HIV patients 107
 lincosamides 571–72
 necrotizing soft-tissue infections 80t12.1, 84–86
 oxazolidinones and lipopeptides 574–75
 penicillin-beta-lactamase inhibitor combinations 561–62
 tetracyclines and glycyclines 571
see also under abscess; furuncle; lesions; necrotizing soft-tissue infections
 skin test, tuberculin 311, 317
 skull fractures, meningitis prophylaxis 61
 small bowel diarrhea, HIV patients 182t27.1
 small bowel resection, anastomotic leak risks 455t63.3
 smallpox 498–504
 — microbiology 498
 — epidemiology 498–99
 — clinical features 499–500
 — differential diagnosis 500–02
 — laboratory and radiographic findings 501t69.1, 502
 — treatment and prophylaxis 502–03
 — complications and admission criteria 501t69.1, 504
 — infection control 504
 — pearls and pitfalls 504
 as a biological weapon 498, 499
 decontamination 504
 flat-type smallpox (malignant smallpox) 500
 generalized vesicular or pustular rash 500–01
 hemorrhagic smallpox 500
 modified smallpox 500
 mortality rates 498
 natural reservoirs 498
Orthopoxvirus genus 498
 patient vaccination history 503
 post-exposure prophylaxis 503
 risk assessment 500–01
 transmission modes 498, 501t69.1
 US occurrence 498–99
 vaccination 498, 503
 vaccine contradictions and complications 503
 variola major 498, 500
 variola minor 498, 500
 variola sine eruption 500
 Working Group for Civilian Biodefense 498
 worldwide occurrence 498
 smell, foul-smelling bite wounds 369
 SNV (Sin Nombre virus) 514, 516t71.2, 519
 Society of Critical Care Medicine (SCCM), sepsis diagnostic criteria 467–68
 soft tissue infections *see under* abscess; furuncle; lesions; necrotizing soft-tissue infections; skin and soft-tissue infections
 solid organ abscess (secondary peritonitis) 164–65
 hepatic abscess 164
 liver abscess 164
 liver abscess classification 164
 peripancreatic abscess 164–65
 splenic abscess 165
 solid organ transplants, infections in
 — epidemiology 458
 — clinical features 458–61
 — differential diagnosis 461–62
 — laboratory and radiographic findings 462–63
 — prophylaxis 463
 — treatment 463
 — complications and admission criteria 463–65
 — pearls and pitfalls 465
 allograft rejection and graft-versus-host disease 461
 biopsies 463
 children, treatment post-transplant 464t64.2
 drug interactions 465t64.3
 drug reaction and hypersensitivity 461–62
 early phase infections 458–59, 463
 immunosuppressive agents 466t64.4
 infectious etiologies 459f64.1
 late-phase infections 461, 463
 mid-phase infections 459–60, 463
 mortality rates, transplants 458
 pathogen transmission 460t64.1
 thromboembolic disease and vascular events 462
 transfusion-related fever 462
see also febrile post-transplant patients
 sonographic findings, acute calculous cholecystitis 148f23.1
 sore throat infections 129
 non-pharyngitis causes 131t20.2
 peritonsillar abscess 132, 134
 pharyngitis 129–32
S. pyogenes, group A 129
 trismus, severe (lockjaw) 130, 131t20.2, 134
 SOTs *see* solid organ transplants, infections in
 South Africa, rickettsial infections 426t60.9
 south America, rickettsial infections 426t60.9
 southeast Asia, rickettsial infections 426t60.9
 “spider bite” lesion (necrotic furuncle), CA-MRSA 543, 543t75.2
 spinal cord infections 42–48
 — epidemiology and microbiology 42
 — clinical features 42–44
 — differential diagnosis 44–45
 — laboratory and radiographic findings 46
 — treatment and prophylaxis 46–47
 — complications and admission criteria 47
 — infection control 47
 — pearls and pitfalls 47–48
 CA-MRSA coverage 545t75.4
 children, initial antibiotic therapy 47t7.3
 CIED complications 16t3.2
 epidural catheter placement 42
 first-pass neurological localization 43t7.1
 focal weakness, infection distinguishing features 45t7.2
 Lyme disease, differential diagnosis 44
 MRI scan, spinal epidural abscess 47f7.1
 MRSA screening 544, 546
 postpartum setting 42
 risk factors 42
 syphilis, differential diagnosis 44
see also epidural abscess; spinal epidural abscess, IDU-associated; vertebral osteomyelitis
 spinal epidural abscess, IDU-associated 437–38
 — epidemiology and microbiology 437
 — clinical features 437
 — differential diagnosis 437
 — laboratory and radiographic findings 438, 438t61.9
 — treatment and prophylaxis 438, 438t61.9
 — pearls and pitfalls 440–41
 immunocompromised patients 438t61.10
 MRSA 437, 438t61.9
 pregnant women 438t61.10
 spinal osteomyelitis, CA-MRSA prevalence 543
 spine, sagittal MRI of 257f40.4
 spine infections 253–57
 — pearls and pitfalls 257
 epidural abscesses 256–57
 vertebral osteomyelitis 253–56, 257
see also spinal cord infections; specific diseases
 spiramycin, toxoplasmosis, pregnant women 399t58.12
Spirillum minus, rat bite fever 369
 spirochetes *see* Lyme disease
 splenic abscess, secondary peritonitis 165
 spontaneous bacterial peritonitis (SBP) 162–63, 167t25.11
 Sporanox *see* itraconazole
Sporothrix schenckii, uveitis and retinitis 276t43.1
 spotted fevers (rickettsial infections) 426t60.9
 sputum studies, community-acquired pneumonia 282, 544
 S-S-I-C-C-C-F-I-T mnemonic, fever in the newborn 331
 SSRIs (selective serotonin reuptake inhibitors)
 hepatotoxicity 159t24.3
 oxazolidinone interactions 574–75

Index

- St. Louis encephalitis virus, aseptic and viral meningitis 54
 staphylococcal scalded skin syndrome, pediatric 344
Staphylococcus
 cat bite infections 369
 catheter-associated peritonitis 163t25.1
 CIED infections 14–15, 16
 dog bite infections 369
 fight bites 233–34, 234t35.1
 glycopeptides 566
 hematopoietic stem cell transplants, phase 1 infections 461
 infective endocarditis 1
 intraparenchymal brain abscess 34t6.2
 keratitis 259
 mite infestations 90t13.4
 open fractures 239
 peripancreatic abscess 164
 prosthetic joint infections 250
 shunt infections, meningitis 61
 SSIs (surgical site infections) (post-operative infections) 453
Staphylococcus aureus
 — antibacterial drug spectra 558t78.1
 abscess 79, 81
 acute bacterial prostatitis 196–97
 acute paronychia 236, 237t35.3
 antibiotic-associated diarrhea (AAD) 456
 bacteremia and fungemia, neutropenic oncology patients 443t62.1
 bacteremia and sepsis, sickle cell patients 474
 blepharitis 267t42.1
 catheter-associated peritonitis 163
 cellulitis 82, 247
 CIED infections 14–15, 16
 community-acquired pneumonia 281t44.1
 conjunctivitis 258, 260t41.1
 diabetic foot infections, acute 228, 231
 diarrhea, HIV patients 182
 endophthalmitis 278t43.2
 felon 236, 237t35.3
 fight bites 234
 HIV patients 107, 182
 infective endocarditis 1, 2t1.1
 infective endocarditis, IDU-associated 431, 431t61.1
 intraparenchymal brain abscess 34t6.2
 keratitis 261t41.3
 meningitis, shunt infections 61
 deep neck space infections 135
 necrotizing soft-tissue infections 84
 necrotizing soft-tissue infections, IDU-associated 434–35
 neutropenic oncology patients 443
 oncology patients 450
 open fractures 239
 osteomyelitis 242, 244
 osteomyelitis, IDU-associated 244
 osteomyelitis, pediatric orthopedic infections 348–49
 otitis externa 114
 parotitis 126, 127t19.1
 pediatric orthopedic infections 348–49
 penetrating head trauma, intraparenchymal brain abscess 34t6.2
 pericarditis 6
 peritonsillar abscess 132
 plantar puncture wounds 246, 247, 247t38.1, 248t38.2
 pneumonia 362
 post neurosurgery, intraparenchymal brain abscess 34t6.2
 post-operative infections 255–56
 prosthetic joint infections 250
 purulent tenosynovitis 235, 236t35.2
 pyelonephritis, adults 324, 326
 scabies rash, superinfection risk 87
 sepsis 467
 septic arthritis, adults 225, 226t33.1
 septic arthritis and osteomyelitis, IDU-associated 435–36
 solid organ transplants 459
 spinal epidural abscess 42, 46
 spinal epidural abscess, IDU-associated 437, 438t61.9
 spinal infections, epidural abscess 256, 256t40.2, 257
 splenic abscess, peritonitis 165
 subcutaneous abscess, IDU-associated 433, 433t61.3
 supraglottitis (epiglottitis) 123
 toxic shock syndrome 100–02
 vertebral osteomyelitis 253, 254t40.1
 see also MRSA
Staphylococcus aureus, antibacterials
 — antibacterials, commonly used 557–59
 cephalosporins, advanced-generation 564, 565
 glycopeptides 566
 nafcillin 561
 penicillin resistance 560
 see also MRSA
Staphylococcus epidermidis
 infective endocarditis 2t1.1
 keratitis 261t41.3
 necrotizing soft-tissue infections 84
 osteomyelitis, injection drug users 244
 solid organ transplants 459
 vertebral osteomyelitis 253, 254t40.1
Staphylococcus saprophyticus
 acute bacterial prostatitis 196–97
 acute cystitis 319
 urinary tract infections, in pregnancy 387–88
 statins, hepatotoxicity 159t24.3
 stavudine
 HIV PEP regimens, occupational 381t57.7
 side effects and toxicities 381t57.7
 STDs see sexually transmitted diseases
 STEC diarrhea (shiga-toxin-producing *Escherichia coli*)
 — microbiology 172
 — clinical features 170t26.1, 173t26.4
 — treatment 172, 173t26.4, 177t26.10
 — complications 172
 — infection control 178
 antibiotic therapy 177t26.10
 HUS (hemolytic-uremic syndrome) 172
 sorbitol-MacConkey's agar 172
 transmission modes 172, 173t26.4
 STEMI (ST segment elevation myocardial infarction) 13
Stenotrophomonas infections, TMP-SMX 572
Stenotrophomonas maltophilia, oncology patients 450
 sterility, operation 454t63.2
 steroid treatments
 bronchiolitis, pediatric 361t54.6
 septic shock 470
 Stevens–Johnson syndrome (SJS)
 fever and rash, in adults 100t14.1, 108, 109
 TMP-SMX cautions 572
 stool test indications, acute infectious diarrhea 178
 stool tests
 C. difficile infection 189, 190
 ova and parasite testing 175t26.8, 178, 186
 strawberry cervix, trichomoniasis 221
Streptobacillus moniliformis, rat bite fever 369
 streptococcal pharyngitis
 botulism differential diagnosis 29
 penicillin G benzathine 132t20.4, 560t78.3
Streptococcus
 acute necrotizing ulcerative gingivitis 145
 acute paronychia 236, 237t35.3
 cat bite infections 369
 cellulitis 83
 deep mandibular space infections 141
 dentoalveolar infections 142t22.1
 diabetic foot infections, acute 228
 dog bite infections 369
 endophthalmitis 278t43.2
 felon 236, 237t35.3
 fever in the newborn 332
 glycopeptides 566
 hematopoietic stem cell transplants, phase 1 infections 461
 infective endocarditis 1
 intraparenchymal brain abscess 34t6.2
 keratitis 261t41.3
 Lemierre's syndrome 138, 138t21.2
 mite infestations 90
 deep neck space infections 135
 necrotizing soft-tissue infections, IDU-associated 435t61.5
 open fractures 239
 osteomyelitis, IDU-associated 435–36
 parotitis 126
 peptic ulcers 163t25.3
 periapical abscess 140–41
 periodontal infections 143
 plantar puncture wounds 248t38.2
 septic arthritis 435–36
 septic arthritis, adults 225
 sinusitis 121t17.3
 spinal epidural abscess 42
 spinal epidural abscess, IDU-associated 437, 438t61.9
 spinal infections, epidural abscess 256, 257
 splenic abscess, peritonitis 165
 spontaneous bacterial peritonitis 163t25.1
 subcutaneous abscess, IDU-associated 433, 433t61.3
 supraglottitis (epiglottitis) 123
Streptococcus, group A
 cellulitis 82
 necrotizing soft-tissue infections 84, 86
Streptococcus, group B see group B *Streptococcus*
Streptococcus anginosus
 fight bites 234, 234t35.1
 human bite infections 369
Streptococcus bovis, infective endocarditis 2t1.1
Streptococcus epidermis, vertebral osteomyelitis
 post-operative infections 255–56
Streptococcus milleri
 abscess 80t12.1
 dentoalveolar infections 142t22.1
Streptococcus mitis
 bacteremia, ARDS 443t62.1
 bacteremia and fungemia, neutropenic oncology patients 443t62.1
Streptococcus mutans
 dentoalveolar infections 140
 periapical abscess 140–41
 pericoronitis 144
 pulpitis 142–43
Streptococcus pneumoniae
 — antibacterial drug spectra 558t78.1
 — antibacterials, commonly used 557–59
 acute bacterial meningitis 50–51, 58t8.9
 acute otitis media 117
 bacteremia and sepsis, in sickle cell disease 475t66.1

Index

- Streptococcus pneumoniae* (cont.)
 cephalosporins,
 advanced-generation 564
 cephalosporins, second-
 generation, caution 563
 cephalosporins, third- and
 fourth-generation 563
 community-acquired bacteria,
 influenza 301
 community-acquired pneumonia
 280, 281, 282, 283
 conjunctivitis 258
 febrile child 334–35
 hematopoietic stem cell
 transplants, phase 3
 infections 461
 keratitis 261t41.3
 macrolide resistance 570
 osteomyelitis, pediatric orthopedic
 infections 348–49
 pericarditis 6
 pneumonia 362
 spontaneous bacterial
 peritonitis 163
 steroid treatment, acute bacterial
 meningitis 56–57
 supraglottitis (epiglottitis) 124t18.1
 susceptibility, sickle cell
 disease 473
- Streptococcus pyogenes*
 — antibacterial drug spectra
 558t78.1
 — antibacterials, commonly used
 557–59
 acute otitis media 117
 deep neck space infections 135
 scabies 87
 scabies rash, superinfection risk 87
- Streptococcus pyogenes*, group A
 see GAS
- Streptococcus toxic shock syndrome*
 necrotizing soft-tissue
 infections 84
- Streptococcus viridans*
 infective endocarditis 2t1.1
 infective endocarditis,
 IDU-associated 431
 intraparenchymal brain abscess
 34t6.2
 vertebral osteomyelitis 253,
 254t40.1
- streptomycin
 plague 495t68.4
 tularemia 511–12
- stroke or CNS tumor, botulism
 differential diagnosis 29
- Strongyloides*, HIV pulmonary
 infections 289t45.1
- Strongyloides stercoralis*, solid organ
 transplants 460t64.1
- subarachnoid hemorrhage,
 differential diagnosis 55t8.4
- subcutaneous abscess, IDU-
 associated 433–34
 — epidemiology and
 microbiology 433
 — clinical features 433
 — differential diagnosis 433
- laboratory and radiographic
 findings 433–34, 433t61.3
 — treatment and prophylaxis 434
 — pearls and pitfalls 440–41
 fight bites 433
 immunocompromised patients
 434t61.4
 loop drain 81f12.6
 MRSA coverage 433
 MSSA 433t61.3
 subdural empyema, intracranial
 abscess 34
 sublingual infections
 dentoalveolar infections 141
 trismus, severe (lockjaw) 141, 145
 submandibular space infections
 deep neck space infections 136
 dentoalveolar infections 141
 trismus, severe (lockjaw) 141, 145
 submental infection, dentoalveolar
 124, 141
 sub-Saharan Africa, rickettsial
 infections 426t60.9
 Sudan ebolavirus 521
 sudden infant death syndrome,
 botulism differential
 diagnosis 29
 sulfa, toxic epidermal necrolysis 109
 sulfadiazine, altered mental status,
 HIV patients 24t4.6
 sulfamethoxazole, cautions 572
 sulfonamides
 hepatotoxicity 159t24.3
 in pregnancy 388
 severe drug reactions 109
 superinfection risk 557
 antimicrobials that may lead to
 superinfections 502, 557
 HBV and HBD co-infection, viral
 hepatitis 156, 158
 influenza chest X-ray 390t58.6
 mite lesions 89
 myiasis 95t13.8
 scabies rash 87, 88
 smallpox skin lesions 502
 tick removal 93
 varicella-zoster virus, skin
 infections 342
 see also *Candida* infections;
 Clostridium difficile infection;
 drug-resistant organisms;
 MRSA; multidrug-resistant
 organisms; *Staphylococcus*
 aureus; *Streptococcus pyogenes*;
 vancomycin-resistant
 Enterococcus infections
- supraglottitis (epiglottitis) 123–25
 — microbiology 123
 — epidemiology 123
 — clinical features 123–24
 — differential diagnosis 124
 — laboratory and radiographic
 findings 124–25
 — treatment and prophylaxis 124
 — complications and admission
 criteria 124
 — pearls and pitfalls 125
 children 123–24
- Hib vaccine 123
 soft-tissue X-ray, swollen epiglottis
 125f18.1
 surgery indications, diabetic foot
 infections 230–31
 surgical approach to diagnosis,
 necrotizing soft-tissue
 infections 85
 surgical interventions
 acute calculous cholecystitis 148,
 149t23.2
 deep neck space infections 137
 tracheotomy, deep neck space
 infections 137
 surgical site infections (SSIs) 453–56
 — epidemiology and
 microbiology 453
 — clinical features 453–54
 — differential diagnosis 454–55
 — laboratory and radiographic
 findings 455
 — treatment and prophylaxis 455
 — complications and admission
 criteria 455–56
 — pearls and pitfalls 456
 anastomotic leak risks 455t63.3
 CA-MRSA 453
 cellulitis 453
 MRSA 453
 operation sterility classification
 454t63.2
 post-operative infection types
 454t63.1
- Surviving Sepsis Campaign
 guidelines 470–71
- swimmer's ear see otitis externa
- swine influenza A viruses
 — microbiology 532
 children 534
 H1N1pdm09 305, 531, 532
 H1N1v, H1N2v, H3N2v 301, 302,
 532, 533, 534t74.3
 H3N2v 299, 305, 531, 534–36,
 540
 transmission 535
 sylvatic typhus (rickettsial infections)
 426t60.9
- syphilis 102–05, 212–16
 — microbiology 102–05
 — epidemiology 212
 — clinical features and
 microbiology 212
 — differential diagnosis 213–14
 — laboratory and radiographic
 findings 212t31.3, 215
 — treatment and prophylaxis
 215–16
 — complications and admission
 criteria 216
 — infection control 216
 — pearls and pitfalls 218
 alopecia 215f31.12
 benzathine penicillin G 105t14.6,
 215–16, 216t31.4, 560t78.2,
 560t78.3
 chancres 212
 condyloma lata 215f31.13,
 215f31.14
- female genitalia, condyloma lata
 215f31.14
 HIV setting, treatment regimens
 107, 216t31.4
 homosexually active men
 212, 213
 incubation periods 212t31.3
 latent syphilis, treatment 216t31.4
 maculopapular rash 214f31.10
 mucous patches 214f31.9
 multiple chancres 213f31.6
 neurosyphilis, treatment 216t31.4
 oral chancre 213f31.7
 palmar rash 214f31.11
 pregnant women, treatment
 216t31.4
 rash and fever evaluation 111
 scrotum, condyloma lata
 215f31.13
 spinal cord infections differential
 diagnosis 44
 tertiary syphilis 213
 tongue chancre 214f31.8
 transmission modes 212t31.3
 ulcers, primary syphilis 212
 urethritis (male infections) 192
 uveitis and retinitis 274
 see also syphilis, primary; syphilis,
 secondary; syphilitic meningitis
- syphilis, primary
 — microbiology 212–14
 — clinical features 212–14
 — treatment 105t14.6, 216t31.4
 — pearls and pitfalls 111
 presentation 102
- syphilis, secondary 102–05, 111
 — clinical features 102–03
 — treatment 105t14.6, 212–13,
 216t31.4
 fever and rash differential
 diagnosis 100t14.1, 111
 plantar surface of foot, AIDS
 setting 104f14.7
 syphilitic meningitis, HIV/AIDS
 patients 21t4.4, 22t4.5
- systemic diseases
 altered mental status, differential
 diagnosis 19t4.2
 lupus erythematosus (SLE)
 100t14.1, 108–09
 non-infected bites 373
 rare, human bites 371
 viral infections 104
- systemic inflammatory response
 syndrome (SIRS)
 acute liver failure, in viral
 hepatitis 156
 and hypoperfusion differential
 diagnosis 469t65.3
 sepsis 467, 468t65.1
- systemic toxicity
 cellulitis 82, 83
 diabetic foot infections 229–30,
 230t34.1
 episiotomy site infection 410
 flat-type smallpox (malignant
 smallpox) 500
 hemorrhagic smallpox 500

Index

- necrotizing soft-tissue infections, IDU-associated 434
 pelvic inflammatory disease 203, 204t30.6
 pericoronitis 144, 145
- tachyarrhythmias and heart block, myocarditis 13t2.4
 tacrolimus/FK-506 (Prograf, Protopic)
 nephrotoxicity 465t64.3
 post-transplant patients 466t64.4
Taenia solium, parasitic meningitis 60
 tagovirus, rubella 106
 Tai Forest ebolavirus 521
 Tamiflu *see* oseltamivir
 Tasmania, rickettsial infections 426t60.9
 TB *see* tuberculosis
 TCAs (tricyclic antidepressants), hepatotoxicity 159t24.3
 Tdap vaccine (tetanus-diphtheria-acellular pertussis vaccine adsorbed) 71, 72, 72t10.2
 in pregnancy 391
 TDF *see* tenofovir DF
 tedizolid (Sivextro) 574–75
 Teflaro *see* ceftaroline
 telavancin (Vibativ)
 — properties 566–68
 warning 567
 telithromycin
 — activity spectrum 557–59
 — properties and dosages 570t78.25
 drug interactions 570t78.24
 TEN (toxic epidermal necrolysis) 100t14.1, 108, 109
 tenofovir DF (Viread, TDF)
 hepatitis B virus, in pregnancy 401t58.14
 HIV PEP regimens, non-occupational 381t57.8
 HIV PEP regimens, occupational 379t57.5, 380t57.6, 381t57.7
 side effects and toxicities 183t27.5, 381t57.7
 terrorism *see* bioterrorism risks
 tertiary peritonitis 162
 tertiary syphilis 213
 tetanolytin toxin 69
 tetanus 69–72
 — microbiology 69
 — epidemiology and microbiology 69, 72
 — clinical features 69–70
 — differential diagnosis 70
 — laboratory and radiographic findings 70, 70t10.1
 — treatment and prophylaxis 70–71, 70t10.1
 — post-exposure prophylaxis 71–72
 — complications 72
 — infection control 72
 — pearls and pitfalls 72
 active tetanus treatment 71
 C. tetani 69, 70t10.1
 cephalic tetanus 70
 DTaP vaccine (tetanus-acellular pertussis vaccine adsorbed) 71
 hemodynamic failure 71, 72
 high-risk wounds, post-exposure prophylaxis 71–72
 HTIG vaccine 71–72
 immunosuppressed individuals 72
 injection drug users 69, 439–40
 mortality rates 72
 muscle spasm treatments 70–71, 440t61.14
 neonatal tetanus 70
 patient vaccination history 70, 71, 72
 plantar puncture wounds, immunization 247
 pregnant women, prophylaxis 72
 spinal cord infections, differential diagnosis 44
 Tdap vaccine 71, 72, 72t10.2
 trismus, severe (lockjaw) 45t7.2, 69–70, 70t10.1, 72, 440
 wound care 71
 tetanus, IDU-associated 439–40
 — microbiology and epidemiology 439
 — clinical features 440
 — differential diagnosis 440
 — laboratory and radiographic findings 440, 440t61.13
 — treatment and prophylaxis 440
 muscle spasm treatments 440t61.14
 tetanus toxin (tetanospasmin) 69
 tetanus toxoid containing vaccine
 active tetanus treatment 70, 71
 immunosuppressed individuals 72
 patient vaccination history 70
 tetanus, IDU-associated 440t61.14
 tetracyclines
 — cautions, pregnancy 403t58.17, 571
 — drug activity spectra 557–59
 — MRSA susceptibilities 545t75.3
 — properties and dosages 571
 abscess 81
 community-acquired pneumonia 571
 P. falciparum malaria 419t60.5
 P. vivax malaria 419t60.5
 pregnant women, contraindications 388, 403t58.17
 tularemia 511–12
 see also specific drugs
 tetrodotoxin (puffer fish poisoning) 29
 botulism differential diagnosis 29
 Thai tick typhus (rickettsial infections) 426t60.9
 Thailand, rickettsial infections 426t60.9
 third- and fourth-generation cephalosporins, community-acquired pneumonia 563
 thrombocytopenia, linezolid (Zyvox) caution 575
 thrombotic thrombocytopenic purpura (TTP)
 fever and rash differential diagnosis 100t14.1
 tibia, grade III open fracture 240f36.3
 tick bites while traveling, associated illnesses 415t60.3
 tick removal 93–94
 tick-borne encephalitis virus 54
 tick-paralysis 29, 93–94, 94t13.7
 ticks/tick-transmitted diseases
 — epidemiology and microbiology 93–94
 — complications and admission criteria 96
 — pearls and pitfalls 97
 children 93
 deeply embedded *I. pacificus* 95f13.5
 disease/treatment table 94t13.7
 hard/soft 88t13.1
 see also Lyme disease; rickettsial infections; Rocky Mountain spotted fever; tularemia
 tigecycline (Tygacil)
 — activity spectrum 557–59
 — properties and dosages 571
 clinical issues 554t77.3
 ESBL-producing organisms and infections 554, 554t77.3
 tinidazole (Tindamax)
 — properties and dosages 573
 bacterial vaginosis, nonpregnant women 221
 E. histolytica diarrhea, HIV patients 185t27.6
 G. lamblia diarrhea 178t26.12
 Giardia diarrhea, HIV patients 185t27.6
 non-gonococcal urethritis, persistent or recurrent 202, 203t30.5
 trichomoniasis, pregnant women 222t32.4
 Tivicay *see* dolutegravir
 TKM Ebola antiviral 523–24
 TMP-SMX (trimethoprim-sulfamethoxazole) (Bactrim, Septra)
 — activity spectrum 557–59
 — properties and dosages 572
 — cautions and guidance 572
 abscess 81
 acute bacterial prostatitis 197t29.5
 acute cystitis 320t48.1
 acute paronychia 237t35.3
 bite infections 372t56.1
 breast abscess 410t59.5
 C. cayetenesis diarrhea 178t26.12
 CA-MRSA coverage 545t75.4
 children, post-transplant, febrile 464t64.2
 Cystoisospora, HIV patients 185t27.6
 diabetic foot infections, mild to moderate 230t34.1
 febrile post-transplant patients 464t64.2
 felon 237t35.3
 Isospora diarrhea 178t26.12
 mastitis 410t59.5
 MRSA susceptibilities 545t75.3
 PCP (*Pneumocystis pneumonia*), HIV 296t45.6
 pertussis, pediatric 360–61, 360t54.5
 plague 494
 plantar puncture wounds 248t38.2
 purulent infections 86
 pyelonephritis, in adults 326t49.2
 pyelonephritis guidance 572
 subcutaneous abscess, IDU-associated 434
 tobramycin (various brands)
 — properties and dosages 569
 — activity spectrum 557–59
 bacterial keratitis 262
 febrile post-transplant patients 464t64.2
 health-care-associated CAP 284t44.3
 keratitis 263t41.4
 Tokyo Guidelines (2013), acute bacterial cholangitis 150, 151t23.4
 tongue chancre, syphilis 214f31.8
 tonsillectomy, pharyngitis 132
 tonsillopharyngitis 129, 130t20.1
 TORCH infections, fever in pregnancy 395–98
 — epidemiology and microbiology 395–96
 — clinical features 396–97
 — differential diagnosis 396
 — laboratory and radiographic findings 396–98
 — treatment and prophylaxis 396
 — complications and admission criteria 396–97
 — infection control 397
 — pearls and pitfalls 404
 coxsackievirus differentiation 396
 mnemonic 395
 vaccines in pregnancy 404
Torulopsis, candidiasis 222
 toxic epidermal necrolysis (TEN) 100t14.1, 108, 109
 toxic shock syndrome
 endometritis 406, 407
 fever and rash, in adults 100–02, 100t14.1
 see also septic shock
 toxicity and allergy, antimicrobial, principles 557
 see also drug reactions, severe; nephrotoxicity; penicillin-allergic patients; toxic epidermal necrolysis; *specific drugs*
 toxocariasis, uveitis and retinitis 276t43.1
Toxoplasma, hematopoietic stem cell transplants 462

Index

- Toxoplasma gondii*
 focal cerebral dysfunction, HIV/AIDS patients 20t4.3
 HIV pulmonary infections 289, 289t45.1, 293–94, 294t45.4
 solid organ transplants 460t64.1
 toxoplasmosis, fever in pregnancy 395
Toxoplasma IgG antibodies (serum)
 altered mental status, HIV patients 21
 fever and focal cerebral dysfunction, AIDS patient 25
 toxoplasmosis, cerebral, AIDS patients 25
 toxoplasmosis, fever in pregnancy
 — epidemiology and microbiology 395
 — clinical features 396–97
 — laboratory tests 398t58.11
 — treatment and prophylaxis 396
 — complications and admission criteria 396–97
 — infection control 397
Toxoplasmosis gondii
 chorioretinitis, severe 275f43.2
 uveitis and retinitis 276t43.1
 tracheotomy, deep neck space infections 137
 transesophageal echocardiography (TEE) 16
 see also echocardiography
 transfusion-related fever
 febrile post-transplant patients 462
 toxic epidermal necrolysis 109
 transmission maps, West Nile virus infections 76
 transmission modes
 Ebola virus disease 522, 524
 ESBL-producing organisms and infections 552–53
 herpes genitalis 210t31.1
 norovirus, acute infectious viral diarrhea 170
 scabies 88t13.2
 smallpox 498, 501t69.1
 syphilis 212t31.3
 tuberculosis 309, 330t50.1
 tularemia 506–07
 viral hepatitis 155
 West Nile virus infections 75t11.1
 Zika virus 527, 529
 transplants *see* febrile post-transplant patients; hematopoietic stem cell transplants (HSCTs), infections in; solid organ transplants, infections in
 travel history, contents (patient history) 412–13
 travel regions, endemic infectious diseases 414t60.1
 travel related diseases 415t60.3
 travelers, returning
 cruise ships 170, 300
 cutaneous larva migrans 88
 D. hominis (botfly) 95
 E. histolytica diarrhea 174
 exposures and associated febrile illnesses 415t60.3
 influenza 300
 obligatory myiasis 97
 ova and parasite testing 175t26.8, 178
 parasitic diarrhea, acute infectious 172–74
 traveller's diarrhea, bismuth subsalicylate 176
 see also dengue fever; enteric fever; fever in the returning traveler; malaria
 trazodone, hepatotoxicity 159t24.3
Treponema pallidum 102–05
 hematopoietic stem cell transplants, transfusion fever 462
 syphilis 212
 uveitis and retinitis 276t43.1
Treponema vincenti, ANUG (Vincent's angina) 145
 trichloroacetic acid, human papilloma virus 206t30.7
Trichomonas vaginalis
 bacterial vaginosis 220
 non-gonococcal urethritis 202, 203t30.5
 trichomoniasis 221
 urethritis (male infections) 192
 trichomoniasis 221–23
 — epidemiology and microbiology 221
 — clinical features 221–22
 — differential diagnosis 223
 — laboratory and radiographic findings 221, 222t32.3
 — treatment 222
 — complications and admission criteria 222
 — infection control 222
 — pearls and pitfalls 223
 nitroimidazoles 573
 pregnant women, complications 222
 pregnant women, treatment 222t32.4
 strawberry cervix 221
 triclabendazole, parasitic cholangitis, *F. hepatica* 153t23.6
 trimethoprim-sulfamethoxazole *see* TMP-SMX
 trismus, severe (lockjaw)
 acute suppurative parotitis 126
 cephalic tetanus 70
 deep mandibular space infections 141
 deep neck space infections 136, 136t21.1
 dentoalveolar infections 142t22.1
 Lemierre's syndrome 138
 Ludwig's angina 136, 141
 parapharyngeal space infections 135–36
 periapical abscess 143
 pericoronitis 144
 peritonsillar abscess 133
 sore throat differential diagnosis 130, 131t20.2, 134
 sublingual infections 141, 145
 submandibular infections 141, 145
 tetanus 45t7.2, 69–70, 70t10.1, 72, 440
Trombicula autumnalis (harvest mite) infestations 89, 90t13.4
 Truvada
 hepatitis B virus, in pregnancy 401t58.14
 HIV PEP regimens, non-occupational 381t57.8
 HIV PEP regimens, occupational 379t57.5, 380t57.6, 381t57.7
 side effects and toxicities 381t57.7
 see also emtricitabine; tenofovir DF
Trypanosoma cruzi parasite
 hematopoietic stem cell transplants, transfusion fever 462
 myocarditis 11
 solid organ transplants 460t64.1
 tse tse fly bites while traveling, associated illnesses 415t60.3
 TT virus (TTV) 156
 TTP (thrombotic thrombocytopenic purpura)
 fever and rash differential diagnosis 100t14.1
 tuberculoma, focal cerebral dysfunction
 HIV/AIDS patients 20t4.3
 tuberculosis 308–17
 — microbiology 308
 — epidemiology 308–09
 — pathogenesis and risk factors 309
 — clinical features 309–10
 — differential diagnosis 281, 310–11
 — laboratory and radiographic findings 310t47.1, 311–12
 — treatment 312–16
 — complications and admission criteria 316
 — infection control 316–17
 — pearls and pitfalls 317
 ATS/IDSA/CDC guidelines, treatment 312
 children under 5, clinical features 310
 combination chemotherapy 313, 317
 community-acquired pneumonia 281
 drug-resistant tuberculosis 308, 316
 drug-susceptible disease treatment 313
 extrapulmonary 136, 309, 310, 312, 316
 first-line antituberculosis drugs 313t47.3, 314t47.5
 fluoroquinolones, warning 313, 317
 general manifestations 309–10
 HIV patients 311, 316
 homeless persons, TB transmission 309
 incubation periods 310t47.1
 interferon gamma release assay 311, 317
 latent 310, 311, 312t47.2, 313–14
 M. tuberculosis complex 308
 MDR-TB (multidrug-resistant tuberculosis) 308–09, 316
 mortality rates 308, 316
 public health risk action 316, 317
 reactivation tuberculosis, findings 311
 screening recommendations 309
 suspected tuberculosis, action 317
 transmission modes 309, 330t50.1
 tuberculin skin test 311, 317
 uveitis and retinitis 274
 XDR-TB (extensively drug-resistant tuberculosis) 308, 316
 tuberculosis, pulmonary
 — clinical features 310
 — microbiologic diagnosis 311–12
 — treatment 312–13
 CDC guidelines, TB tests 311
 drug-susceptible, treatment algorithm 315f47.1
 fluoroquinolones, warning 313, 317
 HIV-related 311
 tuberculosis osteomyelitis of the spine (Pott's disease)
 differential diagnosis 44–45
 vertebral osteomyelitis 255
 tuberculous meningitis, HIV/AIDS patients
 diffuse cerebral dysfunction 21t4.4
 initial treatment 24t4.6
 neuroimaging 22t4.5
 tubo-ovarian abscess, abdominal pain differentiation 165–66
 tularemia 506–13
 — microbiology 506
 — epidemiology 506–08
 — clinical features 508–10
 — differential diagnosis 510–11
 — laboratory and radiographic findings 511
 — treatment and prophylaxis 511–12
 — complications and admission criteria 512
 — infection control 512–13
 — pearls and pitfalls 513
 as a biological weapon 506, 507–08
 bioterrorism risk assessment 513
 children, treatment and PEP 512t70.4
 contained casualty setting 511
 decontamination 513
 F. tularensis 94t13.7, 506, 507–08, 511
 glandular tularemia 508–09, 512
 HICPAC 512
 mass casualty setting 511–12
 natural reservoirs 506

- oculoglandular 508, 510–11, 512
 oropharyngeal 508–09, 511, 512
 pneumonic tularemia 508, 510, 512, 513
 post-exposure prophylaxis 511, 512t70.4
 pregnant women, treatment and PEP 512t70.4
 ticks/tick-borne illnesses 94t13.7
 transmission modes 506–07
 typhoidal (septicemic) 510, 511, 512
 ulceroglandular 508–09, 510, 512
 US occurrence 507
 vaccination 511–12
 Working Group for Civilian Biodefense 506, 512
 worldwide occurrence 507
 zoonotic disease 506
- tumbu fly (*Cordylobia anthropophaga*), myiasis 95t13.8, 96t13.9
- Tygacil *see* tigecycline
- tympanic membrane, perforated, acute otitis media 118
- typhlitis, abdominal pain differentiation 165–66
- typhoid fever *see* enteric fever
- typhoidal (septicemic) tularemia 511, 512
- typhus fevers (rickettsial infections) 426t60.9
- ulcer accompanied by ruptured bulbo, chancroid 217f31.15
- ulcer classification 99, 340t52.1
- ulcerative sexually transmitted diseases *see* sexually transmitted diseases, ulcerative
- ulceroglandular tularemia 508–09, 510, 512
- ulcers, primary syphilis 212
- ultrasound
 bedside 81
 hypoechoic fluid pocket 80f12.2
 point of care, purulent tenosynovitis 235
- Unasyn *see* ampicillin-sulbactam
- unilateral maxillary sinusitis 120, 121
- US occurrence
 botulism 27
 hantavirus 514–15
 rabies 64, 66
 smallpox 498–99
 tularemia 507
 West Nile virus infections 54
- University of Pennsylvania, Zika virus research 529
- untreated water, exposure to while traveling, associated illnesses 415t60.3
- upper abdominal pain
 differentiation, acute calculous cholecystitis 147
- upper respiratory infection (URI) 129
 pregnant women 390–91
- upper urinary tract infection (upper UTI) *see* pregnant women, pyelonephritis and urinary tract infections; pyelonephritis, in adults
- Ureaplasma*, pelvic inflammatory disease 202–03
- Ureaplasma urealyticum*
 bacterial vaginosis 220, 221t32.1
 chorioamnionitis 394t58.8
 non-gonococcal urethritis 202, 203t30.5
 urethritis (male infections) 192
- ureidopenicillin with beta-lactamase inhibitor
 acute calculous cholecystitis 148
- uremia, abdominal pain differentiation 165–66
- urethral discharge, purulent (gonorrhea) 201f30.1
- urethritis (male genitourinary infections) 192–95, 198
 — epidemiology and microbiology 192–93
 — clinical features 193
 — differential diagnosis 193
 — laboratory findings 193–94, 193t29.1
 — treatment and prophylaxis 194
 — complications and admission criteria 194
 — infection control 194–95
 — pearls and pitfalls 198
- gonococcal urethritis 192, 193t29.1
- incubation periods 193t29.1
- M. genitalium* 192, 194t29.2, 202, 203t30.5
- M. hominis* 192
- NAAT testing 193–94
- non-gonococcal urethritis 192, 193f29.2, 193t29.1, 194t29.2
- purulent urethral discharge, gonorrhea patient 193f29.1
- sexually transmitted, risk factors 192–93
- sterile urethritis 192
- urinary diversion, anastomotic leak risks 455t63.3
- urinary tract infections (UTIs)
 aminoglycosides 569
 cephalixin 562
 ESBL-producing organisms and infections 552–53, 554
 febrile child 336
 fever in the newborn 330t50.1
 fluoroquinolones 568–69
 in older men 324–25
 pyelonephritis, cephalosporins, advanced-generation 564
 pyelonephritis, TMP-SMX guidance 572
 TMP-SMX 572
 VRE infections 548–49
see also lower urinary tract infection, in adults; pediatric urinary tract infections; pregnant women, pyelonephritis and urinary tract infections; pyelonephritis, in adults
- urine collection methods 321
- urine culture 321
- urine dipstick 321
- urine microscopy 321
- urolithiasis, abdominal pain differentiation 165–66
- urosepsis, TMP-SMX guidance 572
- US Zika in Pregnancy Registry (USZPR) 528
- UTIs (urinary tract infections) *see* lower urinary tract infection, in adults; pediatric urinary tract infections; pregnant women, pyelonephritis and urinary tract infections; pyelonephritis, in adults; urinary tract infections
- uvea, vitreous, and retina eye infections 274–79
 — general points 274
 — pearls and pitfalls 279
- endophthalmitis 276–79
- uveitis and retinitis 274–77, 279
- uveitis and retinitis 274–77
 — epidemiology and microbiology 274
 — clinical features 274–75
 — differential diagnosis 275–76
 — laboratory and radiographic findings 276
 — treatment 276
 — complications and admission criteria 276
 — pearls and pitfalls 279
- acute retinal necrosis 277f43.4
- AIDS patients, susceptibilities 274
- cat exposure, toxoplasmosis 274
- chorioretinitis, severe 275f43.2
- CMV retinitis 274–75
- eye anatomy 275f43.1
- HIV testing 274
- infants, ocular toxoplasmosis 274
- ocular toxoplasmosis 274
- ophthalmologist involvement 276
- RPORN (rapidly progressive outer retinal necrosis) 277f43.5
- T. gondii* 275f43.2
- vaccination history (patient history)
 smallpox 503
 tetanus 70, 71, 72
 tetanus toxoid containing vaccine 70
- vaccinations (historical), smallpox 2002/3, military personnel 504
- vaccines
 Adacel vaccine, tetanus 71
 AVA (Anthrax vaccine absorbed) 488
 Boostrix, tetanus 71
 botulism 31
 community-acquired pneumonia 284t44.4
 dengue fever, position 422
 DTaP vaccine, tetanus 71
 Ebola virus disease 523–24
- enteric fever 423, 424, 424t60.8
- enteric fever,
 immunocompromised patients 424
- hepatitis A virus 160
- hepatitis B virus 160
- hepatitis E virus 160–61
- Hib vaccine 52, 123
- HRIG, rabies 66
- HTIG, tetanus 71–72
- human papilloma virus 205
- LymeRix vaccine 94t13.7
- meningococcal infection 62
- MMR vaccine 126, 127–28
- parotitis 126, 127–28
- rabies 66
- RIB vaccine, rabies 66
- smallpox 498, 503
- supraglottitis (epiglottitis) 123
- Tdap vaccine 71, 72, 72t10.2
- Tdap vaccine, fever in pregnancy 391
- tularemia 511–12
- varicella-zoster virus, HIV patients 107–08
- viral hepatitis 160–61
- West Nile virus infections 77
- Zika virus, progress 529
- vaccines, influenza viruses
 annual vaccinations 305
 effectiveness 305
 LAIV (live attenuated influenza virus) 303
 novel influenza A 539
 pregnant women 403
see also antivirals; oseltamivir
- vaccines, pregnant women
 enteric fever 424
 influenza 403
 TORCH infections, fever in pregnancy 404
- vaccines, tetanus toxoid-containing vaccine
 active tetanus treatment 70, 71
 immunosuppressed individuals 72
 patient vaccination history 70
 tetanus, IDU-associated 440t61.14
- vaccinia virus, uveitis and retinitis 276t43.1
- VADs (ventricular assist devices) 14
- valacyclovir (Valtrex) 577–78
 herpes genitalis, mucocutaneous 211t31.2
- herpes virus infections 577–78
- HIV varicella zoster 107–08
- viral keratitis 262
- Valtrex *see* valacyclovir
- vancomycin
 — activity spectrum 557–59
 — nephrotoxicity 546t75.5
 — properties and dosages 566–68
- acute bacterial meningitis 58t8.9
- bacteremia and sepsis, in sickle cell disease 475t66.1
- bacterial tracheitis, pediatric 358t54.3
- breast abscess 410t59.5
- C. difficile* diarrhea 177t26.10

Index

- vancomycin (*cont.*)
 C. difficile diarrhea, HIV patients 185t27.6
 C. difficile infection, recommendation 190
 CA-MRSA coverage 545t75.4
 catheter-associated peritonitis 167t25.11
 cellulitis 84t12.3
 children, post-transplant, febrile 464t64.2
 community-acquired pneumonia, ICU patients 284t44.3
 diabetic foot infections, acute 230t34.1
 endophthalmitis 278t43.3
 epiglottitis, pediatric respiratory infections 355t54.1
 epiglottitis infection, pediatric 355t54.1
 health-care-associated CAP 284t44.3
 HIV pulmonary infections, MRSA coverage 294, 296t45.6
 infective endocarditis 4t1.2
 infective endocarditis, IDU-associated 432t61.2
 intracranial abscess 37t6.4
 Lemierre's syndrome 138t21.2
 mastitis 410t59.5
 meningitis, acute bacterial 58t8.9
 meningitis, febrile child 337t51.1
 meningitis, shunt infections 61
 MRSA 545, 547
 MRSA susceptibilities 545t75.3
 musculoskeletal infections, pediatric 352t53.4
 necrotizing soft-tissue infections 86
 osteomyelitis 243t37.1
 parotitis 127
 purulent tenosynovitis 236t35.2
 septic arthritis, adults 226t33.1, 227
 septic arthritis and osteomyelitis, IDU-associated 437t61.8
 severe sepsis 471t65.8
 shunt infections, meningitis 61
 spinal epidural abscess 47, 47t7.3
 spine infections, epidural abscesses 256t40.2
 spontaneous bacterial peritonitis 167t25.11
 supraglottitis (epiglottitis) 124
 toxic shock syndrome 102t14.4
 vertebral osteomyelitis 254t40.1
 vancomycin exposure, VRE risk 549t76.1
 vancomycin resistance
 cephalosporins, third-generation, cautions 564
 CLSI definition (Clinical and Laboratory Standards Institute) 549
 vancomycin-resistant *Enterococcus* infections (VRE infections) 548–51
 — microbiology 548
 — epidemiology 548
 — clinical features 548–49
 — differential diagnosis 549
 — laboratory and radiographic findings 549–50
 — treatment and prophylaxis 549–51, 550t76.3
 — complications and admission criteria 551
 — infection control 551
 — pearls and pitfalls 551
 acute care setting 549
 acute infections 548–49
 antibacterial drug spectra 558t78.1
 bacteremia 549–51
 catheter-associated 549, 551
 cephalosporins, third-generation, cautions 564
 CLSI definition, vancomycin resistance 549
 diabetic foot infections 228, 230
 endocarditis 551
 ESKAPE pathogens 548
 Infectious Diseases Society of America 548
 multidrug-resistant organisms 548, 551
 risk factors 549t76.1
 skin and soft-tissue infections 548–49, 551
 SSTIs, IDSA treatment guidelines 551
 urinary tract infections 548–49
 vancomycin-resistant *Enterococcus* (VRE) 548
 E. faecalis and *E. faecium* 548, 550t76.3, 551
 Enterococcus 548, 549
 variant influenza A viruses *see* avian influenza A viruses; novel influenza A viruses; swine influenza A viruses
 varicella (chickenpox), fever in pregnancy
 — epidemiology and microbiology 395
 — clinical features 396–97
 — laboratory tests 398t58.11
 — treatment and prophylaxis 396
 — complications and admission criteria 396–97
 — infection control 397
 varicella (chickenpox), otitis externa 115t15.1
 varicella immune globulin, HIV patients 107–08
 varicella-zoster virus (VZV)
 encephalitis, HIV patients, initial treatment 24t4.6
 focal signs and symptoms 38
 hematopoietic stem cell transplants 461
 HIV patients 107–08
 keratitis 259, 260, 262
 myocarditis 11
 pediatric fever and rash 342–43
 pericarditis 6
 uveitis and retinitis 274, 276t43.1
 vaccine, HIV patients 107–08
 varicella (chickenpox), fever in pregnancy 395
 vasculopathy, HIV patients 20t4.3
 viral encephalitis 52–53
 viral meningitis 54
 variola major, smallpox 498, 500
 variola minor, smallpox 498, 500
 variola sine eruption, smallpox 500
 vasculitic neuropathy, spinal cord infections differential diagnosis 44–46
 vasculitis, fever and rash differential diagnosis 100t14.1
 vasomotor rhinitis 120
 vasopressors, sepsis/septic shock 470
 ventilation, septic shock 470
 ventricular assist devices (VADs) 14
 ventriculitis, IDSA guidelines 61
 verapamil, hepatotoxicity 159t24.3
 vertebral osteomyelitis 253–56
 — epidemiology and microbiology 253
 — clinical features 253–54
 — differential diagnosis 253–54
 — laboratory and radiographic findings 254–55, 254t40.1
 — treatment 254t40.1, 255
 — complications and admission criteria 256
 — special considerations 255
 — pearls and pitfalls 257
 epidural abscess association 256
 lumbar spine, lateral radiograph 254f40.1
 lumbar spine, sagittal T2-weighted MRI 255f40.2
 post-operative infections 255–56
 Pott's disease (spinal tuberculosis) 255
 sickle cell anemia patients 253
 tuberculosis osteomyelitis 255
 vesicles 99, 340t52.1
 Vfend *see* voriconazole
 Vibativ *see* telavancin
Vibrio cholerae diarrhea
 — microbiology 172
 — clinical features 172
 — differential diagnosis 173t26.4
 — treatment and prophylaxis 173t26.4, 177t26.10
 Non-inflammatory diarrhea 170t26.1
 pregnant women, treatment 177t26.10
 returning traveler 172
Vibrio cholerae, ESBL production 553t77.1
Vibrio diarrhea, HIV patients 182t27.2
Vibrio parahaemolyticus diarrhea 172, 177t26.10
Vibrio vulnificus
 cellulitis, salt water exposure 82t12.2
 diarrhea 172
 necrotizing soft-tissue infections 84
 Vincent's angina *see* acute necrotizing ulcerative gingivitis
 viral conjunctivitis, treatment 259, 260t41.2
 viral diarrhea, acute infectious *see* diarrhea, acute infectious viral
 viral encephalitis 52–53
 viral hemorrhagic fever, acute infectious diarrhea 175t26.7
 viral hemorrhagic fever, returning traveler 417
 viral hepatitis *see* acute liver failure, viral hepatitis; *under* hepatitis
 viral infections, HIV acute diarrhea 182t27.2
 viral infections, persistent and chronic diarrhea in HIV 183t27.3
 viral keratitis 261t41.3, 262, 263t41.4
 viral meningitis *see* aseptic meningitis and viral meningitis
 viral meningitis, and West Nile meningitis 54
 viral myelitis 46
 viral myocarditis 11
 viral pneumonia
 avian influenza A 535, 536t74.5, 538
 clinical features 304
 defined 493
 differential diagnosis 281
 influenza complication 304, 305
 novel influenza A complication 535
 viral rhinosinusitis 120
 viral serology, hepatitis B virus (HBV) 159t24.4
 viral syndrome, botulism differential diagnosis 29
 Viread *see* tenofovir DF
 viscus perforation, secondary peritonitis 163–64
 anastomotic leaks 164
 appendicitis 164
 diverticulitis 162, 164
 NSAID use causing 163
 peptic ulcer perforation 162, 163
 vision changes, sinusitis 122
 visual disturbance, voriconazole (Vfend) 576
 vitritis, West Nile virus infection complications 75
 voriconazole (Vfend)
 — properties and dosages 575–76
 children, post-transplant, febrile 464t64.2
 endophthalmitis 278t43.3
 febrile post-transplant patients 464t64.2
 fungal keratitis 262
 VRE *see* vancomycin-resistant *Enterococcus*
 vulvovaginal candidiasis *see* candidiasis
 vulvovaginitis 220–23
 — microbiology 220
 — differential diagnosis 223
 — pearls and pitfalls 223

Index

- bacterial vaginosis 220–21, 223
 candidiasis 222–23
 trichomoniasis 221–23
see also specific diseases
 VZV *see* varicella-zoster virus
- warfarin, nitroimidazoles
 caution 573
- water (fresh, salt, fish tank), cellulitis
 risks 82t12.2
- Waterhouse-Friderichsen
 syndrome 343
- weapons, biological *see under*
 biodefense; bioterrorism risks
- Wernicke's encephalopathy, botulism
 differential diagnosis 29
- West Nile encephalitis (WNE)
 — microbiology 74
 — clinical features 74–75
 — differential diagnosis 76
 — laboratory and radiographic
 findings 75
 — treatment 77
 — complications and admission
 criteria 77
see also West Nile virus (WNV),
 infections
- West Nile fever 75, 75t11.1, 76–77
- West Nile meningitis (WNM)
 — clinical features 74–75, 75t11.1
 — differential diagnosis 76
 — laboratory and radiographic
 findings 75
 — treatment 76–77
 — complications and admission
 criteria 77
 and viral meningitis 54 *see also*
 West Nile virus (WNV),
 infections
- West Nile virus (WNV),
 infections 74–77
 — microbiology 74
 — epidemiology 74
 — clinical features 38, 74–75
 — differential diagnosis 75t11.1,
 76
 — laboratory and radiographic
 findings 75–76, 75t11.1
 — treatment 76–77
 — complications and admission
 criteria 77
 — infection control 77
 — pearls and pitfalls 77
 acute flaccid paralysis 75, 75t11.1
 elderly patients 74, 76, 77
 ELISA test 75–76
 endemic regions, updates 77
 fever (West Nile fever) 75, 75t11.1
 focal signs and symptoms 38
 Guillain-Barré syndrome 75
 immunosuppressed individuals
 74, 76, 77
- incubation periods 75t11.1
- infants, admission criteria 77
- mosquito inoculations 74
- myocarditis 75
- NAAT testing 75t11.1
- paralysis, acute flaccid 44, 75,
 75t11.1
- post-WNV infection syndrome
 75t11.1
- pregnant women, differential
 diagnosis 76
- therapeutic trials 76–77
- transmission maps 76
- transmission modes 75t11.1,
 460t64.1
- transplants, solid organ 460t64.1
- US occurrence 54
- uveitis and retinitis 276t43.1
- vaccines 77 *see also* West Nile
 encephalitis; West Nile
 meningitis
- wheals 99, 340t52.1
- WHO *see* World Health
 Organization
- whooping cough *see* pertussis,
 pediatric
- winter months
 community-acquired
 pneumonia 281
 sepsis 467
- WNE *see* West Nile encephalitis
- WNM *see* West Nile meningitis
- WNV *see* West Nile virus, infections
- women, wishing to get pregnant,
 Zika virus 530
- Working Group on Civilian
 Biodefense
 anthrax 488
Bacillus anthracis 480
 botulism 26, 31
 plague 490
 smallpox 498
 tularemia 506, 512
- World Health Organization (WHO)
 hepatitis B, neonates,
 breastfeeding 401
- influenza, virus and treatment
 updates 306
- international travel and health
 website 413
- plague levels 491
- smallpox position 498
- tuberculosis levels 308
- Zika virus position 526, 529
- Zika virus testing algorithm
 528f73.1
- worldwide occurrence
 anthrax 480–81
 plague 490–91
 rickettsial infections 426t60.9
 smallpox 498
 tularemia 507
- wound botulism 26, 28, 28t5.1
- wound botulism, IDU-associated
 438–39
 — epidemiology and
 microbiology 438
 — clinical features 438–39
 — differential diagnosis 438–39
 — laboratory and radiographic
 findings 439, 439t61.11
 — treatment and prophylaxis
 439
 — complications and admission
 criteria 439
 black tar heroin users 27, 28, 438
- wound care
 bite infections 373
 myiasis 96
 non-infected bites 373
 plantar puncture wounds 247
 rabies 66
 tetanus 71
- wound closure, non-infected
 bites 373
- wound infections, ESBL-producing
 organisms and infections
 553
- xanthogranulomatous pyelonephritis
 326–27
- XDR-TB (extensively drug-resistant
 tuberculosis) 308, 316
- Yersinia* diarrhea, HIV patients 181,
 182t27.2, 184
- Yersinia enterocolitica*, diarrhea
 — microbiology 172
 — clinical features 173t26.4
 — treatment 173t26.4
 antibiotic therapy 177t26.10
 antibiotic use 176
 children 172
 transmission modes 172
- Yersinia enterocolitica*, pharyngitis
 130t20.1
- Yersinia pestis*
 pharyngitis 130t20.1
 plague 490, 496
- Zaire* Ebolavirus 521, 522
- zanamivir (Relenza), influenza
 antiviral
 — properties and dosages
 578–79
 influenza A and B 304t46.5
 novel influenza A 537, 579
- ZDV *see* zidovudine
- Zerbaxa *see* ceftolozane-tazobactam
- zidovudine (Retrovir, ZDV, AZT)
 HIV PEP regimens, occupational
 379t57.5, 380t57.6, 381t57.7
 side effects and toxicities 183t27.5,
 381t57.7
- Zika virus 526–30
 — microbiology 526
 — epidemiology 526–27
 — clinical features 527–28
 — differential diagnosis 528
 — laboratory and radiographic
 findings 528–29
 — treatment and prophylaxis
 529–30
 — complications and admission
 criteria 530
 — infection control 530
 — pearls and pitfalls 530
A. aegypti mosquito bites 526,
 530
A. albopictus mosquito bites
 527t73.1
 arbovirus testing algorithm
 528f73.1
 children 528, 530
 congenital birth defects 527–28
 congenital infection 527, 530
 Guillain-Barré syndrome
 association 527
 incubation period 527
 infants 528
 meningoencephalitis
 complication 530
 neonates 527
 Neuroviruses Emerging in the
 Americans Study 527
 pregnant, women wishing to
 get 530
 pregnant women *see* Zika virus,
 pregnant women
 sexual transmission 527, 529–30
 transmission modes 527, 529
 US Zika in Pregnancy
 Registry 528
 vaccine progress 529
 WHO 526, 528f73.1, 529
 women wishing to get
 pregnant 530
- Zika virus, pregnant women
 clinical features 527–28
 complications 530
 transmission to fetus 527–28
 traveling partner 529
 Zika virus screening 529
- ZMapp, Ebola virus disease 523–24
- zoonotic diseases
 hantavirus 514
 hepatitis E virus, reservoirs and
 transmission 156
 tularemia 506
see also novel influenza A viruses
- zoster *see* herpes zoster
- zoster *sine herpette*, viral
 meningitis 54
- Zosyn *see* piperacillin-tazobactam
- Zovirax *see* acyclovir
- Zygomycete meningitis 59